<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0134">
    <title>Antiviral Agents</title>
    <sect1 id="ch0134s0001">
      <title>Antiviral Agents</title>
      <anchor id="ch0134s0001a0001"/>
      <anchor id="ch0134s0000a0001"/>
      <para id="ch0134s0000p0001" role="chapterAuthor"><phrase role="chapterNumber"><emphasis role="underline"><phrase role="center">114</phrase></emphasis></phrase>CARLOS A.Q. SANTOS AND MANUELA JANNET REYNA QUITO</para>
      <para id="ch0134s0000p0002">The number of antiviral agents continues to expand. Most of the agents currently approved by the U.S. Food and Drug Administration (FDA) are active against one or more of the following viruses: human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), hepatitis viruses B and C (HBV and HCV), the human herpesviruses, influenza A and B viruses, and SARS-CoV-2. This chapter is organized according to these virus groups, with cross-referencing for agents with activity against more than one group of viruses. The major targets of these agents are viral replication enzymes, proteases, and entry/exit pathways (<link linkend="ch0134s0000li0001">1</link>–<link linkend="ch0134s0000li0004">4</link>). In a few cases, approved drugs for the above families of viruses have also been used to treat viruses in other families. The expanded spectrum of drug usage is discussed in the individual drug sections. During 2022, a global outbreak of monkeypox (mpox) has led to the use of antivirals and immune globulin in serious mpox infections. For the latest information on mpox treatment, see <ulink url="https://www.cdc.gov/poxvirus/mpox/clinicians/treatment.html">https://www.cdc.gov/poxvirus/mpox/clinicians/treatment.html</ulink>.</para>
      <sect2 id="ch0134s0001s0001">
        <title>AGENTS AGAINST HIV-1 AND HIV-2</title>
        <anchor id="ch0134s0001a0002"/>
        <anchor id="ch0134s0000a0002"/>
        <para id="ch0134s0000p0003">There are now five classes of antiviral agents for the treatment of HIV-1: (i) nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs), (ii) nonucleoside reverse transcriptase inhibitors (NNRTIs), (iii) protease inhibitors (PIs), (iv) entry/fusion inhibitors, and (v) integrase strand transfer inhibitors (INSTIs). Updated information on each drug is available at the AIDS info website (<ulink url="https://hivinfo.nih.gov/home-page">https://hivinfo.nih.gov/home-page</ulink>), which has separate guidelines for the use of approved antiretrovirals in adolescents and adults, children, and pregnant women (<link linkend="ch0134s0000li0005">5</link>–<link linkend="ch0134s0000li0007">7</link>). These guidelines describe the agents along with dosage, adverse effects, and drug interactions. Working groups for each of these patient populations regularly update the guidelines. Additional information can be obtained from the package inserts available from the pharmaceutical company websites. Changes in recommended drug doses as well as observed adverse effects and drug interactions occur frequently, making it necessary to consult the most up-to-date sources.</para>
        <para id="ch0134s0000p0004">Antiretrovirals are administered in combinations of different drug classes, termed combined antiretroviral therapy (cART), to maximize efficacy and to minimize the induction of drug resistance. cART is now generally regarded as any combination regimen designed to achieve the goal of complete virus suppression. These regimens comprise a minimum of three drugs, which are usually NNRTI based (two NRTIs and/or NtRTIs plus one NNRTI), PI based (two NRTIs and/or NtRTIs plus one or more PIs), or more recently, INSTI based (two NRTIs and/or NtRTIs plus an INSTI) (<link linkend="ch0134s0000li0005">5</link>). Recently, new data have supported the use of the two-drug regimens: dolutegravir plus lamivudine (Dovato), dolutegravir plus rilpivirine (Juluca), and cabotegravir plus rilpivirine (Cabenuva) (<link linkend="ch0134s0000li0005">5</link>).</para>
        <para id="ch0134s0000p0005">There are currently more than 30 approved antiretroviral drugs (<link linkend="ch0134s0000li0001">1</link>, <link linkend="ch0134s0000li0002">2</link>) with numerous possible combinations for treatment regimens. Recommended regimens for adults and adolescents are given in the guidelines (<link linkend="ch0134s0000li0005">5</link>) for treatment-naive and treatment-experienced patients. The large number of drugs creates a tremendous potential for drug interactions among the different classes as well as interactions with other types of drugs prescribed for conditions associated with HIV infection. Close monitoring of these complex interactions is required to avoid detrimental changes in drug levels and/or toxicity.</para>
        <para id="ch0134s0000p0006"><anchor id="ch0134s0000a0003"/><link linkend="ch0134s0000a0008">Table 1</link> summarizes the structure, mechanism of action, and major adverse effects of the individual drugs and drug combinations approved by the FDA. The drug interactions described below for each drug are only highlights of potential interactions. Frequent updates and more comprehensive information can be obtained from the AIDS info website listed above.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0002">
      <title>Nucleoside and/or Nucleotide Reverse Transcriptase Inhibitors</title>
      <anchor id="ch0134s0002a0001"/>
      <anchor id="ch0134s0000a0004"/>
      <para id="ch0134s0000p0007">The NRTI-NtRTI class of drugs is not active as administered but must be phosphorylated by cellular kinases to the nucleoside triphosphate form, which may lack a 3′ hydroxyl group for DNA chain elongation. The NRTIs require triphosphorylation, while the NtRTIs require only diphosphorylation (<link linkend="ch0134s0000li0001">1</link>). These antiviral agents act as competitive inhibitors of the viral reverse transcriptase (RT), which results in chain termination. They are active against both the HIV-1 and HIV-2 RTs, and they are used as dual-combination backbones in regimens with NNRTIs, PIs, and INSTIs (<link linkend="ch0134s0000li0005">5</link>). Several of them also are active against the HBV DNA polymerase, which has RT activity (see “Agents against Hepatitis B Virus” below) (<link linkend="ch0134s0000li0003">3</link>). Lactic acidosis with hepatic steatosis is a rare but very serious adverse effect associated with all members of this class. These toxic effects of NRTIs and NtRTIs appear to be the result of inhibition of the mitochondrial DNA polymerase γ (<link linkend="ch0134s0000li0008">8</link>).</para>
      <anchor id="ch0134s0000a0005"/>
      <beginpage pagenum="2198"/>
      <anchor id="ch0134s0000a0006"/>
      <beginpage pagenum="2199"/>
      <anchor id="ch0134s0000a0007"/>
      <beginpage pagenum="2200"/>
      <table id="ch0134s0000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0134s0000a0008"/><link linkend="ch0134s0000a0003">TABLE 1</link></phrase></emphasis> Antiviral agents for HIV therapy<superscript><link linkend="ch0134s0000a0012"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0009"/>
</title>
        
        <tgroup cols="4">
          <tbody>
            <row>
              <entry><phrase role="center">Antiviral agent (abbreviation)</phrase>
              </entry>
              <entry><phrase role="center">Trade name (pharmaceutical company<superscript><link linkend="ch0134s0000a0013"><emphasis>b</emphasis></link></superscript>)</phrase>
                <anchor id="ch0134s0000a0010"/>
              </entry>
              <entry><phrase role="center">Mechanism of action/route of administration</phrase>
              </entry>
              <entry><phrase role="center">Major adverse effects<superscript><link linkend="ch0134s0000a0014"><emphasis>c</emphasis></link></superscript></phrase>
                <anchor id="ch0134s0000a0011"/>
              </entry>
            </row>
            <row>
              <entry><emphasis role="strong">Nucleoside or nucleotide reverse transcriptase inhibitors (NRTI-NtRTIs)</emphasis>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Abacavir (ABC)</phrase>
              </entry>
              <entry>Ziagen (GSK)</entry>
              <entry><para id="ch0134s0000p0008">Converted to triphosphate analogue of dGTP by cellular kinases; competitive inhibitor of RT, viral DNA chain terminator</para>
                <para id="ch0134s0000p0009">Administered orally</para>
              </entry>
              <entry>Hypersensitivity reaction associated with HLA-B*5701</entry>
            </row>
            <row>
              <entry><phrase role="center">Didanosine (ddI)</phrase>
              </entry>
              <entry>Videx (BMS)</entry>
              <entry><para id="ch0134s0000p0010">Converted to dideoxy triphosphate analogue of dATP by cellular kinases</para>
                <para id="ch0134s0000p0011">Activity and administration similar to ABC</para>
              </entry>
              <entry>Pancreatitis, peripheral neuropathy, nausea, diarrhea</entry>
            </row>
            <row>
              <entry><phrase role="center">Emtricitabine (FTC)</phrase>
              </entry>
              <entry>Emtriva (Gilead)</entry>
              <entry><para id="ch0134s0000p0012">Converted to triphosphate analogue of dCTP by cellular kinases</para>
                <para id="ch0134s0000p0013">Activity and administration similar to ABC</para>
              </entry>
              <entry>Minimal toxicity, skin hyperpigmentation, posttreatment exacerbation of hepatitis B coinfection</entry>
            </row>
            <row>
              <entry><phrase role="center">Lamivudine (3TC)</phrase>
              </entry>
              <entry>Epivir (GSK)</entry>
              <entry><para id="ch0134s0000p0014">Converted to triphosphate analogue of dCTP by cellular kinases</para>
                <para id="ch0134s0000p0015">Activity and administration similar to ABC</para>
              </entry>
              <entry>Minimal toxicity, posttreatment exacerbation of hepatitis B coinfection</entry>
            </row>
            <row>
              <entry><phrase role="center">Stavudine (d4T)</phrase>
              </entry>
              <entry>Zerit (BMS)</entry>
              <entry><para id="ch0134s0000p0016">Converted to triphosphate analogue of dTTP by cellular kinases</para>
                <para id="ch0134s0000p0017">Activity and administration similar to ABC</para>
              </entry>
              <entry>Peripheral neuropathy, lipodystrophy; motor weakness</entry>
            </row>
            <row>
              <entry><phrase role="center">Tenofovir alafenamide (TAF)</phrase>
              </entry>
              <entry>Vemlidy (Gilead)</entry>
              <entry><para id="ch0134s0000p0018">Diester hydrolysis required for conversion to tenofovir, monophosphate analogue requires diphosphorylation by cellular kinases</para>
                <para id="ch0134s0000p0019">Activity and administration similar to ABC</para>
              </entry>
              <entry>Asthenia, headache, GI symptoms, cough, posttreatment exacerbation of hepatitis B coinfection; nephrotoxicity and bone mineral density loss less likely than TDF</entry>
            </row>
            <row>
              <entry><phrase role="center">Tenofovir disoproxil fumarate (TDF)</phrase>
              </entry>
              <entry>Viread (Gilead)</entry>
              <entry>Same as TAF</entry>
              <entry>Asthenia, headache, GI symptoms, cough, decrease in bone mineral density, proximal renal tubulopathy, lipodystrophy, posttreatment exacerbation of hepatitis B coinfection</entry>
            </row>
            <row>
              <entry><phrase role="center">Zidovudine (AZT or ZDV)</phrase>
              </entry>
              <entry>Retrovir (GSK)</entry>
              <entry><para id="ch0134s0000p0020">Converted to triphosphate analogue of dTTP by cellular kinases</para>
                <para id="ch0134s0000p0021">Activity and administration similar to ABC</para>
              </entry>
              <entry>Bone marrow suppression, GI symptoms, headache, insomnia</entry>
            </row>
            <row>
              <entry><emphasis role="strong">Nonnucleoside reverse transcriptase inhibitors (NNRTIs)</emphasis>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Efavirenz (EFV)</phrase>
              </entry>
              <entry>Sustiva (BMS)</entry>
              <entry><para id="ch0134s0000p0022">Noncompetitive inhibitor binds to HIV-1 RT close to catalytic site, disrupts normal polymerization function.</para>
                <para id="ch0134s0000p0023">Administered orally</para>
              </entry>
              <entry>Skin rash (Stevens-Johnson syndrome, higher risk), psychiatric symptoms, CNS symptoms (e.g., dizziness, insomnia, confusion), elevated transaminases, teratogenic; QTc prolongation</entry>
            </row>
            <row>
              <entry><phrase role="center">Etravirine (ETR)</phrase>
              </entry>
              <entry>Intelence (Tibotec)</entry>
              <entry>Activity and administration similar to EFV</entry>
              <entry>Skin rash (Stevens-Johnson syndrome), GI symptoms</entry>
            </row>
            <row>
              <entry><phrase role="center">Nevirapine (NVP)</phrase>
              </entry>
              <entry>Viramune (BI)</entry>
              <entry>Activity and administration similar to EFV</entry>
              <entry>Severe hepatotoxicity, skin rashes (Stevens-Johnson syndrome)</entry>
            </row>
            <row>
              <entry><phrase role="center">Rilpivirine (RPV)</phrase>
              </entry>
              <entry>Edurant (Tibotec)</entry>
              <entry>Activity and administration similar to EFV</entry>
              <entry>Rash, CNS symptoms (depression, headache, insomnia less than efavirenz), hepatotoxicity; QTc prolongation</entry>
            </row>
            <row>
              <entry><phrase role="center">Doravirine (DOR)</phrase>
              </entry>
              <entry>Pifeltro (Merk)</entry>
              <entry>Activity and administration similar to EFV</entry>
              <entry>Rash, CNS symptoms (depression, headache, insomnia less then efavirenz). Usually well tolerated</entry>
            </row>
            <row>
              <entry><emphasis role="strong">Nucleoside or nucleotide reverse transcriptase inhibitors (NRTI-NtRTI) and nonnucleoside reverse transcriptase inhibitors (NNRTIs)</emphasis>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Abacavir (ABC) + lamivudine (3TC)</phrase>
              </entry>
              <entry>Epzicom (GSK)</entry>
              <entry>See individual NRTIs above</entry>
              <entry>See individual NRTIs above</entry>
            </row>
            <row>
              <entry><phrase role="center">Zidovudine (AZT) + lamivudine (3TC)</phrase>
              </entry>
              <entry>Combivir<emphasis role="strong">(</emphasis>ViiV Healthcare)</entry>
              <entry>See individual NRTIs above</entry>
              <entry>See individual NRTIs above</entry>
            </row>
            <row>
              <entry><phrase role="center">Abacavir (ABC) + zidovudine (AZT) + lamivudine (3TC)</phrase>
              </entry>
              <entry>Trizivir (GSK)</entry>
              <entry>See individual NRTIs above</entry>
              <entry>See individual NRTIs above</entry>
            </row>
            <row>
              <entry><phrase role="center">Tenofovir (TDF) + emtricitabine (FTC)</phrase>
              </entry>
              <entry>Truvada (Gilead)</entry>
              <entry>See individual NTRIs-NtRTIs above</entry>
              <entry>See individual NTRIs-NtRTIs above</entry>
            </row>
            <row>
              <entry><phrase role="center">Tenofovir (TAF) + emtricitabine (FTC)</phrase>
              </entry>
              <entry>Descovy (Gilead)</entry>
              <entry>See individual NRTIs above</entry>
              <entry>See individual NRTIs above</entry>
            </row>
            <row>
              <entry><phrase role="center">Tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)</phrase>
              </entry>
              <entry>Atripla (Gilead and BMS)</entry>
              <entry>See individual NTRIs-NtRTIs above</entry>
              <entry>See individual NTRIs-NtRTIs above</entry>
            </row>
            <row>
              <entry><phrase role="center">Tenofovir (TAF) + emtricitabine (FTC) + rilpi-virine (RPV)</phrase>
              </entry>
              <entry>Odefsey (Gilead)</entry>
              <entry>See individual NTRIs-NtRTIs above</entry>
              <entry>See individual NTRIs-NtRTIs above</entry>
            </row>
            <row>
              <entry><phrase role="center">Tenofovir (TDF) + emtricitabine (FTC) + rilpi-virine (RVP)</phrase>
              </entry>
              <entry>Complera (Gilead)</entry>
              <entry>See individual NTRIs-NtRTIs above</entry>
              <entry>See individual NTRIs-NtRTIs above</entry>
            </row>
            <row>
              <entry><phrase role="center">Tenofovir (TDF) + lamivudine (3TC) + doravirine</phrase>
              </entry>
              <entry>Delstrigo (Merck)</entry>
              <entry>See individual NTRIs-NtRTIs above</entry>
              <entry>See individual NTRIs-NtRTIs above</entry>
            </row>
            <row>
              <entry><emphasis role="strong">Protease inhibitors</emphasis>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Atazanavir (ATV)</phrase>
              </entry>
              <entry>Reyataz (BMS)</entry>
              <entry><para id="ch0134s0000p0024">Peptidomimetic protease; binds competitively to active site of HIV protease, prevents cleavage of viral polyprotein precursors, produces immature, noninfectious viral particles</para>
                <para id="ch0134s0000p0025">Administered orally</para>
              </entry>
              <entry>Indirect hyperbilirubinemia, prolonged PR interval, hyperglycemia; fat redistribution; increased bleeding episodes with hemophilia, nephrolithiasis</entry>
            </row>
            <row>
              <entry><phrase role="center">Darunavir (DRV)</phrase>
              </entry>
              <entry>Prezista (Tibotec)</entry>
              <entry><para id="ch0134s0000p0026">Nonpeptidic protease; inhibits protease dimerization; prevents cleavage of viral polyprotein</para>
                <para id="ch0134s0000p0027">Administered orally</para>
              </entry>
              <entry>Skin rash (Stevens-Johnson syndrome), hepatotoxicity, hyperglycemia, fat redistribution, GI symptoms, elevated transaminase, increased bleeding episodes with hemophilia, nephrolithiasis</entry>
            </row>
            <row>
              <entry><phrase role="center">Fosamprenavir (FPV)</phrase>
              </entry>
              <entry>Lexiva (GSK)</entry>
              <entry><para id="ch0134s0000p0028">Converted to amprenavir by cellular phosphatases</para>
                <para id="ch0134s0000p0029">Activity and administration similar to ATV</para>
              </entry>
              <entry>Skin rash, GI symptoms, headache, hyperlipidemia, fat redistribution, elevated transaminases, hyperglycemia, increased bleeding episodes with hemophilia</entry>
            </row>
            <row>
              <entry><phrase role="center">Indinavir (IDV)</phrase>
              </entry>
              <entry>Crixivan (Merck)</entry>
              <entry>Activity and administration similar to ATV</entry>
              <entry>Nephrolithiasis/urolithiasis, GI symptoms, indirect hyperbilirubinemia, hyperlipidemia, hemolytic anemia, headache, hyperglycemia, fat redistribution, increased bleeding episodes with hemophilia</entry>
            </row>
            <row>
              <entry><phrase role="center">Lopinavir (LPV) + ritonavir (RTV or r)</phrase>
              </entry>
              <entry>Kaletra (Abbott)</entry>
              <entry>Activity and administration similar to ATV</entry>
              <entry>GI symptoms, asthenia, hyperlipidemia, elevated transaminase, hyperglycemia, hyperlipidemia, fat redistribution, elevated transaminases, increased bleeding episodes with hemophilia</entry>
            </row>
            <row>
              <entry><phrase role="center">Nelfinavir (NFV)</phrase>
              </entry>
              <entry>Viracept (Pfizer)</entry>
              <entry>Activity and administration similar to ATV</entry>
              <entry>Diarrhea, hyperlipidemia, hyperglycemia, fat redistribution, elevated transaminases, increased bleeding episodes with hemophilia</entry>
            </row>
            <row>
              <entry><phrase role="center">Ritonavir (RTV or r)</phrase>
              </entry>
              <entry>Norvir (Abbott)</entry>
              <entry>Activity and administration similar to ATV</entry>
              <entry>Severe GI symptoms, circumoral paresthesia, hyperlipidemia, hepatitis, asthenia, taste disturbance, hyperglycemia, fat redistribution, increased bleeding episodes with hemophilia</entry>
            </row>
            <row>
              <entry><phrase role="center">Saquinavir (SQV)</phrase>
              </entry>
              <entry>Invirase (Roche)</entry>
              <entry>Activity and administration similar to ATV</entry>
              <entry>GI symptoms, hyperlipidemia, elevated transaminase, headache, hyperglycemia, hyperlipidemia, fat redistribution, increased bleeding episodes with hemophilia</entry>
            </row>
            <row>
              <entry><phrase role="center">Tipranavir (TPV)</phrase>
              </entry>
              <entry>Aptivus (BI)</entry>
              <entry><para id="ch0134s0000p0030">Nonpeptidic protease</para>
                <para id="ch0134s0000p0031">Activity and administration similar to DRV</para>
              </entry>
              <entry>Hepatotoxicity, hyperglycemia, sulfa allergy skin rash, hyperlipidemia, fat redistribution, increased bleeding episodes with hemophilia, rare intracranial hemorrhage</entry>
            </row>
            <row>
              <entry><emphasis role="strong">Entry inhibitors</emphasis>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Enfuvirtide (T20)</phrase>
              </entry>
              <entry>Fuzeon (Roche)</entry>
              <entry><para id="ch0134s0000p0032">Binds to first heptad repeat in gp41, prevents conformational changes required for fusion of viral and cellular membranes</para>
                <para id="ch0134s0000p0033">Administered by injection</para>
              </entry>
              <entry>Local injection site reactions, pneumonia, hypersensitivity reactions</entry>
            </row>
            <row>
              <entry><phrase role="center">Maraviroc (MVC)</phrase>
              </entry>
              <entry>Selzentry (Pfizer)</entry>
              <entry><para id="ch0134s0000p0034">CCR5 coreceptor antagonist; allosteric binding to CCR5 alters conformation, prevents gp120 binding</para>
                <para id="ch0134s0000p0035">Administered orally</para>
              </entry>
              <entry>Upper respiratory infections, cough, pyrexia, rash, dizziness</entry>
            </row>
            <row>
              <entry><phrase role="center">Ibalizumab</phrase>
              </entry>
              <entry>Trogarzo (TaiMed)</entry>
              <entry>Humanized monoclonal antibody that binds to domain 2 of CD4 on the surface of immune cells</entry>
              <entry>Diarrhea (8%), dizziness (8%), nausea (5%), rash (5%)</entry>
            </row>
            <row>
              <entry><emphasis role="strong">Integrase strand transfer inhibitors</emphasis>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Dolutegravir (DTG)</phrase>
              </entry>
              <entry>Tivicay (Viiv/GSK)</entry>
              <entry><para id="ch0134s0000p0036">Prevents formation of covalent bond between unintegrated HIV DNA and host DNA, preventing formation of provirus</para>
                <para id="ch0134s0000p0037">Administered orally</para>
              </entry>
              <entry>Headache, insomnia, fatigue, elevated AST/ALT, elevated CPK</entry>
            </row>
            <row>
              <entry><phrase role="center">Elvitegravir (EVG) + Cobicistat (COBI or c)</phrase>
              </entry>
              <entry>Stribild (Gilead)</entry>
              <entry><para id="ch0134s0000p0038">Prevents formation of covalent bond between unintegrated HIV DNA and host DNA, preventing formation of provirus; requires pharmacologic boosting</para>
                <para id="ch0134s0000p0039">Administered orally</para>
                <para id="ch0134s0000p0040">Cobicistat: pharmacokinetic enhancer, inhibits CYP3A4</para>
              </entry>
              <entry>Coformulation EG/COBI/TDF/FTC: GI symptoms, renal impairment, decreased bone density</entry>
            </row>
            <row>
              <entry>Raltegravir (RAL)</entry>
              <entry>Isentress (Merck)</entry>
              <entry><para id="ch0134s0000p0041">Prevents formation of covalent bond between unintegrated HIV DNA and host DNA, preventing formation of provirus</para>
                <para id="ch0134s0000p0042">Administered orally</para>
              </entry>
              <entry>Headache, GI symptoms, asthenia, fatigue, pyrexia, CPK elevation</entry>
            </row>
            <row>
              <entry>Bictegravir (BIC)</entry>
              <entry>(Gilead)</entry>
              <entry><para id="ch0134s0000p0043">Same as rest of INSTI</para>
                <para id="ch0134s0000p0044">Administered orally</para>
              </entry>
              <entry>Diarrhea, nausea, headache. Weight gain has been reported in adults who were receiving Biktarvy</entry>
            </row>
            <row>
              <entry>Cabotegravir (CAB)</entry>
              <entry>Vocabria (ViiV)</entry>
              <entry>Inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration</entry>
              <entry>Headaches, nausea, abnormal dreams, anxiety, or insomnia</entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para id="ch0134s0000p0045" role="table-footnote"><superscript><link linkend="ch0134s0000a0009"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0012"/>Note: all NRTI/NtRTIs carry the warning of lactic acidosis and severe hepatomegaly with steatosis.</para>
      <para id="ch0134s0000p0046" role="table-footnote"><superscript><link linkend="ch0134s0000a0010"><emphasis>b</emphasis></link></superscript><anchor id="ch0134s0000a0013"/>Pharmaceutical companies: Abbott Laboratories, North Chicago, IL; BI, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT; BMS, Bristol-Meyers Squibb, Princeton, NJ; Gilead Sciences, Foster City, CA; GSK, GlaxoSmithKline, Research Triangle Park, NC; Merck &amp; Co., Whitehouse Station, NJ; Pfizer, New York, NY; Roche Pharmaceuticals, Nutley, NJ; Tibotec Therapeutics, Division of Ortho Biotech Products, L.P., Raritan, NJ.</para>
      <para id="ch0134s0000p0047" role="table-footnote"><superscript><link linkend="ch0134s0000a0011"><emphasis>c</emphasis></link></superscript><anchor id="ch0134s0000a0014"/>Abbreviations: HLA, human leukocyte antigen; PR, P-wave to R-wave interval; QTc, Q-wave to T-wave interval corrected for heart rate; GI, gastrointestinal (symptoms include nausea, vomiting, and diarrhea); AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPK, creatine phosphokinase; CNS, central nervous system.</para>
      <sect2 id="ch0134s0002s0001">
        <title>Abacavir</title>
        <anchor id="ch0134s0002a0002"/>
        <anchor id="ch0134s0000a0015"/>
        <sect3 id="ch0134s0002s0001">
          <title>Pharmacology</title>
          <anchor id="ch0134s0002a0003"/>
          <anchor id="ch0134s0000a0016"/>
          <para id="ch0134s0000p0048">The oral bioavailability of abacavir (ABC) is 83%. The plasma half-life is 1.5 h, and the intracellular half-life is 12 to 26 h. ABC can be administered with or without food. It is metabolized by alcohol dehydrogenase and glucuronyl transferase, and 82% of the metabolites are excreted by the kidneys. Placental passage has been demonstrated in animal studies (<link linkend="ch0134s0000li0007">7</link>). ABC penetration of the central nervous system (CNS) is adequate to inhibit HIV replication (<link linkend="ch0134s0000li0009">9</link>). ABC is recommended for therapy in combination with dolutegravir (DTG) and lamivudine (3TC). The guidelines recommend using caution when prescribing ABC in patients with high risk for cardiovascular disease, because studies have shown both a lack of association as well as increased risk of cardiovascular disease (<link linkend="ch0134s0000li0010">10</link>–<link linkend="ch0134s0000li0012">12</link>). ABC is contraindicated in patients who are positive for the HLA-B*5701 major histocompatibility complex class I allele, which is associated with a hypersensitivity reaction to the drug (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0013">13</link>). Combination formulations of two and three NRTIs and/or NtRTIs containing ABC are commercially available (<link linkend="ch0134s0000a0008">Table 1</link>).</para>
          <anchor id="ch0134s0000a0017"/>
          <beginpage pagenum="2201"/>
        </sect3>
        <sect3 id="ch0134s0002s0002">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0002a0004"/>
          <anchor id="ch0134s0000a0018"/>
          <para id="ch0134s0000p0049">ABC decreases the level of methadone. Ethanol increases the concentration of ABC in plasma through common metabolic pathways (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0002s0002">
        <title>Didanosine</title>
        <anchor id="ch0134s0002a0005"/>
        <anchor id="ch0134s0000a0019"/>
        <sect3 id="ch0134s0002s0003">
          <title>Pharmacology</title>
          <anchor id="ch0134s0002a0006"/>
          <anchor id="ch0134s0000a0020"/>
          <para id="ch0134s0000p0050">The oral bioavailability of didanosine (ddI) is 30 to 40%. The serum half-life is 1.5 h, and the intracellular half-life is &gt;20 h. It should be administered without food. One-half of the drug is excreted by the kidney. There is low penetration of the CNS, but ddI has been shown to cross the human placenta (<link linkend="ch0134s0000li0007">7</link>). ddI is no longer recommended for use in treatment-naive patients (<link linkend="ch0134s0000li0007">7</link>).</para>
        </sect3>
        <sect3 id="ch0134s0002s0004">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0002a0007"/>
          <anchor id="ch0134s0000a0021"/>
          <para id="ch0134s0000p0051">Administration of ddI with either d4T or tenofovir disoproxil fumarate (TDF) can increase the rate and severity of toxicities associated with each individual drug. Ganciclovir (GCV), valganciclovir (val-GCV), ribavirin (RBV), and allopurinol also increase ddI exposure, leading to increased ddI toxicity (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0014">14</link>, <link linkend="ch0134s0000li0015">15</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0002s0003">
        <title>Emtricitabine</title>
        <anchor id="ch0134s0002a0008"/>
        <anchor id="ch0134s0000a0022"/>
        <sect3 id="ch0134s0002s0005">
          <title>Pharmacology</title>
          <anchor id="ch0134s0002a0009"/>
          <anchor id="ch0134s0000a0023"/>
          <para id="ch0134s0000p0052">The oral bioavailability of emtricitabine (FTC) is 93%. The plasma half-life is 10 h, and the intracellular half-life is &gt;20 h. FTC can be administered with or without food. It is excreted mostly unchanged (86%) by the kidneys, and the remainder is eliminated in the feces. It has intermediate penetration of cells of the CNS (<link linkend="ch0134s0000li0016">16</link>) and has been shown to cross the placenta (<link linkend="ch0134s0000li0007">7</link>). FTC is recommended as a preferred drug in combination with tenofovir (TDF) in NNRTI-based, PI-based, or INSTI-based regimens for treatment-naive patients. Coadministration with 3TC is not recommended, because both drugs have similar resistance patterns and there is no therapeutic advantage for the combination (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
        <sect3 id="ch0134s0002s0006">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0002a0010"/>
          <anchor id="ch0134s0000a0024"/>
          <para id="ch0134s0000p0053">No significant interactions with other antiretroviral agents have been reported (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0017">17</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0002s0004">
        <title>Lamivudine</title>
        <anchor id="ch0134s0002a0011"/>
        <anchor id="ch0134s0000a0025"/>
        <sect3 id="ch0134s0002s0007">
          <title>Pharmacology</title>
          <anchor id="ch0134s0002a0012"/>
          <anchor id="ch0134s0000a0026"/>
          <para id="ch0134s0000p0054">The oral bioavailability of lamivudine (3TC) is 86%. The serum half-life is 5 to 7 h, and the intracellular half-life is 18 to 22 h. The drug can be administered with or without food, and 71% is excreted by the kidney. 3TC crosses the human placenta (<link linkend="ch0134s0000li0007">7</link>) and has intermediate penetration of the CNS (<link linkend="ch0134s0000li0016">16</link>). 3TC is recommended in alternative dual-NRTI regimens with tenofovir (TDF or tenofovir alafenamide [TAF]), combined with either an NNRTI, PI, or INSTI for treatment-naive patients (<link linkend="ch0134s0000li0005">5</link>). Coadministration of 3TC with FTC is not recommended (see “Emtricitabine” above).</para>
        </sect3>
        <sect3 id="ch0134s0002s0008">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0002a0013"/>
          <anchor id="ch0134s0000a0027"/>
          <para id="ch0134s0000p0055">3TC is actively excreted by the kidney by the organic cationic transport system; therefore, possible interactions should be considered with other drugs that use the same pathway, such as trimethoprim-sulfamethoxazole (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0002s0005">
        <title>Stavudine</title>
        <anchor id="ch0134s0002a0014"/>
        <anchor id="ch0134s0000a0028"/>
        <sect3 id="ch0134s0002s0009">
          <title>Pharmacology</title>
          <anchor id="ch0134s0002a0015"/>
          <anchor id="ch0134s0000a0029"/>
          <para id="ch0134s0000p0056">The oral bioavailability of stavudine (d4T) is 86%. The serum half-life is 1.0 h, and the intracellular half-life is 7.5 h. d4T can be administered with or without food. Half of the drug is excreted by the kidneys. Placental passage occurs in animals, and d4T has intermediate penetration of the CNS (<link linkend="ch0134s0000li0007">7</link>, <link linkend="ch0134s0000li0018">18</link>). d4T is no longer recommended for use in treatment-naive patients because of toxicity (<link linkend="ch0134s0000li0005">5</link>). It has been replaced by ABC or zidovudine (ZDV) in first-line pediatric regimens (<link linkend="ch0134s0000li0019">19</link>).</para>
        </sect3>
        <sect3 id="ch0134s0002s0010">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0002a0016"/>
          <anchor id="ch0134s0000a0030"/>
          <para id="ch0134s0000p0057">d4T combined with ddI can increase the rate and severity of toxicities associated with each individual drug. ZDV and RBV inhibit the phosphorylation of d4T (<link linkend="ch0134s0000li0020">20</link>, <link linkend="ch0134s0000li0021">21</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0002s0006">
        <title>Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide</title>
        <anchor id="ch0134s0002a0017"/>
        <anchor id="ch0134s0000a0031"/>
        <sect3 id="ch0134s0002s0011">
          <title>Pharmacology</title>
          <anchor id="ch0134s0002a0018"/>
          <anchor id="ch0134s0000a0032"/>
          <para id="ch0134s0000p0058">The oral bioavailability of the prodrug tenofovir disoproxil fumarate (TDF) metabolized to tenofovir is 25% without food and 39% with a high-fat meal, although the drug is administered without regard to meals. The serum half-life is 17 h, and the intracellular half-life is &gt;60 h. The drug is excreted mostly unchanged (70 to 80%) by the kidneys. TDF has been shown to cross the placenta in animal studies, but it has low penetration of the CNS (<link linkend="ch0134s0000li0007">7</link>, <link linkend="ch0134s0000li0016">16</link>). It is less likely than other NRTIs-NtRTIs to be associated with mitochondrial toxicity; however, renal dysfunction and decreased bone mineral density have been reported with TDF use. TDF is recommended in initial regimens with dual NRTI-NtRTI combinations including FTC with elvitegravir (EVG) and cobicistat (COBI) (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0022">22</link>).</para>
          <para id="ch0134s0000p0059">Tenofovir alafenamide (TAF) is another prodrug of tenofovir, which appears to be equally effective as an antiretroviral agent as TDF, but at a much lower dose (<link linkend="ch0134s0000li0023">23</link>). Consequently, TAF is associated with lower bone density loss and nephrotoxicity compared to TDF (<link linkend="ch0134s0000li0022">22</link>, <link linkend="ch0134s0000li0024">24</link>, <link linkend="ch0134s0000li0025">25</link>). TAF is approved in combined formulations such as EVG/COBI/FTC or darunavir (DRV)/ritonavir (RTV)/FTC for initial antiretroviral therapy (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
        <sect3 id="ch0134s0002s0012">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0002a0019"/>
          <anchor id="ch0134s0000a0033"/>
          <para id="ch0134s0000p0060">TDF increases the concentration of ddI in plasma, leading to increased toxicity (<link linkend="ch0134s0000li0014">14</link>). There may be increased toxicity associated with coadministration of GCV, val-GCV, acyclovir (ACV), or cidofovir (CDV) (<link linkend="ch0134s0000li0005">5</link>).</para>
          <para id="ch0134s0000p0061">TAF is a substrate for P-glycoprotein. Drugs that decrease TAF through this pathway include anticonvulsants, antimycobacterials, and St. John’s wort (<link linkend="ch0134s0000li0005">5</link>).</para>
          <anchor id="ch0134s0000a0034"/>
          <beginpage pagenum="2202"/>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0002s0007">
        <title>Zidovudine</title>
        <anchor id="ch0134s0002a0020"/>
        <anchor id="ch0134s0000a0035"/>
        <sect3 id="ch0134s0002s0013">
          <title>Pharmacology</title>
          <anchor id="ch0134s0002a0021"/>
          <anchor id="ch0134s0000a0036"/>
          <para id="ch0134s0000p0062">The oral bioavailability of zidovudine (ZDV) is 60%, with a serum half-life of 1.1 h and intracellular half-life of 7 h. ZDV can be administered without regard to meals. It is metabolized to the glucuronide form, which is excreted by the kidneys.</para>
          <para id="ch0134s0000p0063">ZDV crosses the blood-brain barrier to achieve effective concentrations in the CNS (<link linkend="ch0134s0000li0016">16</link>) and crosses the placenta. ZDV with 3TC is an alternative dual-NRTI backbone for combination regimens in pregnant women (<link linkend="ch0134s0000li0007">7</link>). It can be given intravenously to pregnant women during labor to prevent maternal-fetal transmission if the mother has ≥400 copies/ml of HIV or if the HIV viral load is unknown near the time of delivery. Intrapartum ZDV is no longer recommended for HIV-infected mothers who achieve virologic control on cART. ZDV can be administered orally to the child at birth either alone or in combination with nevirapine (NVP) and/or 3TC (<link linkend="ch0134s0000li0007">7</link>, <link linkend="ch0134s0000li0026">26</link>). For adults and adolescents, ZDV can be given with 3TC as a dual-NRTI backbone with NNRTI-based and PI-based regimens. However, this is no longer considered a preferred or alternative regimen because it requires twice-daily dosing and has greater associated toxicity than TDF-FTC or ABC-3TC (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
        <sect3 id="ch0134s0002s0014">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0002a0022"/>
          <anchor id="ch0134s0000a0037"/>
          <para id="ch0134s0000p0064">ZDV inhibits the phosphorylation of d4T by thymidine kinase (<link linkend="ch0134s0000li0026">26</link>). RBV inhibits phosphorylation of ZDV (<link linkend="ch0134s0000li0021">21</link>). GCV and alpha interferon may enhance the hematologic toxicity associated with ZDV (<link linkend="ch0134s0000li0027">27</link>, <link linkend="ch0134s0000li0028">28</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0002s0008">
        <title>NRTI/NtRTI Combination Formulations</title>
        <anchor id="ch0134s0002a0023"/>
        <anchor id="ch0134s0000a0038"/>
        <para id="ch0134s0000p0065">NRTIs and NtRTIs remain the backbone of the initial ART regimen for a treatment-naive patient. Usually either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), plus a drug from one of three drug classes—INSTIs, NNRTIs, or boosted PIs—are used as initial treatments showing suppression of HIV replication and improvement of CD4 count (<link linkend="ch0134s0000li0029">29</link>–<link linkend="ch0134s0000li0031">31</link>).</para>
        <para id="ch0134s0000p0066">There are multiple fixed-dose combinations involving NRTIs and NtRTIs, which are available as commercial formulations for convenience of administration: ABC/3TC/ZDV (Trizivir), ABC/3TC (Epzicom), FTC/TDF (Truvada), 3TC/ZDV (Combivir), FTC/TDF/EFV (Atripla), FTC/rilpivirine (RPV)/TDF (Complera), FTC/EVG/COBI/TDF (Stribild), FTC/RPV/TAF (Odefsey), FTC/TAF (Descovy), EVG/COBI/FTC/TAF (Genvoya), and bictegravir (BIC)/FTC/TAF (Biktarvy).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0003">
      <title>Nonnucleoside Reverse Transcriptase Inhibitors</title>
      <anchor id="ch0134s0003a0001"/>
      <anchor id="ch0134s0000a0039"/>
      <para id="ch0134s0000p0067">Drugs in the NNRTI class do not require intracellular anabolism for activation. There is no common structure; however, they bind noncompetitively to the HIV-1 RT close to the catalytic site. Disruption of DNA polymerization activity leads to premature DNA chain termination. The HIV-2 RT is resistant to this class of drugs (<link linkend="ch0134s0000li0001">1</link>).</para>
      <para id="ch0134s0000p0068">There are currently five available NNRTIs: NVP, EFV, etravirine (ETR), rilpivirine (RPV), and doravirine (DOR). All are metabolized by the cytochrome P450 (CYP450) system, which also metabolizes the PIs (see below) and other drugs used to treat conditions associated with HIV infection. The common pathway can lead to serious interactions, which either induce or inhibit individual drug metabolism.</para>
      <para id="ch0134s0000p0069">In the past, NNRTIs were preferred for first-line therapeutic regimens with two NRTIs and/or NtRTIs for the following reasons: (i) there is a low incidence of gastrointestinal symptoms; (ii) NNRTIs have a long half-life that tolerates missed doses; and (iii) use of NNRTIs saves PIs for future regimens. The disadvantages of the NNRTIs are (i) the relatively low number of mutations required to confer cross-resistance to many of the drugs in this class and (ii) side effects related to the CNS (<link linkend="ch0134s0000li0007">7</link>). As a result, NNRTIs are now components of recommended alternative regimens, with INSTIs replacing them in the preferred initial regimens.</para>
      <sect2 id="ch0134s0003s0001">
        <title>Efavirenz</title>
        <anchor id="ch0134s0003a0002"/>
        <anchor id="ch0134s0000a0040"/>
        <sect3 id="ch0134s0003s0001">
          <title>Pharmacology</title>
          <anchor id="ch0134s0003a0003"/>
          <anchor id="ch0134s0000a0041"/>
          <para id="ch0134s0000p0070">The oral bioavailability of efavirenz (EFV) is 40 to 45%. The serum half-life is 52 to 76 h. EFV is 99.5% protein bound in the plasma, mainly to albumin. CNS penetration is intermediate (<link linkend="ch0134s0000li0016">16</link>), but EFV has been shown to cross the placenta in animals (<link linkend="ch0134s0000li0007">7</link>). EFV is metabolized by CYP3A4 and CYP2B6 and is an inducer and inhibitor of CYP3A4. Glucuronidated metabolites are excreted in the urine (14 to 34%) and eliminated in the feces (16 to 61%). The absorption is increased when taken with high-fat meals, which may increase the risk for adverse events. It is recommended to be given on an empty stomach, typically before bed (<link linkend="ch0134s0000li0005">5</link>–<link linkend="ch0134s0000li0007">7</link>).</para>
          <para id="ch0134s0000p0071">EFV/FTC/TDF (or TAF) is recommended as an alternative regimen except in pregnant women, because teratogenic effects have been observed in cynomolgus monkeys during the first trimester of pregnancy (<link linkend="ch0134s0000li0007">7</link>).</para>
        </sect3>
        <sect3 id="ch0134s0003s0002">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0003a0004"/>
          <anchor id="ch0134s0000a0042"/>
          <para id="ch0134s0000p0072">Dose modifications may be necessary for potential drug interactions between EFV and the following: indinavir (IDV), lopinavir-RTV (LPV/r), fosamprenavir (FPV), nelfinavir (NFV), saquinavir (SQV), clarithromycin, rifabutin, rifampin, simvastatin, lovastatin, methadone, itraconazole, anticonvulsants, and oral contraceptives (<link linkend="ch0134s0000li0005">5</link>). Contraindicated drugs are rifapentine, cisapride, midazolam, triazolam, ergot derivatives, St. John’s wort, voriconazole, HCV PIs, and in treatment-experienced patients, atazanavir (ATV).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0003s0002">
        <title>Etravirine</title>
        <anchor id="ch0134s0003a0005"/>
        <anchor id="ch0134s0000a0043"/>
        <sect3 id="ch0134s0003s0003">
          <title>Pharmacology</title>
          <anchor id="ch0134s0003a0006"/>
          <anchor id="ch0134s0000a0044"/>
          <para id="ch0134s0000p0073">The oral bioavailability of etravirine (ETR) is unknown. The serum half-life is 41 h ± 21 h. Drug levels are reduced under fasting conditions; therefore, ETR should be taken with meals. ETR is 99.9% protein bound in plasma, mainly to albumin. It is not known whether ETR penetrates the CNS or crosses the placenta. ETR is metabolized by CYP3A4, CYP2C9, and CYP2C19. It induces CYP3A4 and inhibits CYP2C9 and CYP2C19. It is also an inducer of P-glycoprotein (<link linkend="ch0134s0000li0005">5</link>). ETR is eliminated in the feces (93.7%) and excreted in the urine (1.2%) (<link linkend="ch0134s0000li0032">32</link>). It has not been studied in large trials of treatment-naive patients and therefore is not recommended for treatment in this population. ETR is reported to be active against HIV-1 strains that are resistant to other NNRTIs, including HIV-1 group O (<link linkend="ch0134s0000li0033">33</link>); therefore, it is currently used in regimens for treatment-experienced patients who have failed therapy (<link linkend="ch0134s0000li0001">1</link>, <link linkend="ch0134s0000li0032">32</link>, <link linkend="ch0134s0000li0034">34</link>).</para>
        </sect3>
        <sect3 id="ch0134s0003s0004">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0003a0007"/>
          <anchor id="ch0134s0000a0045"/>
          <anchor id="ch0134s0000a0046"/>
          <para id="ch0134s0000p0074">Dose modifications may be required for the following: lopinavir/ritonavir (LPV/r), saquinavir (SQV), antiarrhythmics, dexamethasone, erectile dysfunction drugs, warfarin, lipid-lowering drugs, diazepam, and antifungal agents.</para>
          <para id="ch0134s0000p0075">ETR should not be coadministered with the following drugs: efavirenz (EFV), nevirapine (NVP), atazanavir (ATV), fosamprenavir (FPV), tipranavir (TPV), hormonal contraceptives, St. John’s wort, clarithromycin, antimycobacterials (if coadministered with ritonavir-boosted PI), and phenobarbital (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0032">32</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0003s0003">
        <title>Nevirapine</title>
        <anchor id="ch0134s0003a0008"/>
        <anchor id="ch0134s0000a0047"/>
        <sect3 id="ch0134s0003s0005">
          <title>Pharmacology</title>
          <anchor id="ch0134s0003a0009"/>
          <anchor id="ch0134s0000a0048"/>
          <para id="ch0134s0000p0076">The oral bioavailability of nevirapine (NVP) is &gt;90%, and the serum half-life is 25 to 30 h. NVP is 60% protein bound. Penetration into the CNS is high; the concentration in the cerebrospinal fluid is 45% of the concentration in plasma (<link linkend="ch0134s0000li0016">16</link>). NVP can be administered with or without food. It is both a substrate and an inducer of CYP3A4 and CYP2B6 (<link linkend="ch0134s0000li0005">5</link>). Glucuronidated metabolites are excreted in the urine (80%) and feces (10%). NVP is known to cross the human placenta (<link linkend="ch0134s0000li0007">7</link>). It has been used in resource-limited regions as a single oral agent in an intrapartum/newborn prophylaxis regimen to prevent mother-to-child transmission (<link linkend="ch0134s0000li0007">7</link>, <link linkend="ch0134s0000li0035">35</link>). It is also under study as part of three-drug regimens to prevent perinatal transmission (<link linkend="ch0134s0000li0007">7</link>, <link linkend="ch0134s0000li0036">36</link>). However, NVP has been associated with serious hepatic events and has a low barrier to resistance, and therefore, it is no longer considered a preferred or alternative agent for initial therapy. In certain circumstances NVP may be considered in women with CD4<superscript>+</superscript> T cell counts of ≤250 cells/mm<superscript>3</superscript> or in males with counts of ≤400 cells/mm<superscript>3</superscript> in the absence of moderate to severe hepatic impairment (Child-Pugh class B or C) (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
        <sect3 id="ch0134s0003s0006">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0003a0010"/>
          <anchor id="ch0134s0000a0049"/>
          <para id="ch0134s0000p0077">NVP reduces the concentrations in plasma of indinavir (IDV), saquinavir (SQV), oral contraceptives, fluconazole, ketoconazole, clarithromycin, and methadone (<link linkend="ch0134s0000li0021">21</link>). Coadministration of atazanavir (ATV), etravirine (ETR), rifampin, rifapentine, St. John’s wort, or hepatitis C virus PIs with nevirapine (NVP) is contraindicated (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0003s0004">
        <title>Rilpivirine</title>
        <anchor id="ch0134s0003a0011"/>
        <anchor id="ch0134s0000a0050"/>
        <sect3 id="ch0134s0003s0007">
          <title>Pharmacology</title>
          <anchor id="ch0134s0003a0012"/>
          <anchor id="ch0134s0000a0051"/>
          <para id="ch0134s0000p0078">The oral bioavailability of rilpivirine (RPV) is unknown, and the serum half-life is 50 h. It is not known whether RPV penetrates the CNS or crosses the placenta. RPV should be administered with food. It is a CYP3A4 substrate (<link linkend="ch0134s0000li0005">5</link>). RPV in combination with TDF/FTC or ABC/3TC is an alternative regimen for treatment-naive patients. However, RPV use is not recommended in patients with a pretreatment HIV viral load of &gt;100,000 copies/ml, because it has been associated with virologic failure in these patients. In addition, patients with CD4<superscript>+</superscript> T cell counts of &lt;200 cells/mm<superscript>3</superscript> are more likely to experience virologic failure when treated with an RPV-based regimen (<link linkend="ch0134s0000li0005">5</link>). RPV is metabolized by CYP3A4 and eliminated in urine and feces.</para>
        </sect3>
        <sect3 id="ch0134s0003s0008">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0003a0013"/>
          <anchor id="ch0134s0000a0052"/>
          <para id="ch0134s0000p0079">Drugs that are contraindicated are antimycobacterials, anticonvulsants, proton pump inhibitors, HCV PIs, dexamethasone, and St. John’s wort (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0003s0005">
        <title>Doravirine</title>
        <anchor id="ch0134s0003a0014"/>
        <anchor id="ch0134s0000a0053"/>
        <sect3 id="ch0134s0003s0009">
          <title>Pharmacology</title>
          <anchor id="ch0134s0003a0015"/>
          <anchor id="ch0134s0000a0054"/>
          <para id="ch0134s0000p0080">The bioavailability of doravirine (DOR) is about 64%. Following absorption, unchanged original drug is the major circulating component in plasma. It can be administered with or without food. The primary route of elimination is via cytochrome P450 3A4/5 metabolism. Only 6% of an administered dose is recovered in the urine unchanged.</para>
          <para id="ch0134s0000p0081">The elimination half-life is 15 hours. DOR is approximately 76% protein bound in plasma (<link linkend="ch0134s0000li0037">37</link>). It is coformulated with TDF/3TC (Delstrigo).</para>
        </sect3>
        <sect3 id="ch0134s0003s0010">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0003a0016"/>
          <anchor id="ch0134s0000a0055"/>
          <para id="ch0134s0000p0082">Compared to EFV, DOR has fewer CNS side effects. The most common adverse reactions are nausea, dizziness, headache, fatigue, diarrhea, abdominal pain, and abnormal dreams. DOR resistance mutations may confer resistance to certain NNRTIs.</para>
        </sect3>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0004">
      <title>Protease Inhibitors</title>
      <anchor id="ch0134s0004a0001"/>
      <anchor id="ch0134s0000a0056"/>
      <para id="ch0134s0000p0083">PIs, like the NNRTIs, require no intracellular anabolism for antiviral activity. The target is the HIV-encoded protease, which is required for posttranslational processing of the precursor<emphasis>gag</emphasis> polyprotein (<link linkend="ch0134s0000li0038">38</link>). Most PIs are peptidomimetic because they contain the peptide bond normally cleaved by the protease (<link linkend="ch0134s0000li0001">1</link>). TPV and DRV are nonpeptidic molecules that are reported to inhibit protease dimerization as well as normal enzymatic activity (<link linkend="ch0134s0000li0039">39</link>). The relative activity of PIs against the HIV-1 versus HIV-2 protease varies among the drugs and is dependent on the amino acid sequences of the target binding sites (<link linkend="ch0134s0000li0040">40</link>).</para>
      <para id="ch0134s0000p0084">PIs are commonly used in cART regimens in combination with NRTI and/or NtRTIs for maximum antiretroviral activity and to minimize the development of resistance. PI-based regimens introduced initially led to treatment failure related to their limited bioavailability, frequent dosing, and toxicity. There are several characteristics of these drugs that lead to these treatment-related problems. They are highly bound to plasma protein, mainly alpha-1 acid glycoprotein (AAG) (<link linkend="ch0134s0000li0041">41</link>). The low concentration of unbound drug is responsible for the therapeutic activity as well as toxicity. PIs are substrates for P-glycoprotein and multidrug resistance-associated protein. These are efflux transporters, which enhance elimination of the drugs from cells in the intestine, liver, and kidneys and reduce intracellular drug concentrations (<link linkend="ch0134s0000li0042">42</link>). All the PIs are metabolized in the intestine and liver by enzymes of the CYP450 system (<link linkend="ch0134s0000li0043">43</link>), mainly by CYP3A4, CYP2C9, and CYP2C19. An individual PI can induce and/or inhibit specific CYP450 isoenzymes, which can enhance or reduce its own metabolism or that of other PIs. As noted above, the CYP450 system metabolizes the NNRTIs and numerous other drugs that may be used for conditions associated with HIV infection. Thus, the choice of treatment regimens is complicated by multiple potential drug-drug interactions, which may enhance toxicity and/or require dose modifications of coadministered drugs (<link linkend="ch0134s0000li0005">5</link>).</para>
      <para id="ch0134s0000p0085">Although most PIs are inhibitors of CYP3A4, RTV is the most inhibitory. For this reason, RTV is used in boosting regimens to improve the pharmacokinetic profile of a second PI (<link linkend="ch0134s0000li0044">44</link>). Subtherapeutic concentrations of RTV increase the systemic exposure of a second PI by reducing the rate of metabolism and increasing the half-life (<link linkend="ch0134s0000li0043">43</link>), which lowers dosing requirements and food effects for the second drug. An example is LPV, which alone has very little bioavailability and a very short half-life but in combination with RTV is used therapeutically in alternative regimens for treatment-naive patients and in salvage therapy (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0044">44</link>, <link linkend="ch0134s0000li0045">45</link>). The effect of RTV on the pharmacokinetics of other PIs varies because of differences in interaction with components of the CYP450 system that determine bioavailability. Specific recommendations are described below for each drug.</para>
      <anchor id="ch0134s0000a0057"/>
      <beginpage pagenum="2204"/>
      <sect2 id="ch0134s0004s0001">
        <title>Atazanavir</title>
        <anchor id="ch0134s0004a0002"/>
        <anchor id="ch0134s0000a0058"/>
        <sect3 id="ch0134s0004s0001">
          <title>Pharmacology</title>
          <anchor id="ch0134s0004a0003"/>
          <anchor id="ch0134s0000a0059"/>
          <para id="ch0134s0000p0086">Atazanavir (ATV) is an azapeptide PI that differs structurally from other peptidomimetic PIs. The bioavailability is undetermined, and the serum half-life is 7 h. The bioavailability, however, is increased by administration with food. ATV is 86% protein bound and penetrates the CNS (<link linkend="ch0134s0000li0046">46</link>). It is metabolized in the liver by CYP3A4, and it is also an inhibitor of this enzyme. The metabolites are eliminated in the feces (79%) and urine (13%). ATV crosses the placenta at minimal levels. It is an inhibitor, inducer, and substrate for P-glycoprotein (<link linkend="ch0134s0000li0007">7</link>).</para>
          <para id="ch0134s0000p0087">ATV has the advantage of once-daily dosing as well as a high genetic barrier to resistance. ATV boosted with RTV or COBI is a recommended alternative PI in regimens with TDF (or TAF)/FTC (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0047">47</link>).</para>
        </sect3>
        <sect3 id="ch0134s0004s0002">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0004a0004"/>
          <anchor id="ch0134s0000a0060"/>
          <para id="ch0134s0000p0088">Drugs that may require dose modifications or cautious use with ATV include antifungal agents, antiarrhythmics, clarithromycin, colchicine, oral contraceptives, anticonvulsants, rifabutin, erectile dysfunction agents, H2 receptor antagonists, antacids, and buffered medications. Drugs that are contraindicated for coadministration with ATV include indinavir, nevirapine, etravirine, efavirenz (in treatment-experienced patients), HCV PIs, antihistamines, bepridil, simvastatin, lovastatin, antimycobacterials, cisapride, proton pump inhibitors, neurologic agents, ergot derivatives, St. John’s wort, and irinotecan (<link linkend="ch0134s0000li0005">5</link>).</para>
          <anchor id="ch0134s0000a0061"/>
          <beginpage pagenum="2205"/>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0004s0002">
        <title>Cobicistat</title>
        <anchor id="ch0134s0004a0005"/>
        <anchor id="ch0134s0000a0062"/>
        <sect3 id="ch0134s0004s0003">
          <title>Pharmacology</title>
          <anchor id="ch0134s0004a0006"/>
          <anchor id="ch0134s0000a0063"/>
          <para id="ch0134s0000p0089">Cobicistat (COBI or c) is a structural analogue of ritonavir, but it has no direct antiviral activity for HIV or HCV. Like ritonavir it serves as a pharmacoenhancer for other antiviral agents. It is a component of several fixed dose antiretroviral regimens: ATV/c, DRV/c, and EVG/c /FTC/ TDF (or TAF) (<link linkend="ch0134s0000li0048">48</link>, <link linkend="ch0134s0000li0049">49</link>). It is not interchangeable with ritonavir for boosting FPV, SQV, or TPV. COBI should be given with food and, it is 97 to 98% protein bound. The half-life is 3 to 4 h (higher with ATV than DRV), and it is excreted in feces and urine. COBI is a substrate and a very strong inhibitor of CYP3A4 as well as an inhibitor of CYP2D6 and P-glycoprotein.</para>
        </sect3>
        <sect3 id="ch0134s0004s0004">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0004a0007"/>
          <anchor id="ch0134s0000a0064"/>
          <anchor id="ch0134s0000a0065"/>
          <para id="ch0134s0000p0090">As an analogue of an HIV PI, COBI has a similar profile of drug interactions. It should not be administered with any PIs coformulated with ritonavir ((RTV or r) fosamprenavir, saquinavir, tipranavir, lopinavir). Other contraindicated drugs include efavirenz, nevirapine, antiarrhythmics, macrolide/ketolide antibiotics, antifungals, antimycobacterials, HCV antivirals, neurologic agents, erectile dysfunction drugs, and anticonvulsants.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0004s0003">
        <title>Darunavir</title>
        <anchor id="ch0134s0004a0008"/>
        <anchor id="ch0134s0000a0066"/>
        <sect3 id="ch0134s0004s0005">
          <title>Pharmacology</title>
          <anchor id="ch0134s0004a0009"/>
          <anchor id="ch0134s0000a0067"/>
          <para id="ch0134s0000p0091">The bioavailability of darunavir (DRV) is 37% alone and 82% when boosted with ritonavir, and the serum half-life is 15 h when boosted. It should be administered with food. The plasma protein binding is 95%, mainly to AAG. DRV is metabolized in the liver by CYP3A4, for which it is an inhibitor, and it is an inducer of CYP2C9 and P-glycoprotein. It is eliminated in the feces (79.5%) and the urine (13.9%). DRV boosted with ritonavir is a preferred PI in regimens with two NRTIs or NtRTIs for treatment-naive patients and pregnant women (<link linkend="ch0134s0000li0007">7</link>).</para>
        </sect3>
        <sect3 id="ch0134s0004s0006">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0004a0010"/>
          <anchor id="ch0134s0000a0068"/>
          <para id="ch0134s0000p0092">Drugs that may require dose modifications are the antidepressants paroxetine and sertraline, erectile dysfunction drugs, antifungals, atorvastatin, and rosuvastatin. Drugs that are contraindicated are efavirenz, etravirine, nevirapine, HCV PIs, neurologic agents, lovastatin, simvastatin, antimycobacterials, ergot derivatives, St. John’s wort, cisapride, anticonvulsants, and fluticasone.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0004s0004">
        <title>Fosamprenavir</title>
        <anchor id="ch0134s0004a0011"/>
        <anchor id="ch0134s0000a0069"/>
        <sect3 id="ch0134s0004s0007">
          <title>Pharmacology</title>
          <anchor id="ch0134s0004a0012"/>
          <anchor id="ch0134s0000a0070"/>
          <para id="ch0134s0000p0093">Fosamprenavir (FPV) is a prodrug with no antiviral activity which must be converted to amprenavir (APV) by cellular phosphatases (<link linkend="ch0134s0000li0050">50</link>). The bioavailability of APV is undetermined, and the serum half-life is 7.7 h. It can be administered with or without food. The plasma protein binding is 90%. APV is metabolized in the liver by CYP3A4, for which it is an inhibitor and inducer (<link linkend="ch0134s0000li0051">51</link>). It is eliminated in the feces (75%) and urine (14%). It is not known whether APV crosses the placenta (<link linkend="ch0134s0000li0007">7</link>). FPV boosted with ritonavir has high penetration in the CNS (<link linkend="ch0134s0000li0016">16</link>). However, it is not recommended for treatment-naive patients (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
        <sect3 id="ch0134s0004s0008">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0004a0013"/>
          <anchor id="ch0134s0000a0071"/>
          <para id="ch0134s0000p0094">Drugs that may require dose modifications or cautious use with FPV include erectile dysfunction drugs, antifungals, efavirenz, nevirapine, lopinavir-ritonavir (LPV/r), saquinavir, ritonavir, rifabutin, atorvastatin, and methadone. Drugs that are contraindicated for coadministration with FPV include etravirine, HCV protease and NS5A inhibitors, simvastatin, lovastatin, antimycobacterials, cardiac agents, cisapride, neurologic agents, antihistamines, ergot derivatives, St. John’s wort, and oral contraceptives (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0021">21</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0004s0005">
        <title>Indinavir</title>
        <anchor id="ch0134s0004a0014"/>
        <anchor id="ch0134s0000a0072"/>
        <sect3 id="ch0134s0004s0009">
          <title>Pharmacology</title>
          <anchor id="ch0134s0004a0015"/>
          <anchor id="ch0134s0000a0073"/>
          <para id="ch0134s0000p0095">The bioavailability of indinavir (IDV) is 65%, and the serum half-life is 1.5 to 2.0 h. IDV should be administered with low-caloric, low-fat food. It is 60% plasma protein bound, mainly to AAG (<link linkend="ch0134s0000li0052">52</link>). IDV is a substrate and an inhibitor of CYP3A4. Most of the drug (83%) is eliminated as metabolites in the feces. There is minimal passage of IDV across the placenta (<link linkend="ch0134s0000li0007">7</link>), but RTV-boosted IDV penetrates the CNS (<link linkend="ch0134s0000li0016">16</link>, <link linkend="ch0134s0000li0053">53</link>).</para>
          <para id="ch0134s0000p0096">RTV-boosted or unboosted IDV is not recommended as a component of PI-based regimens for treatment-naive patients, because of inconvenient dosing (unboosted) and the adverse complication of nephrolithiasis (RTV-boosted) (<link linkend="ch0134s0000li0005">5</link>).</para>
          <anchor id="ch0134s0000a0074"/>
          <beginpage pagenum="2207"/>
        </sect3>
        <sect3 id="ch0134s0004s0010">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0004a0016"/>
          <anchor id="ch0134s0000a0075"/>
          <para id="ch0134s0000p0097">Coadministered drugs that may require dose modifications or cautious use include DTG, ddI, EFV, NFV, NVP, RTV, SQV, antiarrhymics, antifungal agents, anticonvulsants, calcium channel blockers, atorvastatin, methadone, colchicine, and vitamin C, especially in grapefruit juice. Drugs that are contraindicated for coadministration with IDV include ATV, TPV, amiodarone, simvastatin, lovastatin, antimycobacterials, ergot derivatives, neurologic agents, cisapride, erectile dysfunction drugs, and St. John’s wort (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0021">21</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0004s0006">
        <title>Lopinavir-Ritonavir</title>
        <anchor id="ch0134s0004a0017"/>
        <anchor id="ch0134s0000a0076"/>
        <sect3 id="ch0134s0004s0011">
          <title>Pharmacology</title>
          <anchor id="ch0134s0004a0018"/>
          <anchor id="ch0134s0000a0077"/>
          <para id="ch0134s0000p0098">LPV is administered only in combination with low-dose RTV (LPV/r), and the combined formulation (Kaletra) is commercially available. The bioavailability of LPV/r is undetermined, and the half-life is 5 to 6 h. The oral tablet formulation can be taken with or without food; the oral solution should be taken with food of moderate fat content. The plasma protein binding is 99%, mainly to AAG. LPV/r is an inhibitor and a substrate of CYP3A4 and to a lesser extent CYP2D6. It is eliminated mainly in the feces (82.6%) and urine (10.4%) as metabolites. LPV crosses the placenta (<link linkend="ch0134s0000li0007">7</link>). LPV/r has high penetration of the CNS (<link linkend="ch0134s0000li0016">16</link>) and is a component of recommended alternative PI-based regimens with two NRTIs/NtRTIs for treatment-naive patients (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
        <sect3 id="ch0134s0004s0012">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0004a0019"/>
          <anchor id="ch0134s0000a0078"/>
          <para id="ch0134s0000p0099">Drugs that may require dose modifications when coadministered with LPV/r include erectile dysfunction drugs, rosuvastatin, atorvastatin, calcium channel blockers, and methadone. Drugs that are contraindicated for coadministration include DRV, FPV, TPV, simvastatin, lovastatin, oral contraceptives, neurologic agents, anticonvulsants, antiarrhythmics, antimycobacterials, antihistamines, cisapride, cardiac agents, HCV antivirals, ergot derivatives, fluticasone, and St. John’s wort (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0021">21</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0004s0007">
        <title>Nelfinavir</title>
        <anchor id="ch0134s0004a0020"/>
        <anchor id="ch0134s0000a0079"/>
        <sect3 id="ch0134s0004s0013">
          <title>Pharmacology</title>
          <anchor id="ch0134s0004a0021"/>
          <anchor id="ch0134s0000a0080"/>
          <para id="ch0134s0000p0100">The bioavailability of nelfinavir (NFV) is 20 to 80%, depending on whether it is administered with food, and the serum half-life is 3.5 to 5 h. NFV shows the greatest accumulation in cells of all the PIs; however, the protein binding is &gt;98% (<link linkend="ch0134s0000li0041">41</link>). It should be administered with food. NFV is both an inhibitor and inducer of CYP3A4 (<link linkend="ch0134s0000li0051">51</link>). Most of the drug (87%) is eliminated in the feces. There is minimal placental passage (<link linkend="ch0134s0000li0007">7</link>) and low penetration of the CNS (<link linkend="ch0134s0000li0016">16</link>). NFV is not recommended in PI-based regimens with two NRTIs and/or NtRTIs for treatment-naive patients because of lower antiretroviral efficacy (<link linkend="ch0134s0000li0005">5</link>). Boosting with RTV does not affect exposure.</para>
        </sect3>
        <sect3 id="ch0134s0004s0014">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0004a0022"/>
          <anchor id="ch0134s0000a0081"/>
          <para id="ch0134s0000p0101">Drugs that require dose modifications or cautious use include rifabutin, atorvastatin, anticonvulsants, methadone, and erectile dysfunction agents. Drugs that are contraindicated for coadministration with NFV include TPV, antiarrhythmics, simvastatin, lovastatin, antimycobacterials, cisapride, neurologic agents, antihistamines, ergot derivatives, St. John’s wort, proton pump inhibitors, and oral contraceptives (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0021">21</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0004s0008">
        <title>Ritonavir</title>
        <anchor id="ch0134s0004a0023"/>
        <anchor id="ch0134s0000a0082"/>
        <sect3 id="ch0134s0004s0015">
          <title>Pharmacology</title>
          <anchor id="ch0134s0004a0024"/>
          <anchor id="ch0134s0000a0083"/>
          <para id="ch0134s0000p0102">The oral bioavailability of ritonavir (RTV) is undetermined, and the serum half-life is 3 to 5 h. RTV should be administered with food. It is 98% plasma protein bound and is metabolized by CYP3A. The major metabolite is isopropyl thiazole, which has the same antiviral activity as the parent drug. RTV is eliminated in the feces (86.4%) and urine (11.3%) (<link linkend="ch0134s0000li0005">5</link>). Passage across the placenta is minimal (<link linkend="ch0134s0000li0007">7</link>).</para>
          <para id="ch0134s0000p0103">The main role of RTV in current HIV therapeutics is to enhance the pharmacokinetics of a second PI (<link linkend="ch0134s0000li0044">44</link>), because RTV is a very strong inhibitor of CYP3A4. Low-dose RTV is a pharmacoenhancer of IDV, FPV, SQV, LPV, ATV, TPV, and DRV. RTV alone in PI-based regimens is not recommended because of gastrointestinal intolerance (<link linkend="ch0134s0000li0005">5</link>). RTV-boosted PIs are recommended in combination with two NRTIs and/or NtRTIs in PI-based regimens for treatment-naive and treatment-experienced patients (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0044">44</link>).</para>
        </sect3>
        <sect3 id="ch0134s0004s0016">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0004a0025"/>
          <anchor id="ch0134s0000a0084"/>
          <para id="ch0134s0000p0104">As a very strong inhibitor of CYP3A4, RTV has numerous potential drug interactions requiring close monitoring (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0021">21</link>). Coadministered drugs that may require dose modifications or cautious use include antifungals, clarithromycin, atorvastatin, pravastatin, rosuvastatin, anticonvulsants, methadone, erectile dysfunction drugs, atovaquone, quinine, antidepressants, and theophylline. Drugs that are contraindicated for coadministration with RTV include ETR, antiarrhythmics, simvastatin, lovastatin, antimycobacterials, cisapride, neurologic agents, ergot derivatives, oral contraceptives, and St. John’s wort.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0004s0009">
        <title>Saquinavir</title>
        <anchor id="ch0134s0004a0026"/>
        <anchor id="ch0134s0000a0085"/>
        <sect3 id="ch0134s0004s0017">
          <title>Pharmacology</title>
          <anchor id="ch0134s0004a0027"/>
          <anchor id="ch0134s0000a0086"/>
          <para id="ch0134s0000p0105">The oral bioavailability of saquinavir (SQV) is approximately 4%. The serum half-life is 1 to 2 h. SQV is both a substrate and inhibitor of CYP3A4 and P-glycoprotein. It should be administered with food. SQV is 97% bound to plasma proteins and is eliminated mainly in the feces (81%) (<link linkend="ch0134s0000li0005">5</link>). There is minimal passage of SQV across the placenta (<link linkend="ch0134s0000li0007">7</link>) and very low penetration of the CNS (<link linkend="ch0134s0000li0016">16</link>). SQV RTV-boosted and unboosted regimens with two NRTIs and/or NtRTIs are not recommended for treatment-naive patients (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
        <sect3 id="ch0134s0004s0018">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0004a0028"/>
          <anchor id="ch0134s0000a0087"/>
          <para id="ch0134s0000p0106">Coadministered drugs or foods that require dose modifications or cautious use include antifungal agents, antiarrhythmics, atorvastatin, rosuvastatin, anticonvulsants, methadone, erectile dysfunction agents, proton pump inhibitors, and grapefruit juice. Drugs that are contraindicated for coadministration with SQV include TPV, DRV, antihistamines, fluticasone, simvastatin, lovastatin, antimycobacterials, cisapride, neurologic agents, oral contraceptives, ergot derivatives, HCV antivirals, St. John’s wort, garlic supplements, and dexamethasone (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0021">21</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0004s0010">
        <title>Tipranavir</title>
        <anchor id="ch0134s0004a0029"/>
        <anchor id="ch0134s0000a0088"/>
        <sect3 id="ch0134s0004s0019">
          <title>Pharmacology</title>
          <anchor id="ch0134s0004a0030"/>
          <anchor id="ch0134s0000a0089"/>
          <para id="ch0134s0000p0107">Tipranavir (TPV) is a nonpeptidic PI (<link linkend="ch0134s0000li0054">54</link>). The oral bioavailability is undetermined, and the half-life is 6 h. It can be administered with or without food. TPV is &gt;99.9% protein bound in plasma to both albumin and AAG. It is metabolized mainly through CYP3A4, and it is also a CYP3A4 and CYP2C19 inducer. TPV is eliminated in the feces (82.3%) and urine (4.4%). It is not known whether TPV crosses the placenta (<link linkend="ch0134s0000li0007">7</link>), and penetration of the CNS is low (<link linkend="ch0134s0000li0016">16</link>). TPV requires coadministration with RTV to reach effective levels in plasma (<link linkend="ch0134s0000li0043">43</link>, <link linkend="ch0134s0000li0055">55</link>). TPV is not recommended for use in PI-based regimens for treatment-naive patients. The current indicated use is in patients who are highly treatment experienced or who are infected with virus strains resistant to multiple PIs.</para>
        </sect3>
        <sect3 id="ch0134s0004s0020">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0004a0031"/>
          <anchor id="ch0134s0000a0090"/>
          <para id="ch0134s0000p0108">Coadministration of TPV with the following drugs may require dose modification: colchicine, rosuvastatin, methadone, antifungals, and anticonvulsants. Coadministration of the following drugs is contraindicated: ATV, ETR, FPV, LPV, NFV, SQV, cardiac agents, antimycobacterials, lovastatin, simvastatin, neurologic agents, ergot derivatives, cisapride, antihistamines, HCV antivirals, oral contraceptives, erectile dysfunction agents, St. John’s wort, and fluticasone (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0043">43</link>, <link linkend="ch0134s0000li0055">55</link>).</para>
        </sect3>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0005">
      <title>Entry Inhibitors</title>
      <anchor id="ch0134s0005a0001"/>
      <anchor id="ch0134s0000a0091"/>
      <para id="ch0134s0000p0109">Antiretroviral agents that target the entry of HIV into the host cell have been developed. Enfuvirtide (T20), a fusion inhibitor, was the first of these drugs to be approved. It is a linear synthetic peptide of 36<phrase role="small">L</phrase>-amino acids that binds to the first heptad repeat in the gp41 subunit of the HIV-1 envelope glycoprotein. The sequence of the peptide was derived from that of HIV-1 LAI, a subtype B strain (<link linkend="ch0134s0000li0056">56</link>). The binding prevents conformational changes that are required for fusion between the virus envelope and the cell membrane (<link linkend="ch0134s0000li0057">57</link>). Entry is inhibited, thereby preventing infection of the target cell.</para>
      <para id="ch0134s0000p0110">Maraviroc (MVC), a CCR5 antagonist, is a second drug that targets viral entry. The use of this drug is dependent on the prior determination of the viral tropism, because only virus strains utilizing the CCR5 coreceptor (R5) are susceptible. The rationale for this antiviral target is that coreceptor tropism of primary HIV-1 infection is most commonly CCR5, and the switch to CXCR4 or dual tropism occurs much later in the course of infection. Allosteric binding of MVC to the CCR5 coreceptor results in a conformational change, which inhibits HIV-1 gp120 binding and viral entry into the target cell (<link linkend="ch0134s0000li0058">58</link>). More recently, ibalizumab, a CD4 postattachment HIV inhibitor, became the first antibody to be approved for patients who experienced virological failure to all HIV drugs (<link linkend="ch0134s0000li0059">59</link>, <link linkend="ch0134s0000li0060">60</link>). Ibalizumab is active against HIV-1 resistant to all approved antiretroviral drugs and exhibits antiretroviral activity against R5-tropic, X4-tropic, and dual-tropic HIV-1. Phenotypic and genotypic test results show no evidence of cross-resistance among ibalizumab and any of the approved classes of antiretroviral drugs (<link linkend="ch0134s0000li0059">59</link>).</para>
      <sect2 id="ch0134s0005s0001">
        <title>Enfuvirtide</title>
        <anchor id="ch0134s0005a0002"/>
        <anchor id="ch0134s0000a0092"/>
        <sect3 id="ch0134s0005s0001">
          <title>Pharmacology</title>
          <anchor id="ch0134s0005a0003"/>
          <anchor id="ch0134s0000a0093"/>
          <para id="ch0134s0000p0111">The bioavailability of enfuvirtide (T20) by subcutaneous injection is 84% (<link linkend="ch0134s0000li0057">57</link>), and the serum half-life is 3.8 h. T20 is 92% protein bound in plasma. It is assumed that the metabolism of the drug produces the constituent amino acids, which enter the amino acid pool in the body and are recycled. It is not active against HIV-2, but there are recent data suggesting that it is active against HIV-1 non-B subtypes and possibly group O as well (<link linkend="ch0134s0000li0061">61</link>). Limited data indicate that T20 does not cross the placenta (<link linkend="ch0134s0000li0007">7</link>) and that it does not penetrate the CNS (<link linkend="ch0134s0000li0062">62</link>). T20 is not recommended for use in NNRTI- or PI-based regimens in treatment-naive patients, because of its low barrier to resistance, and it requires injection for delivery. T20 is currently used in salvage therapy regimens for treatment-experienced patients who have not responded to their current antiretroviral therapy (<link linkend="ch0134s0000li0007">7</link>, <link linkend="ch0134s0000li0063">63</link>).</para>
        </sect3>
        <sect3 id="ch0134s0005s0002">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0005a0004"/>
          <anchor id="ch0134s0000a0094"/>
          <para id="ch0134s0000p0112">There is no evidence that T20 induces or inhibits any of the CYP450 isoenzymes; therefore, it is unlikely to interact with any of the drugs that are metabolized by the CYP450 system. No significant interactions with other antiretroviral drugs have been identified (<link linkend="ch0134s0000li0057">57</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0005s0002">
        <title>Maraviroc</title>
        <anchor id="ch0134s0005a0005"/>
        <anchor id="ch0134s0000a0095"/>
        <sect3 id="ch0134s0005s0003">
          <title>Pharmacology</title>
          <anchor id="ch0134s0005a0006"/>
          <anchor id="ch0134s0000a0096"/>
          <para id="ch0134s0000p0113">Maraviroc (MVC) prevents HIV-1 binding of CCR5 (R5) strains to the CCR5 coreceptor but has no activity against CXCR4 (X4) strains. The bioavailability is 33%, and the serum half-life is 14 to 18 h. It is 76% protein bound in the plasma to both albumin and AAG. It can be administered with or without food. MVC is a substrate for CYP3A4 and P-glycoprotein and is eliminated in the feces (76%) and urine (20%). It is not known whether MVC crosses the placenta (<link linkend="ch0134s0000li0007">7</link>). Although MVC may be used in combination with two NRTIs and/or NtRTIs in treatment-naive patients known to have R5-tropic virus, it is not considered a preferred or alternative agent because of its twice-daily dosing schedule and need for tropism testing (<link linkend="ch0134s0000li0007">7</link>, <link linkend="ch0134s0000li0064">64</link>).</para>
        </sect3>
        <sect3 id="ch0134s0005s0004">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0005a0007"/>
          <anchor id="ch0134s0000a0097"/>
          <para id="ch0134s0000p0114">Coadministration of MVC with the following drugs may require dose modification: antifungals, anticonvulsants, rifabutin, EFV, EVG boosted with COBI (EVG/c), raltegravir (RAL), ETR, and all PIs except TPV. Coadministration with antimycobacterials, HCV antivirals, and St. John’s wort is contraindicated.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0005s0003">
        <title>Ibalizumab</title>
        <anchor id="ch0134s0005a0008"/>
        <anchor id="ch0134s0000a0098"/>
        <sect3 id="ch0134s0005s0005">
          <title>Pharmacology</title>
          <anchor id="ch0134s0005a0009"/>
          <anchor id="ch0134s0000a0099"/>
          <para id="ch0134s0000p0115">Ibalizumab is a recombinant humanized IgG4 monoclonal antibody that inhibits HIV entry into the CD4 T cell while preserving normal immune function. It is FDA approved as an intravenous infusion and used in combination with other antiretrovirals for the treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 infection (<link linkend="ch0134s0000li0059">59</link>, <link linkend="ch0134s0000li0060">60</link>, <link linkend="ch0134s0000li0065">65</link>, <link linkend="ch0134s0000li0066">66</link>).</para>
          <para id="ch0134s0000p0116">Human pharmacokinetic data for ibalizumab are derived from several clinical trials (<link linkend="ch0134s0000li0065">65</link>, <link linkend="ch0134s0000li0067">67</link>). In the phase III study, a loading dose of 2,000 mg, followed by 800 mg every 14 days, was utilized (<link linkend="ch0134s0000li0060">60</link>). The estimated half-life of ibalizumab with maintenance dosing is 72 to 84 h. This is shorter than an IgG molecule under normal physiological circumstances.</para>
        </sect3>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0006">
      <title>Drug Interactions</title>
      <anchor id="ch0134s0006a0001"/>
      <anchor id="ch0134s0000a0100"/>
      <para id="ch0134s0000p0117">When administered with other medications, including antiretrovirals, ibalizumab does not require dose adjustment. No drug interaction studies have been conducted, but based on ibalizumab’s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. No studies have been performed to evaluate the effect of hepatic or renal dysfunction, including effects from renal replacement therapy. Renal and hepatic dysfunction are not expected to alter the pharmacokinetic parameters.</para>
    </sect1>
    <sect1 id="ch0134s0007">
      <title>Integrase Strand Transfer Inhibitors</title>
      <anchor id="ch0134s0007a0001"/>
      <anchor id="ch0134s0000a0101"/>
      <para id="ch0134s0000p0118">INSTIs, a class of antiretroviral drugs, target the HIV-1 integrase enzyme that mediates transfer of the reverse-transcribed HIV-1 DNA into the host chromosome. The activity of this enzyme includes 3′ processing of the reverse transcribed DNA to generate hydroxyls at the 3′ ends of both strands, followed by strand transfer that joins viral and host DNA. The approved integrase inhibitors are recommended with two NRTI/NtRTIs for first-line therapy regimens for treatment-naive patients (<link linkend="ch0134s0000li0001">1</link>, <link linkend="ch0134s0000li0007">7</link>). This drug class includes bictegravir (BIC), DTG, EVG, RAL, and cabotegravir (CAB) (<link linkend="ch0134s0000li0068">68</link>–<link linkend="ch0134s0000li0070">70</link>).</para>
      <para id="ch0134s0000p0119">Very rare resistance has been reported in individuals receiving DTG-based therapy, and no resistance has been reported in those receiving BIC-based regimens. Because of this high barrier to resistance and tolerability, BIC- and DTG-containing regimens may be considered before resistance test results are available (<link linkend="ch0134s0000li0071">71</link>, <link linkend="ch0134s0000li0072">72</link>).</para>
      <para id="ch0134s0000p0120">Among cART-naive individuals, initiation of INSTI-containing regimens has been associated with greater weight gain than NNRTI or boosted PI regimens. Further investigations will establish the mechanism and risk factors for weight gain, and whether it is associated with cardiometabolic risk (<link linkend="ch0134s0000li0073">73</link>, <link linkend="ch0134s0000li0074">74</link>).</para>
      <para id="ch0134s0000p0121">Data suggest that there is an increased risk of neural tube defect in infants born to women who were receiving dolutegravir at the time of conception compared to infants who were exposed to other forms of cART (0.1%) (<link linkend="ch0134s0000li0075">75</link>–<link linkend="ch0134s0000li0078">78</link>). Furthermore, before initiating an INSTI-based regimen in a person with childbearing potential, the clinician should discuss the risk and benefits of starting this regimen with patients to allow them to make an informed decision.</para>
      <sect2 id="ch0134s0007s0001">
        <title>Raltegravir</title>
        <anchor id="ch0134s0007a0002"/>
        <anchor id="ch0134s0000a0102"/>
        <sect3 id="ch0134s0007s0001">
          <title>Pharmacology</title>
          <anchor id="ch0134s0007a0003"/>
          <anchor id="ch0134s0000a0103"/>
          <para id="ch0134s0000p0122">Raltegravir (RAL) is active against HIV-1 group O isolates (<link linkend="ch0134s0000li0033">33</link>) as well as HIV-1 group M and HIV-2 (<link linkend="ch0134s0000li0079">79</link>). Its bioavailability has not been established, and its serum half-life is 7 to 12 h. It is 83% protein bound in plasma. RAL crosses the placenta (<link linkend="ch0134s0000li0007">7</link>). It can be administered with or without food. It is eliminated in the feces (51%) and urine (32%). Clearance is by UDP-glucuronosyltransferase glucuronidation. It is not metabolized by the CYP450 enzymes. RAL with FTC/TDF or TAF is now an INSTI-based recommended regimen for treatment-naive patients (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0080">80</link>, <link linkend="ch0134s0000li0081">81</link>).</para>
        </sect3>
        <sect3 id="ch0134s0007s0002">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0007a0004"/>
          <anchor id="ch0134s0000a0104"/>
          <para id="ch0134s0000p0123">Because RAL is not an inducer, inhibitor, or substrate of CYP450 enzymes, it does not affect the pharmacokinetics of most of the drugs that interact with the other classes of antiretroviral agents (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0079">79</link>, <link linkend="ch0134s0000li0081">81</link>). Coadministration of the following drugs may require dose modification: antacids, antimycobacterials, anticonvulsants, ETR, and TPV boosted with RTV (TPV/r).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0007s0002">
        <title>Elvitegravir</title>
        <anchor id="ch0134s0007a0005"/>
        <anchor id="ch0134s0000a0105"/>
        <sect3 id="ch0134s0007s0003">
          <title>Pharmacology</title>
          <anchor id="ch0134s0007a0006"/>
          <anchor id="ch0134s0000a0106"/>
          <para id="ch0134s0000p0124">Currently, elvitegravir (EVG) is approved only in coformulation with other antivirals plus the pharmacoenhancer COBI (EVG/COBI/TDF or TAF/FTC; Stribild). It achieves therapeutic concentrations only when combined with COBI. EVG has a serum half-life of 13 h. It is 99% protein bound in plasma (<link linkend="ch0134s0000li0082">82</link>). EVG should be taken with food. Cerebrospinal fluid and placental penetration levels are unknown. The combination pill EVG/COBI/TDF/FTC is a recommended option for treatment-naive patients (<link linkend="ch0134s0000li0005">5</link>).</para>
          <para id="ch0134s0000p0125">EVG is a CYP3A4 substrate and CYP2C9 inducer. COBI was developed for use with EVG, because COBI has no anti-HIV activity, but like RTV, it is a strong inhibitor of CYP3A4. The result is higher concentrations of EVG at lower doses (<link linkend="ch0134s0000li0083">83</link>). COBI also interacts with intestinal transport proteins to increase absorption of other anti-HIV drugs, including ATV/c and DRV/c (<link linkend="ch0134s0000li0048">48</link>, <link linkend="ch0134s0000li0049">49</link>, <link linkend="ch0134s0000li0081">81</link>).</para>
        </sect3>
        <sect3 id="ch0134s0007s0004">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0007a0007"/>
          <anchor id="ch0134s0000a0107"/>
          <para id="ch0134s0000p0126">EVG is primarily metabolized by the CYP450 pathway and therefore interacts with other drugs that utilize this pathway. Because EVG is available only as a coformulated tablet, data regarding interactions of EVG alone are lacking. EVG/COBI/TDF/FTC administration should be separated from antacid administration by more than 2 hours. Coadministration with NVP, RPV, ATV/c (or r), DRV/c (or r), FPV/r, LPV/r, SQV/r, TPV/r, antimycobacterials, anticonvulsants, antidepressants, antifungal agents, neurologic agents, HCV antivirals, ergot derivatives, lovastatin, simvastatin, and St. John’s wort is contraindicated (<link linkend="ch0134s0000li0005">5</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0007s0003">
        <title>Dolutegravir</title>
        <anchor id="ch0134s0007a0008"/>
        <anchor id="ch0134s0000a0108"/>
        <sect3 id="ch0134s0007s0005">
          <title>Pharmacology</title>
          <anchor id="ch0134s0007a0009"/>
          <anchor id="ch0134s0000a0109"/>
          <para id="ch0134s0000p0127">DTG is approved for use in both HIV treatment-naive and treatment-experienced patients. It has been shown to have little cross-resistance with the other INSTIs, RAL, and EVG (<link linkend="ch0134s0000li0084">84</link>). DTG has a 14-hour half-life and can therefore be administered once a day in select patients. Twice-daily dosing is recommended in patients with known or suspected INSTI resistance and when coadministered with EFV, FPV/r, TPV/r, or rifampin (<link linkend="ch0134s0000li0085">85</link>). DTG can be administered with or without food (<link linkend="ch0134s0000li0086">86</link>). It is a P-glycoprotein substrate and is eliminated in the feces (53%) and urine (31%). DTG does not inhibit CYP450 enzymes, and therefore, like RAL, it does not interact with drugs that are metabolized by these enzymes.</para>
          <para id="ch0134s0000p0128">It can be used as a two-drug combination, e.g., dolutegravir/lamivudine (Dovato) or dolutegravir/rilpivirine (Juluca), as a complete regimen for the treatment of HIV-1 infection in adults with no antiretroviral treatment history, or to replace current antiretroviral regimens in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with unknown substitutions associated with resistance to the individual components (<link linkend="ch0134s0000li0087">87</link>, <link linkend="ch0134s0000li0088">88</link>).</para>
        </sect3>
        <sect3 id="ch0134s0007s0006">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0007a0010"/>
          <anchor id="ch0134s0000a0110"/>
          <para id="ch0134s0000p0129">Coadministration with the following drugs may require dose modification: anticonvulsants, EFV, FPV/r, TPV/r, and mycobacterials. The following drugs should not be coadministered with DTG: carbamazepine, phenytoin, NVP, phenobarbital, and St. John’s wort.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0007s0004">
        <title>Bictegravir</title>
        <anchor id="ch0134s0007a0011"/>
        <anchor id="ch0134s0000a0111"/>
        <sect3 id="ch0134s0007s0007">
          <title>Pharmacology</title>
          <anchor id="ch0134s0007a0012"/>
          <anchor id="ch0134s0000a0112"/>
          <para id="ch0134s0000p0130">Bictegravir (BIC) is available as the fixed-dose combination of bictegravir, emtricitabine, and tenofovir and it is recommended as initial therapy by the HHS Antiretroviral Panel.<emphasis>In vitro</emphasis> studies of BIC against INSTI-resistant strains suggest that it could be active against many known variants with INSTI-associated mutations (<link linkend="ch0134s0000li0089">89</link>). It has a half-life of 18 hours, is highly protein bound (99%), and is mainly eliminated through UGT1A1 glucuronidation and CYP3A4 oxidation equally, with 35% excreted in the urine and 60% excreted in feces (<link linkend="ch0134s0000li0090">90</link>). Bictegravir can be administered with or without food.</para>
        </sect3>
        <sect3 id="ch0134s0007s0008">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0007a0013"/>
          <anchor id="ch0134s0000a0113"/>
          <para id="ch0134s0000p0131">BIC is a substrate of CYP3A and UGT1A1 and inhibits OCT2 and MATE1. Antacids containing Mg, Al, Ca, and Fe should be given 2 hours before BIC administration. Coadministration of anticonvulsants such as phenobarbital, phenytoin, or oxcarbazepine should be avoided. Rifampin is contraindicated simultaneously with bictegravir-containing regimens (<link linkend="ch0134s0000li0089">89</link>).</para>
          <anchor id="ch0134s0000a0114"/>
          <beginpage pagenum="2208"/>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0007s0005">
        <title>Cabotegravir</title>
        <anchor id="ch0134s0007a0014"/>
        <anchor id="ch0134s0000a0115"/>
        <sect3 id="ch0134s0007s0009">
          <title>Pharmacology</title>
          <anchor id="ch0134s0007a0015"/>
          <anchor id="ch0134s0000a0116"/>
          <para id="ch0134s0000p0132">Cabotegravir (CAB) in combination with rilpivirine is indicated for treatment of HIV-1-infected adults who are virologically suppressed (HIV-1 RNA less than 50 copies/ml) on a stable antiretroviral regimen with no history of virologic failure or known resistance affecting either of the component drugs (<link linkend="ch0134s0000li0091">91</link>–<link linkend="ch0134s0000li0094">94</link>). Cabotegravir has a half-life of 41 hours, is highly protein bound (&gt;99%), and is primarily eliminated by uridine diphosphate–glucuronosyl transferase UGT1A1 with some contribution from UGT1A9. It is excreted 27% in the urine and 59% in the feces (<link linkend="ch0134s0000li0005">5</link>). No dosage adjustment for cabotegravir is necessary for patients with severe renal impairment, but close monitoring is necessary. The pharmacokinetics of cabotegravir in patients with end-stage renal disease is unknown. It can be administered with or without food.</para>
        </sect3>
        <sect3 id="ch0134s0007s0010">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0007a0016"/>
          <anchor id="ch0134s0000a0117"/>
          <para id="ch0134s0000p0133">Drugs that are strong inducers of UGT1A1 or 1A9 can decrease cabotegravir plasma concentrations and may result in reduction of viral suppression. Among these medications are anticonvulsants (carbamazepine, phenobarbital, phenytoin) and antimycobacterials (rifampin, rifapentine). Oral contraceptives containing levonorgestrel and ethinyl estradiol can be coadministered with cabotegravir without dose adjustment. Coadministration with rifabutin is contraindicated (<link linkend="ch0134s0000li0091">91</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0007s0006">
        <title>AGENTS AGAINST HEPATITIS C VIRUS</title>
        <anchor id="ch0134s0007a0017"/>
        <anchor id="ch0134s0000a0118"/>
        <para id="ch0134s0000p0134">Increased understanding of the genome and virology of HCV has led to advances in the efficacy and tolerability of HCV treatment. Multiple direct-acting antivirals (DAAs) which interfere with specific steps in HCV replication have been developed. This has led to combination treatment regimens that are interferon free, pangenotypic, and administered in single daily doses. The four classes of DAAs defined according to their mechanism of action and therapeutic target are the nonstructural protein (NS) NS3/4A protease inhibitors (PIs), NS5B nucleoside polymerase inhibitors, NS5B nonnucleoside polymerase inhibitors, and NS5A inhibitors (<link linkend="ch0134s0000li0095">95</link>). DAAs are available in multiple fixed-dose combinations (summarized in <anchor id="ch0134s0000a0119"/><link linkend="ch0134s0000a0130">Table 2</link>). While ribavirin (RBV) is still used in combination with DAAs, interferon-based regimens are no longer used because of their poor tolerability. Given the rapidly changing landscape of HCV treatment, please visit <ulink url="http://www.hcvguidelines.org">www.hcvguidelines.org</ulink> for the most current information (<link linkend="ch0134s0000li0096">96</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0008">
      <title>Nonstructural Protein (NS) NS3/4A Protease Inhibitors (PIs)</title>
      <anchor id="ch0134s0008a0001"/>
      <anchor id="ch0134s0000a0120"/>
      <para id="ch0134s0000p0135">NS3/4A PIs inhibit a serine protease involved in posttranslational processing of HCV by blocking the NS3 catalytic site or the NS3/NS4A interaction. In addition, NS3/4A PIs prevent blockage of TIR domain-containing adaptor protein-inducing interferon beta (TRIF)-mediated Toll-like receptor and Cardif-mediated retinoic acid inducible gene 1 signaling, which results in induction of interferons and promotion of viral elimination (<link linkend="ch0134s0000li0097">97</link>). The first-generation PIs telaprevir and boceprevir have been replaced by more potent and better-tolerated antivirals. Grazoprevir, paritaprevir, simeprevir, voxilaprevir, and glecaprevir are PIs available in the United States.</para>
      <sect2 id="ch0134s0008s0001">
        <title>Grazoprevir</title>
        <anchor id="ch0134s0008a0002"/>
        <anchor id="ch0134s0000a0121"/>
        <sect3 id="ch0134s0008s0001">
          <title>Pharmacology</title>
          <anchor id="ch0134s0008a0003"/>
          <anchor id="ch0134s0000a0122"/>
          <para id="ch0134s0000p0136">Grazoprevir is a pangenotypic PI that is only available in combination with the NS5A inhibitor elbasvir (<link linkend="ch0134s0000li0098">98</link>). Its absorption is not affected by meals and it is 27% bioavailable. It has a predominantly hepatic distribution and is highly protein bound. It is metabolized hepatically, has a half-life of 31 hours, and is predominantly excreted in the feces. It can be used in patients with any degree of renal impairment, including those on dialysis, without the need for dose modifications. It is contraindicated in patients with Child-Pugh class B or C cirrhosis.</para>
        </sect3>
        <sect3 id="ch0134s0008s0002">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0008a0004"/>
          <anchor id="ch0134s0000a0123"/>
          <para id="ch0134s0000p0137">Grazoprevir is metabolized by CYP3A enzymes and should not be given with moderate and strong inducers or strong inhibitors of this system (<link linkend="ch0134s0000li0099">99</link>). It is also a substrate of OATP1B1/3 and should not be coadministered with drugs that inhibit this enzyme. Coadministration is contraindicated with rifampin, phenytoin, carbamazepine, St. John’s wort, cyclosporine, and some antiretroviral agents such as PIs and efavirenz (EFV). Coadministration is not recommended with nafcillin, ketoconazole, etravirine, cobicistat, or modafinil.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0008s0002">
        <title>Paritaprevir</title>
        <anchor id="ch0134s0008a0005"/>
        <anchor id="ch0134s0000a0124"/>
        <sect3 id="ch0134s0008s0003">
          <title>Pharmacology</title>
          <anchor id="ch0134s0008a0006"/>
          <anchor id="ch0134s0000a0125"/>
          <para id="ch0134s0000p0138">Paritaprevir is coadministered with low-dose ritonavir for a pharmacologic boosting effect, and these drugs are available as a fixed-dose combination with ombitasvir, which is an NS5A inhibitor (<link linkend="ch0134s0000li0100">100</link>). Ombitasvir, paritaprevir, and ritonavir are typically given with the nonnucleoside NS5B inhibitor dasabuvir. Paritaprevir is well absorbed when administered with food, has a 53% bioavailability, and is very highly protein bound. Its half-life is 5.5 hours, and it is primarily excreted in the feces. Renal insufficiency is not expected to clinically affect levels of paritaprevir, and no dose adjustment is warranted by mild hepatic impairment. Its use is contraindicated in moderate to severe (Child-Pugh classes B and C) hepatic impairment.</para>
        </sect3>
        <sect3 id="ch0134s0008s0004">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0008a0007"/>
          <anchor id="ch0134s0000a0126"/>
          <para id="ch0134s0000p0139">Paritaprevir is metabolized by CYP3A4 and to a lesser extent by CYP3A5 (<link linkend="ch0134s0000li0101">101</link>). Common drugs that should not be coadministered are anticonvulsants, rifampin, St. John’s wort, certain oral contraceptives, and salmeterol. Close monitoring with statins, cyclosporine, tacrolimus, and antiarrhythmics is warranted.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0008s0003">
        <title>Simeprevir</title>
        <anchor id="ch0134s0008a0008"/>
        <anchor id="ch0134s0000a0127"/>
        <sect3 id="ch0134s0008s0005">
          <title>Pharmacology</title>
          <anchor id="ch0134s0008a0009"/>
          <anchor id="ch0134s0000a0128"/>
          <para id="ch0134s0000p0140">Simeprevir was the first available second-generation PI, and it has been used in combination with sofosbuvir with or without ribavirin for chronic genotype 1 infection (<link linkend="ch0134s0000li0102">102</link>). It has a bioavailability of 62% with food and is very highly protein bound. Its half-life is 41 hours, and it is primarily excreted in the feces. No dose adjustment is necessary with renal insufficiency, and its use is not recommended in patients with moderate or severe (Child-Pugh classes B and C) hepatic impairment.</para>
          <anchor id="ch0134s0000a0129"/>
          <beginpage pagenum="2209"/>
          <table id="ch0134s0000t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0134s0000a0130"/><link linkend="ch0134s0000a0119">TABLE 2</link></phrase></emphasis> Antiviral agents for HCV therapy<superscript><link linkend="ch0134s0000a0135"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0131"/>
</title>
            
            <tgroup cols="4">
              <tbody>
                <row>
                  <entry><phrase role="center">Antiviral agents and approved fixed combinations</phrase>
                  </entry>
                  <entry><phrase role="center">Trade name (pharmaceutical company<superscript><link linkend="ch0134s0000a0136"><emphasis>b</emphasis></link></superscript>)</phrase>
                    <anchor id="ch0134s0000a0132"/>
                  </entry>
                  <entry><phrase role="center">Mechanism of action/route of administration</phrase>
                  </entry>
                  <entry><phrase role="center">Major adverse effects</phrase>
                  </entry>
                </row>
                <row>
                  <entry>Ribavirin</entry>
                  <entry>Copegus (Genentech)</entry>
                  <entry>Mechanism not established</entry>
                  <entry>Anemia<superscript><link linkend="ch0134s0000a0137"><emphasis>c</emphasis></link></superscript><anchor id="ch0134s0000a0133"/>, myocardial infarction, teratogenic, hypersensitivity, impairment of pulmonary function, GI symptoms<superscript><link linkend="ch0134s0000a0138"><emphasis>d</emphasis></link></superscript><anchor id="ch0134s0000a0134"/></entry>
                </row>
                <row>
                  <entry>Rebetol (Merck)</entry>
                  <entry>Administered orally only in combination with another DAA</entry>
                </row>
                <row>
                  <entry>Sofosbuvir</entry>
                  <entry>Sovaldi (Gilead)</entry>
                  <entry><para id="ch0134s0000p0141">A nucleotide analogue inhibitor of HCV NS5B polymerase; inhibits viral RNA synthesis</para>
                    <para id="ch0134s0000p0142">Administered orally</para>
                  </entry>
                  <entry>Fatigue, insomnia, headache, GI symptoms, bradycardia with amiodarone</entry>
                </row>
                <row>
                  <entry>Simeprevir</entry>
                  <entry>Olysio (Janssen)</entry>
                  <entry><para id="ch0134s0000p0143">Binds to NS3/4A protease active site, preventing viral replication</para>
                    <para id="ch0134s0000p0144">Administered orally</para>
                  </entry>
                  <entry>Photosensitivity, rash, bradycardia with amiodarone</entry>
                </row>
                <row>
                  <entry>Sofosbuvir + ledipasvir</entry>
                  <entry>Harvoni (Gilead)</entry>
                  <entry><para id="ch0134s0000p0145">NS5A inhibitor (ledipasvir) and nucleotide analogue inhibitor of HCV NS5B polymerase (sofosbuvir)</para>
                    <para id="ch0134s0000p0146">Administered orally</para>
                  </entry>
                  <entry>Fatigue, insomnia, headache, GI symptoms</entry>
                </row>
                <row>
                  <entry>Ombitasvir + paritaprevir + ritonavir + dasabuvir</entry>
                  <entry>Viekira Pak (AbbVie)</entry>
                  <entry><para id="ch0134s0000p0147">NS5A inhibitor (ombitasvir), NS3/4A protease inhibitor (paritaprevir), and NS5B RNA polymerase inhibitor (dasabuvir)</para>
                    <para id="ch0134s0000p0148">Ritonavir is an HIV protease inhibitor with no anti-HCV activity</para>
                  </entry>
                  <entry>Fatigue, rash, GI symptoms, insomnia, pruritus</entry>
                </row>
                <row>
                  <entry>Ombitasvir + paritaprevir + ritonavir</entry>
                  <entry>Technivie (AbbVie)</entry>
                  <entry>Same combination of antiviral agents as above, without dasabuvir</entry>
                  <entry>Same as above</entry>
                </row>
                <row>
                  <entry>Grazoprevir + elbasvir</entry>
                  <entry>Zepatier (Merck)</entry>
                  <entry>NS5A inhibitor (elbasvir), NS3/4A protease inhibitor (grazoprevir)</entry>
                  <entry>Fatigue, headache, GI symptoms</entry>
                </row>
                <row>
                  <entry>Daclatasvir</entry>
                  <entry>Daklinza (Bristol-Meyers Squibb)</entry>
                  <entry>NS5A inhibitor for use with sofosbuvir (NS5B inhibitor)</entry>
                  <entry>Fatigue, headache</entry>
                </row>
                <row>
                  <entry>Velpatasvir + sofosbuvir</entry>
                  <entry>Epclusa (Gilead)</entry>
                  <entry>NS5A inhibitor (velpatasvir), NS5B inhibitor (sofosbuvir)</entry>
                  <entry>Fatigue, headache</entry>
                </row>
                <row>
                  <entry>Voxilaprevir + velpatasvir + sofosbuvir</entry>
                  <entry>Vosevi (Gilead)</entry>
                  <entry>NS3/4A protease inhibitor (voxilaprevir), NS5A inhibitor (velpatasvir), NS5B inhibitor (sofosbuvir)</entry>
                  <entry>Headache, fatigue, GI symptoms</entry>
                </row>
                <row>
                  <entry>Glecaprevir + pibrentasvir</entry>
                  <entry>Mavyret (Gilead)</entry>
                  <entry>NS3/4A protease inhibitor (glecaprevir), NS5A inhibitor (pibrentasvir)</entry>
                  <entry>Headache, fatigue</entry>
                </row>
              </tbody>
            </tgroup>
          </table>
          <para id="ch0134s0000p0149" role="table-footnote"><superscript><link linkend="ch0134s0000a0131"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0135"/>Note: all DAA HCV antiviral agents carry the warning that HBV reactivation has been reported in coinfected patients being treated for HCV but not HBV and can lead to fulminant hepatitis.</para>
          <para id="ch0134s0000p0150" role="table-footnote"><superscript><link linkend="ch0134s0000a0132"><emphasis>b</emphasis></link></superscript><anchor id="ch0134s0000a0136"/>Pharmaceutical companies: AbbVie, North Chicago, IL; Bristol-Meyers Squibb, Princeton, NJ; Genentech, San Francisco, CA; Gilead, Foster City, CA; Janssen Pharmaceutical, Beerse, Belgium; Merck &amp; Co., Inc., Whitehouse Station, NJ; Roche Pharmaceuticals, Nutley, NJ.</para>
          <para id="ch0134s0000p0151" role="table-footnote"><superscript><link linkend="ch0134s0000a0133"><emphasis>c</emphasis></link></superscript><anchor id="ch0134s0000a0137"/>Ribavirin can cause anemia via hemolysis or decreased red cell production.</para>
          <para id="ch0134s0000p0152" role="table-footnote"><superscript><link linkend="ch0134s0000a0134"><emphasis>d</emphasis></link></superscript><anchor id="ch0134s0000a0138"/>GI (gastrointestinal) symptoms include nausea, vomiting, and diarrhea.</para>
        </sect3>
        <sect3 id="ch0134s0008s0006">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0008a0010"/>
          <anchor id="ch0134s0000a0139"/>
          <para id="ch0134s0000p0153">Simeprevir undergoes oxidative metabolism by CYP3A4 and possibly CYP2C8 and CYP2C19 (<link linkend="ch0134s0000li0102">102</link>). Significant inducers or inhibitors of these enzymes will lead to alterations in simeprevir concentrations. Simeprevir in turn can affect the levels of other drugs by inhibiting OATP1B1/3. Coadministration with ritonavir, HIV protease inhibitors, efavirenz, nevirapine, statins, St. John’s wort, and cyclosporine among many others is not recommended. Simeprevir can be safely administered with tacrolimus or sirolimus.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0008s0004">
        <title>Voxilaprevir</title>
        <anchor id="ch0134s0008a0011"/>
        <anchor id="ch0134s0000a0140"/>
        <sect3 id="ch0134s0008s0007">
          <title>Pharmacology</title>
          <anchor id="ch0134s0008a0012"/>
          <anchor id="ch0134s0000a0141"/>
          <para id="ch0134s0000p0154">Voxilaprevir is a pangenotypic inhibitor of the NS3/4A protease that has been studied in combination with sofosbuvir and velpatasvir for previously treated patients without sustained virologic response (<link linkend="ch0134s0000li0103">103</link>). It is well absorbed and highly protein bound and is primarily excreted in the feces. No dosage adjustment is required for mild or moderate renal impairment, and use is not recommended in patients with moderate or severe hepatic impairment.</para>
          <anchor id="ch0134s0000a0142"/>
          <beginpage pagenum="2210"/>
        </sect3>
        <sect3 id="ch0134s0008s0008">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0008a0013"/>
          <anchor id="ch0134s0000a0143"/>
          <para id="ch0134s0000p0155">Voxilaprevir is metabolized through CYP3A4. Coadministration with phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifapentine, atazanavir, lopinavir, tipranavir, efavirenz, and cyclosporine is not recommended (<link linkend="ch0134s0000li0104">104</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0008s0005">
        <title>Glecaprevir</title>
        <anchor id="ch0134s0008a0014"/>
        <anchor id="ch0134s0000a0144"/>
        <sect3 id="ch0134s0008s0009">
          <title>Pharmacology</title>
          <anchor id="ch0134s0008a0015"/>
          <anchor id="ch0134s0000a0145"/>
          <para id="ch0134s0000p0156">Glecaprevir is a pangenotypic inhibitor of the NS3/4A protease that has been formulated in combination with the NS5A inhibitor pibrentasvir for previously treated patients without sustained virologic response (<link linkend="ch0134s0000li0105">105</link>). It is highly protein bound and is primarily excreted in feces. No dosage adjustment is required with mild, moderate, or severe renal impairment, including those on dialysis. It is not recommended in patients with moderate or severe hepatic impairment.</para>
        </sect3>
        <sect3 id="ch0134s0008s0010">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0008a0016"/>
          <anchor id="ch0134s0000a0146"/>
          <para id="ch0134s0000p0157">Glecaprevir is metabolized by CYP3A. Coadministration with digoxin, carbamazepine, rifampin, ethinyl estradiol-containing medications such as combined oral contraceptives, St. John’s wort, atazanavir, darunavir, lopinavir, ritonavir, HMG-CoA reductase inhibitors, and cyclosporine is not recommended (<link linkend="ch0134s0000li0105">105</link>).</para>
        </sect3>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0009">
      <title>NS5A Inhibitors</title>
      <anchor id="ch0134s0009a0001"/>
      <anchor id="ch0134s0000a0147"/>
      <para id="ch0134s0000p0158">The NS5A protein plays a role in hepatitis C viral replication and assembly (<link linkend="ch0134s0000li0106">106</link>, <link linkend="ch0134s0000li0107">107</link>). However, the precise molecular mechanisms by which it accomplishes these functions remain poorly characterized. While NS5A inhibitors are effective across all genotypes, they have a low barrier to resistance and variable toxicity profiles. They have been shown to have very high sustained virologic response rates among patients with genotype 1 infection when given in combination with other direct-acting antivirals with or without ribavirin (<link linkend="ch0134s0000li0108">108</link>, <link linkend="ch0134s0000li0109">109</link>). Available NS5A inhibitors are ledipasvir, ombitasvir, elbasvir, velpatasvir, and pibrentasvir, each available in fixed-dose combinations with other direct-acting antivirals, and daclatasvir.</para>
      <sect2 id="ch0134s0009s0001">
        <title>Ledipasvir</title>
        <anchor id="ch0134s0009a0002"/>
        <anchor id="ch0134s0000a0148"/>
        <sect3 id="ch0134s0009s0001">
          <title>Pharmacology</title>
          <anchor id="ch0134s0009a0003"/>
          <anchor id="ch0134s0000a0149"/>
          <para id="ch0134s0000p0159">Ledipasvir is coformulated with sofosbuvir and is administered with or without RBV depending on the patient population (<link linkend="ch0134s0000li0108">108</link>). It is well absorbed and is highly protein bound. Its half-life is 47 h, and it is primarily excreted in the feces. While ledipasvir needs no dose adjustment for severe renal insufficiency, its coformulated drug sofosbuvir accumulates with severe renal impairment. No dose adjustment is needed for mild or moderate renal insufficiency or in the setting of moderate or severe (Child Pugh class B or C) hepatic impairment.</para>
        </sect3>
        <sect3 id="ch0134s0009s0002">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0009a0004"/>
          <anchor id="ch0134s0000a0150"/>
          <para id="ch0134s0000p0160">Ledipasvir undergoes slow oxidative metabolism via an unknown mechanism and is a substrate of the P-glycoprotein drug transporter (<link linkend="ch0134s0000li0108">108</link>). Coadministration is not recommended with rifampin, St. John’s wort, carbamazepine, phenytoin, phenobarbital, or TPV. Increased gastric pH levels may decrease its absorption. Acid-suppressing agents can be coadministered if needed, but low doses should be used.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0009s0002">
        <title>Ombitasvir</title>
        <anchor id="ch0134s0009a0005"/>
        <anchor id="ch0134s0000a0151"/>
        <sect3 id="ch0134s0009s0003">
          <title>Pharmacology</title>
          <anchor id="ch0134s0009a0006"/>
          <anchor id="ch0134s0000a0152"/>
          <para id="ch0134s0000p0161">Ombitasvir is only available as a fixed-dose coformulation with the PIs paritaprevir and RTV, which is typically given with the NS5B inhibitor dasabuvir (<link linkend="ch0134s0000li0100">100</link>). These drugs are administered with or without RBV, depending on the patient population, for the treatment of chronic genotype 1 infection (<link linkend="ch0134s0000li0110">110</link>). Ombitasvir-paritaprevir-RTV coadministered with ribavirin but without dasabuvir is used for genotype 4 infections (<link linkend="ch0134s0000li0111">111</link>). Ombitasvir is well absorbed when administered with food and has a bioavailability of 48%. Its half-life is 21 to 25 h, and it is primarily excreted in the feces. Renal impairment is not expected to significantly alter its levels, but it has not been studied in patients with severe renal insufficiency. Its use is contraindicated for patients with moderate to severe (Child Pugh classes B and C) hepatic impairment.</para>
        </sect3>
        <sect3 id="ch0134s0009s0004">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0009a0007"/>
          <anchor id="ch0134s0000a0153"/>
          <para id="ch0134s0000p0162">Ombitasvir is metabolized by amide hydrolysis and oxidative metabolism (<link linkend="ch0134s0000li0100">100</link>). Because it is coformulated with paritaprevir and RTV, which are metabolized by CYP3A4 and CYP3A5, the fixed-dose combination has considerable drug interactions and should not be administered with anticonvulsants, rifampin, St. John’s wort, certain oral contraceptives, or salmeterol.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0009s0003">
        <title>Elbasvir</title>
        <anchor id="ch0134s0009a0008"/>
        <anchor id="ch0134s0000a0154"/>
        <sect3 id="ch0134s0009s0005">
          <title>Pharmacology</title>
          <anchor id="ch0134s0009a0009"/>
          <anchor id="ch0134s0000a0155"/>
          <para id="ch0134s0000p0163">Elbasvir is only available as a fixed-dose combination with the PI grazoprevir (<link linkend="ch0134s0000li0099">99</link>). It is administered with or without ribavirin, depending on certain patient characteristics (<link linkend="ch0134s0000li0112">112</link>). Prior to administration of this drug, patients with genotype 1a infection should be tested for the presence of NS5A resistance-associated substitutions. Elbasvir has a bioavailability of 32% and is highly protein bound. Its half-life is 24 h, and it is primarily excreted in the feces. It can be used in patients with any degree of renal impairment without the need for dose modifications. It is contraindicated in patients with Child-Pugh class B or C cirrhosis.</para>
        </sect3>
        <sect3 id="ch0134s0009s0006">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0009a0010"/>
          <anchor id="ch0134s0000a0156"/>
          <para id="ch0134s0000p0164">Elbasvir undergoes partial oxidative metabolism via CYP3A, just like its coformulated drug grazoprevir (<link linkend="ch0134s0000li0099">99</link>). Coadministration is contraindicated with rifampin, phenytoin, carbamazepine, St. John’s wort, cyclosporine, and some antiretroviral agents such as PIs and efavirenz. Coadministration is not recommended with nafcillin, ketoconazole, etravirine, cobicistat, or modafinil.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0009s0004">
        <title>Velpatasvir</title>
        <anchor id="ch0134s0009a0011"/>
        <anchor id="ch0134s0000a0157"/>
        <sect3 id="ch0134s0009s0007">
          <title>Pharmacology</title>
          <anchor id="ch0134s0009a0012"/>
          <anchor id="ch0134s0000a0158"/>
          <para id="ch0134s0000p0165">Velpatasvir is a pangenotypic NS5A inhibitor that is only available as a fixed-dose combination with the NS5B inhibitor sofosbuvir (<link linkend="ch0134s0000li0113">113</link>). It is highly protein bound and has a half-life of 15 h. It is primarily excreted in the feces. No dose adjustment is necessary for mild or moderate renal insufficiency or Child-Pugh class B or C hepatic impairment. Preliminary studies suggest that severe renal impairment does not affect levels of velpatasvir. However, its coformulated drug sofosbuvir accumulates with renal impairment.</para>
        </sect3>
        <sect3 id="ch0134s0009s0008">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0009a0013"/>
          <anchor id="ch0134s0000a0159"/>
          <para id="ch0134s0000p0166">Velpatasvir is a substrate of the P-glycoprotein drug transporter and should not be coadministered with rifampin, rifabutin, rifapentine, St. John’s wort, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, or TPV (<link linkend="ch0134s0000li0113">113</link>). Increased gastric pH levels may decrease its absorption. If acid-suppressing agents need to be used, only low doses of proton pump inhibitors should be given, and velpatasvir should be administered without food.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0009s0005">
        <title>Pibrentasvir</title>
        <anchor id="ch0134s0009a0014"/>
        <anchor id="ch0134s0000a0160"/>
        <sect3 id="ch0134s0009s0009">
          <title>Pharmacology</title>
          <anchor id="ch0134s0009a0015"/>
          <anchor id="ch0134s0000a0161"/>
          <para id="ch0134s0000p0167">Pibrentasvir is an NS5A inhibitor that is formulated in combination with glecaprevir for previously treated patients without sustained virologic response (<link linkend="ch0134s0000li0105">105</link>). It is highly protein bound and is primarily excreted in the feces. No dosage adjustment is required with mild, moderate, or severe renal impairment, including those on dialysis. It is not recommended in patients with moderate or severe hepatic impairment.</para>
        </sect3>
        <sect3 id="ch0134s0009s0010">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0009a0016"/>
          <anchor id="ch0134s0000a0162"/>
          <anchor id="ch0134s0000a0163"/>
          <para id="ch0134s0000p0168">Pibrentasvir is not extensively metabolized and is excreted unchanged in the feces (<link linkend="ch0134s0000li0105">105</link>). Since it is coformulated with glecaprevir, which is metabolized by CYP3A, coadministration with digoxin, carbamazepine, rifampin, ethinyl estradiol-containing medications such as combined oral contraceptives, St. John’s wort, atazanavir, darunavir, lopinavir, ritonavir, HMG-CoA reductase inhibitors, and cyclosporine is not recommended.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0009s0006">
        <title>Daclatasvir</title>
        <anchor id="ch0134s0009a0017"/>
        <anchor id="ch0134s0000a0164"/>
        <sect3 id="ch0134s0009s0011">
          <title>Pharmacology</title>
          <anchor id="ch0134s0009a0018"/>
          <anchor id="ch0134s0000a0165"/>
          <para id="ch0134s0000p0169">Daclatasvir is typically used in combination with sofosbuvir (<link linkend="ch0134s0000li0109">109</link>). It is 67% bioavailable and is highly protein bound. Its half-life is 12 to 15 h, and it is primarily excreted in the feces. No dosage adjustments are required for renal or hepatic impairment.</para>
        </sect3>
        <sect3 id="ch0134s0009s0012">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0009a0019"/>
          <anchor id="ch0134s0000a0166"/>
          <para id="ch0134s0000p0170">Daclatasvir is primarily metabolized by CYP3A4 and should not be given with strong inducers or inhibitors of this enzyme (<link linkend="ch0134s0000li0114">114</link>). Coadministration is not recommended with rifampin, phenytoin, carbamazepine, or St. John’s wort. Daclatasvir is also an inhibitor of P-glycoprotein transporter and organic anion transporting polypeptide 1B1 and 1B3. Dose adjustments of digoxin may be warranted when it is coadministered with daclatasvir.</para>
        </sect3>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0010">
      <title>NS5B RNA-Dependent RNA Polymerase Inhibitors</title>
      <anchor id="ch0134s0010a0001"/>
      <anchor id="ch0134s0000a0167"/>
      <para id="ch0134s0000p0171">NS5B is an RNA-dependent RNA polymerase that is also involved in posttranslational processing. Its structure is highly conserved across all hepatitis C virus genotypes, giving NS5B inhibitors activity against all six genotypes (<link linkend="ch0134s0000li0097">97</link>). There are two kinds of polymerase inhibitors: nucleoside/nucleotide analogues such as sofosbuvir and nonnucleoside analogues such as dasabuvir. Nucleoside/nucleotide analogues are activated within the hepatocyte through phosphorylation which competes with nucleotides, resulting in chain termination during RNA replication. As a class, nucleoside polymerase inhibitors have moderate to high efficacy against all six genotypes and a very high barrier to resistance. In contrast, nonnucleoside polymerase inhibitors are less potent and more genotype specific, with all drugs from this class having been optimized for genotype 1.</para>
      <sect2 id="ch0134s0010s0001">
        <title>Sofosbuvir</title>
        <anchor id="ch0134s0010a0002"/>
        <anchor id="ch0134s0000a0168"/>
        <sect3 id="ch0134s0010s0001">
          <title>Pharmacology</title>
          <anchor id="ch0134s0010a0003"/>
          <anchor id="ch0134s0000a0169"/>
          <para id="ch0134s0000p0172">Sofosbuvir is the first NS5B nucleoside polymerase inhibitor to have been developed, and it is used in various combinations with other direct-acting antivirals against hepatitis C (<link linkend="ch0134s0000li0115">115</link>, <link linkend="ch0134s0000li0116">116</link>). It can be taken without regard to food and has a half-life of 0.4 h. It is primarily excreted in the urine. No dose adjustment is necessary for patients with a glomerular filtration rate greater than 30 ml/minute. Sofosbuvir exposure is increased in patients with severe renal impairment, including patients on dialysis. It can be used without regard to hepatic impairment.</para>
        </sect3>
        <sect3 id="ch0134s0010s0002">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0010a0004"/>
          <anchor id="ch0134s0000a0170"/>
          <para id="ch0134s0000p0173">Sofosbuvir is a substrate of the P-glycoprotein drug transporter, so inducers of these enzymes may decrease sofosbuvir levels (<link linkend="ch0134s0000li0115">115</link>). Coadministration is not recommended with rifampin, rifabutin, rifapentine, St. John’s wort, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, or tipranavir. Coadministration of sofosbuvir and amiodarone is also not recommended, because of reports of symptomatic bradycardia and fatal cardiac arrest.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0010s0002">
        <title>Dasabuvir</title>
        <anchor id="ch0134s0010a0005"/>
        <anchor id="ch0134s0000a0171"/>
        <sect3 id="ch0134s0010s0003">
          <title>Pharmacology</title>
          <anchor id="ch0134s0010a0006"/>
          <anchor id="ch0134s0000a0172"/>
          <para id="ch0134s0000p0174">Dasabuvir is packaged with ombitasvir/paritaprevir/RTV (<link linkend="ch0134s0000li0100">100</link>, <link linkend="ch0134s0000li0101">101</link>). It is 70% bioavailable and very highly protein bound. Its half-life is 6 hours, and it is excreted primarily in the feces. Because of its lower potency and higher threshold for resistance, it is used as an adjunct to more potent direct-acting antivirals.</para>
        </sect3>
        <sect3 id="ch0134s0010s0004">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0010a0007"/>
          <anchor id="ch0134s0000a0173"/>
          <para id="ch0134s0000p0175">Dasabuvir is metabolized by CYP2C8 and CYP3A. It should not be coadministered with anticonvulsants, rifampin, St. John’s wort, ethinyl estradiol-containing products, or salmeterol.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0010s0003">
        <title>Ribavirin</title>
        <anchor id="ch0134s0010a0008"/>
        <anchor id="ch0134s0000a0174"/>
        <sect3 id="ch0134s0010s0005">
          <title>Pharmacology</title>
          <anchor id="ch0134s0010a0009"/>
          <anchor id="ch0134s0000a0175"/>
          <para id="ch0134s0000p0176">The bioavailability of ribavirin (RBV) is reported to be 52% (<link linkend="ch0134s0000li0117">117</link>) and is increased by a high-fat meal; therefore, RBV should be administered with food. The half-life in plasma is 120 to 170 h, and the drug may persist in other body compartments for up to 6 months. The pathway for elimination has not been determined. Ribavirin appears not to be a substrate for the CYP450 isoenzymes. It is used as a standard therapy, always in combination with other antiviral agents, for the treatment of HCV. RBV monotherapy is not effective against HCV infection.</para>
          <para id="ch0134s0000p0177">RBV has been used as a monotherapy to treat other RNA viruses, including respiratory syncytial virus, Lassa fever virus, influenza virus, parainfluenza virus, and hantavirus; however, there are no conclusive data demonstrating RBV treatment efficacy (<link linkend="ch0134s0000li0118">118</link>–<link linkend="ch0134s0000li0125">125</link>). An aerosolized formulation of RBV (Virazole; Valeant Pharmaceuticals, Costa Mesa, CA) has been approved for the treatment of hospitalized infants and young children with severe respiratory syncytial virus lower respiratory tract infections.</para>
        </sect3>
        <sect3 id="ch0134s0010s0006">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0010a0010"/>
          <anchor id="ch0134s0000a0176"/>
          <para id="ch0134s0000p0178">Coadministration of ddI or d4T with ribavirin is contraindicated. Zidovudine plus ribavirin is linked to higher rates of anemia (<link linkend="ch0134s0000li0005">5</link>, <link linkend="ch0134s0000li0126">126</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0010s0004">
        <title>AGENTS AGAINST HEPATITIS B VIRUS</title>
        <anchor id="ch0134s0010a0011"/>
        <anchor id="ch0134s0000a0177"/>
        <para id="ch0134s0000p0179">Because a large percentage of patients are coinfected with HIV, agents with activity against hepatitis B virus (HBV) are categorized according to whether they have activity against both viruses or only HBV. Of the drugs that are specifically approved for HBV, only telbivudine (LdT) is active against HBV, while lamivudine (3TC), tenofovir (TDF, TAF), adefovir (ADV), and entecavir (ETV) are active against both HBV and HIV (<anchor id="ch0134s0000a0178"/><link linkend="ch0134s0000a0180">Table 3</link>). Though neither ADV nor ETV is currently recommended for the treatment of HIV, use of these agents should be avoided in HIV/HBV-coinfected patients who are not on a suppressive antiretroviral regimen, to prevent the development of HIV resistance. Emtricitabine is approved only for HIV, but it has been shown to have activity against HBV (<link linkend="ch0134s0000li0125">125</link>, <link linkend="ch0134s0000li0127">127</link>). The common target for antiviral drugs active against both viruses is the reverse transcriptase (RT) function of the HIV and HBV replication enzymes (<link linkend="ch0134s0000li0128">128</link>–<link linkend="ch0134s0000li0130">130</link>).</para>
        <para id="ch0134s0000p0180">Chronic HBV infection plays an important role in the morbidity and mortality of HIV-infected patients (<link linkend="ch0134s0000li0131">131</link>). The strategy for selecting antiviral therapy regimens for coinfected patients is based on the need to treat one or both viruses. If only HIV requires treatment, drugs with activity against both HIV and HBV, such as 3TC or TDF, should be withheld. If only HBV needs to be treated, drugs without HIV activity, such as LdT, can be used. However, it is recommended that all patients with HIV and HBV coinfection be started on cART regardless of CD4 count, because this may slow the progression of liver disease (<link linkend="ch0134s0000li0125">125</link>). cART regimens with dual NRTIs and/or NtRTIs, such as TDF with 3TC or FTC, that suppress replication of both viruses are preferred (<link linkend="ch0134s0000li0125">125</link>, <link linkend="ch0134s0000li0131">131</link>). 3TC monotherapy rapidly selects for HBV resistance (<link linkend="ch0134s0000li0132">132</link>); therefore, combination therapy with one NRTI (3TC or FTC) and one NtRTI (TDF or ADV) is required. Of note, there are eight HBV genotypes (A to H), each with certain geographic predilections (<link linkend="ch0134s0000li0133">133</link>). There is evidence that the genotype impacts interferon responsiveness. In the treatment of hepatitis B e antigen-positive chronic hepatitis B, greater rates of hepatitis B e antigen seroconversion have been observed for genotype A than for genotype D and for genotype B than for genotype C (<link linkend="ch0134s0000li0134">134</link>). A correlation between genotype and treatment response to other anti-HBV therapies has not been established.</para>
        <anchor id="ch0134s0000a0179"/>
        <beginpage pagenum="2212"/>
        <table id="ch0134s0000t0003"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0134s0000a0180"/><link linkend="ch0134s0000a0178">TABLE 3</link></phrase></emphasis> Antiviral agents for HBV therapy<superscript><link linkend="ch0134s0000a0185"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0181"/>
</title>
          
          <tgroup cols="4">
            <tbody>
              <row>
                <entry><phrase role="center">Antiviral agent (abbreviation)</phrase>
                </entry>
                <entry><phrase role="center">Trade name (pharmaceutical company<superscript><link linkend="ch0134s0000a0186"><emphasis>b</emphasis></link></superscript>)</phrase>
                  <anchor id="ch0134s0000a0182"/>
                </entry>
                <entry><phrase role="center">Mechanism of action/route of administration</phrase>
                </entry>
                <entry><phrase role="center">Major adverse effects</phrase>
                </entry>
              </row>
              <row>
                <entry>Adefovir dipovoxil (ADV)</entry>
                <entry>Hepsera (Gilead)</entry>
                <entry><para id="ch0134s0000p0181">Prodrug converted to the nucleotide monophosphate analogue of adenosine</para>
                  <para id="ch0134s0000p0182">Inhibitor of HBV RT DNA polymerase<superscript><link linkend="ch0134s0000a0188"><emphasis>d</emphasis></link></superscript><anchor id="ch0134s0000a0183"/>, viral DNA chain terminator</para>
                  <para id="ch0134s0000p0183">Administered orally</para>
                </entry>
                <entry>Headache, asthenia, GI<superscript><link linkend="ch0134s0000a0187"><emphasis>c</emphasis></link></superscript><anchor id="ch0134s0000a0184"/> symptoms, nephrotoxicity</entry>
              </row>
              <row>
                <entry>Entecavir (ETV)</entry>
                <entry>Baraclude (BMS)</entry>
                <entry><para id="ch0134s0000p0184">Guanosine analogue inhibitor of HBV RT DNA polymerase functions: priming, reverse transcription, positive-strand DNA synthesis</para>
                  <para id="ch0134s0000p0185">Administered orally</para>
                </entry>
                <entry>Headache, fatigue, dizziness</entry>
              </row>
              <row>
                <entry>Lamivudine (3TC)</entry>
                <entry>See HIV antivirals,<link linkend="ch0134s0000a0008">Table 1</link></entry>
                <entry>Cytidine analogue inhibitor of HBV RT DNA polymerase</entry>
                <entry>Minimal toxicity (see HIV antivirals)</entry>
              </row>
              <row>
                <entry>Telbivudine (LdT)</entry>
                <entry>Tyzeka (Novartis)</entry>
                <entry>Thymidine analogue inhibitor of HBV RT DNA polymerase</entry>
                <entry>Fatigue, increased creatine kinase, headache, myopathy, cough, GI symptoms</entry>
              </row>
              <row>
                <entry>Tenofovir (TDF/TAF)</entry>
                <entry>See HIV antivirals,<link linkend="ch0134s0000a0008">Table 1</link></entry>
                <entry>Inhibitor of HBV DNA polymerase</entry>
                <entry>Asthenia, headache, GI symptoms (see HIV antivirals)</entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para id="ch0134s0000p0186" role="table-footnote"><superscript><link linkend="ch0134s0000a0181"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0185"/>Note: Except for interferon, all HBV antiviral agents are N(t)RTIs, some of which have anti-HIV activity (see <link linkend="ch0134s0000a0008">Table 1</link>), and all carry the warning of lactic acidosis and severe hepatomegaly with steatosis. All agents also carry a warning of severe acute exacerbations (flares) of HBV in patients who have discontinued anti-HBV therapy.</para>
        <para id="ch0134s0000p0187" role="table-footnote"><superscript><link linkend="ch0134s0000a0182"><emphasis>b</emphasis></link></superscript><anchor id="ch0134s0000a0186"/>Pharmaceutical companies: BMS, Bristol-Meyers Squibb, Princeton, NJ; Gilead Sciences, Foster City, CA; Novartis Pharmaceuticals Corporation, East Hanover, NJ.</para>
        <para id="ch0134s0000p0188" role="table-footnote"><superscript><link linkend="ch0134s0000a0184"><emphasis>c</emphasis></link></superscript><anchor id="ch0134s0000a0187"/>GI (gastrointestinal) symptoms include nausea, vomiting, and diarrhea.</para>
        <para id="ch0134s0000p0189" role="table-footnote"><superscript><link linkend="ch0134s0000a0183"><emphasis>d</emphasis></link></superscript><anchor id="ch0134s0000a0188"/>HBV RT DNA polymerase, hepatitis B reverse transcriptase DNA polymerase.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0011">
      <title>Nucleoside/Nucleotide Analogues</title>
      <anchor id="ch0134s0011a0001"/>
      <anchor id="ch0134s0000a0189"/>
      <sect2 id="ch0134s0011s0001">
        <title>Adefovir/Dipivoxil</title>
        <anchor id="ch0134s0011a0002"/>
        <anchor id="ch0134s0000a0190"/>
        <sect3 id="ch0134s0011s0001">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0003"/>
          <anchor id="ch0134s0000a0191"/>
          <para id="ch0134s0000p0190">Adefovir (ADV)/dipivoxil is a diester prodrug that is converted to the active drug ADV. ADV/dipivoxil is administered without regard to food, and the bioavailability is 59%. The half-life of ADV is 7.5 h, and it is excreted by the kidneys. There are no data for placental passage of the drug.</para>
          <para id="ch0134s0000p0191">ADV was originally developed as an antiretroviral drug; however, the high dose required for HIV therapy is associated with nephrotoxicity (<link linkend="ch0134s0000li0130">130</link>). A much lower dosage is effective against HBV (<link linkend="ch0134s0000li0128">128</link>, <link linkend="ch0134s0000li0131">131</link>). ADV is effective for treatment of chronic HBV infection. The rate of viral load decline is slower, but development of drug resistance is delayed compared to that seen with other NRTIs and NtRTIs (<link linkend="ch0134s0000li0135">135</link>) that are active against HBV. The primary role of ADV is in the treatment of 3TC-resistant HBV infection (<link linkend="ch0134s0000li0136">136</link>). However, TDF and entecavir have largely replaced ADV for this indication.</para>
        </sect3>
        <sect3 id="ch0134s0011s0002">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0004"/>
          <anchor id="ch0134s0000a0192"/>
          <para id="ch0134s0000p0192">ADV is not a substrate, inhibitor, or inducer of any of the CYP450 isoenzymes. There is no interaction with 3TC, ETV, or TDF. It is possible that drugs that reduce renal function or compete for active tubular secretion could increase the concentration of ADV and/or the coadministered drug in serum.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0002">
        <title>Emtricitabine</title>
        <anchor id="ch0134s0011a0005"/>
        <anchor id="ch0134s0000a0193"/>
        <sect3 id="ch0134s0011s0003">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0006"/>
          <anchor id="ch0134s0000a0194"/>
          <para id="ch0134s0000p0193">See the discussion on HIV antiviral agents above and<link linkend="ch0134s0000a0008">Table 1</link>. Emtricitabine (FTC) is approved for antiviral therapy in HIV-infected patients. It has activity against HBV but is not licensed for HBV antiviral therapy. FTC and 3TC are biochemically similar and appear to be interchangeable for potential use in treatment of HIV/HBV-coinfected patients. However, they also share the same HBV resistance mutations; therefore, combined therapy with these two drugs is not recommended (<link linkend="ch0134s0000li0130">130</link>, <link linkend="ch0134s0000li0131">131</link>). In addition, as with 3TC, severe acute exacerbations of HBV can occur once therapy is discontinued (<link linkend="ch0134s0000li0125">125</link>).</para>
          <anchor id="ch0134s0000a0195"/>
          <beginpage pagenum="2213"/>
        </sect3>
        <sect3 id="ch0134s0011s0004">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0007"/>
          <anchor id="ch0134s0000a0196"/>
          <para id="ch0134s0000p0194">See the discussion on HIV antiviral agents above.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0003">
        <title>Entecavir</title>
        <anchor id="ch0134s0011a0008"/>
        <anchor id="ch0134s0000a0197"/>
        <sect3 id="ch0134s0011s0005">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0009"/>
          <anchor id="ch0134s0000a0198"/>
          <para id="ch0134s0000p0195">The bioavailability of entecavir (ETV) is approximately 100%, and the half-life is 24 h. ETV should be administered without food. It is excreted by the kidney (62 to 73%) mainly as unmetabolized drug. ETV maintains activity against 3TC-resistant HBV, but a higher dose is recommended for patients with 3TC-resistant HBV infection (<link linkend="ch0134s0000li0131">131</link>). ETV has shown low activity against HIV; however, there is evidence that resistance mutations are selected. For this reason, it is recommended that ETV be used in HIV-coinfected patients only if they are receiving effective antiretroviral therapy (<link linkend="ch0134s0000li0128">128</link>, <link linkend="ch0134s0000li0131">131</link>, <link linkend="ch0134s0000li0137">137</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0006">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0010"/>
          <anchor id="ch0134s0000a0199"/>
          <para id="ch0134s0000p0196">ETV is not a substrate, inhibitor, or inducer of any of the CYP450 isoenzymes. There is no interaction with 3TC, ADV, or TDF. It is possible that drugs that reduce renal function or compete for active tubular secretion could increase the concentration of ETV and/or the coadministered drug in serum.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0004">
        <title>Lamivudine</title>
        <anchor id="ch0134s0011a0011"/>
        <anchor id="ch0134s0000a0200"/>
        <sect3 id="ch0134s0011s0007">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0012"/>
          <anchor id="ch0134s0000a0201"/>
          <para id="ch0134s0000p0197">See the discussion on HIV antiviral agents above as well as<link linkend="ch0134s0000a0008">Table 1</link>. Lamivudine (3TC) was the first nucleoside analogue that was approved for chronic HBV infection. Because it has activity against both HIV and HBV, it has been effective in reducing loads of both viruses in plasma as part of cART regimens. However, HBV-specific drug resistance mutations are selected over long-term therapy at a higher rate (20% per year) in coinfected patients than in those that are HIV negative (<link linkend="ch0134s0000li0120">120</link>). Selection of HBV drug resistance mutations eventually decreases efficacy for treatment of chronic hepatitis. Discontinuation of 3TC in HBV-infected patients can produce severe flare-ups of hepatitis, which are usually self-limited but have been fatal in a few cases. Another common problem is the rebound viremia that occurs when therapy is terminated (<link linkend="ch0134s0000li0125">125</link>). This is thought to be derived from the viral covalently closed circular DNA (cccDNA), which is not affected by nucleoside or nucleotide therapy and remains in the infected hepatocytes (<link linkend="ch0134s0000li0130">130</link>). For coinfected patients, recent recommendations suggest using combination dual NTRI-NtRTI therapy that includes TDF to reduce the rate of selection of HBV 3TC-resistant strains (<link linkend="ch0134s0000li0138">138</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0008">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0013"/>
          <anchor id="ch0134s0000a0202"/>
          <para id="ch0134s0000p0198">See the discussion on HIV antiviral agents above.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0005">
        <title>Telbivudine</title>
        <anchor id="ch0134s0011a0014"/>
        <anchor id="ch0134s0000a0203"/>
        <sect3 id="ch0134s0011s0009">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0015"/>
          <anchor id="ch0134s0000a0204"/>
          <para id="ch0134s0000p0199">The bioavailability of telbivudine (LdT) is 68%, and it can be administered with or without food. The half-life is 40 to 50 h, and the drug is excreted mainly by the kidneys. LdT has a relatively low genetic barrier to resistance; therefore, it is not recommended as a first-line drug for treatment of chronic HBV (<link linkend="ch0134s0000li0139">139</link>). Hepatitis exacerbations have been reported upon discontinuation of LdT.</para>
        </sect3>
        <sect3 id="ch0134s0011s0010">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0016"/>
          <anchor id="ch0134s0000a0205"/>
          <para id="ch0134s0000p0200">LdT does not alter the pharmacokinetics of other nucleoside or nucleotide analogues used in the treatment of HBV (e.g., 3TC, ADV, or TDF). Coadministration with PEG-IFN 2a may be associated with increased risk of peripheral neuropathy (<link linkend="ch0134s0000li0128">128</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0006">
        <title>Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF)</title>
        <anchor id="ch0134s0011a0017"/>
        <anchor id="ch0134s0000a0206"/>
        <sect3 id="ch0134s0011s0011">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0018"/>
          <anchor id="ch0134s0000a0207"/>
          <para id="ch0134s0000p0201">See the discussion on HIV antiviral agents above as well as<link linkend="ch0134s0000a0008">Table 1</link>. Tenofovir disoproxil fumarate (TDF) is approved for treatment of both HBV- and HIV-infected patients. It does not show cross-resistance with HBV 3TC-resistant mutants, and it appears to have a lower potential for selection of resistance mutations. For this reason, TDF and FTC or TDF and 3TC are recommended as dual-nucleoside backbones in therapeutic regimens to reduce the possibility of selection of HBV drug-resistant strains in coinfected patients who are on antiretroviral therapy (<link linkend="ch0134s0000li0125">125</link>, <link linkend="ch0134s0000li0128">128</link>, <link linkend="ch0134s0000li0131">131</link>, <link linkend="ch0134s0000li0138">138</link>). TAF is another prodrug of tenofovir which appears to be as effective as TDF in treating hepatitis B but at a much lower dose (<link linkend="ch0134s0000li0140">140</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0012">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0019"/>
          <anchor id="ch0134s0000a0208"/>
          <para id="ch0134s0000p0202">See the discussion on HIV antiviral drugs above.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0007">
        <title>AGENTS AGAINST HERPESVIRUSES</title>
        <anchor id="ch0134s0011a0020"/>
        <anchor id="ch0134s0000a0209"/>
        <para id="ch0134s0000p0203">Most of the antiviral compounds that are approved to treat the eight human herpesviruses are nucleoside or nucleotide analogues, which inhibit DNA replication. Several of these compounds require phosphorylation by a virus-encoded enzyme as well as cellular kinases for activation. The ultimate target of most of these drugs is the viral DNA polymerase, although other enzymatic steps in DNA synthesis also may be inhibited (<link linkend="ch0134s0000li0001">1</link>). In addition to the nucleoside and nucleotide analogues, the anti-herpes virus compounds include a pyrophosphate analogue (foscarnet [FOS]) that targets the viral DNA polymerase directly and an entry inhibitor (docosanol). The structure, mode of action, route of administration, and adverse effects of each drug are summarized in <anchor id="ch0134s0000a0210"/><link linkend="ch0134s0000a0214">Table 4</link>.</para>
      </sect2>
      <sect2 id="ch0134s0011s0008">
        <title>Acyclovir and Valacyclovir</title>
        <anchor id="ch0134s0011a0021"/>
        <anchor id="ch0134s0000a0211"/>
        <sect3 id="ch0134s0011s0013">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0022"/>
          <anchor id="ch0134s0000a0212"/>
          <para id="ch0134s0000p0204">The pharmacokinetics of acyclovir (ACV) after oral administration has been evaluated in healthy volunteers and in immunocompromised patients with herpes simplex virus (HSV) and varicella-zoster virus (VZV) infection. ACV is phosphorylated by the viral thymidine kinases of HSV-1 and 2, and VZV and by the UL97 kinase of human cytomegalovirus (HCMV). Valacyclovir (val-ACV), the<phrase role="small">L</phrase>-valyl ester prodrug, is rapidly converted to ACV after oral administration (<link linkend="ch0134s0000li0141">141</link>, <link linkend="ch0134s0000li0143">143</link>). The plasma protein binding for ACV is 22 to 33%. and for val-ACV is 13.5 to 17.9%. The bioavailability resulting from oral ACV is 12 to 20% and for val-ACV is 54%. The ACV half-life is 2.5 to 3.3 h in patients with normal renal function but increases to 14 h in patients with end-stage renal disease (<link linkend="ch0134s0000li0142">142</link>). ACV may be administered with or without food. ACV is excreted by the kidney with inactive metabolites 9-[(carboxymethoxy) methyl] guanine and 8-hydroxy-9-[2-(hydroxyethoxy)methyl] guanine. A dosage adjustment is recommended for patients with reduced renal function (<link linkend="ch0134s0000li0141">141</link>).</para>
          <anchor id="ch0134s0000a0213"/>
          <beginpage pagenum="2214"/>
          <para id="ch0134s0000p0205">ACV is excreted by the kidney with inactive metabolites 9-[(carboxymethoxy) methyl] guanine and 8-hydroxy-9-[2-(hydroxyethoxy)methyl] guanine. A dosage adjustment is recommended for patients with reduced renal function (<link linkend="ch0134s0000li0141">141</link>).</para>
          <table id="ch0134s0000t0004"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0134s0000a0214"/><link linkend="ch0134s0000a0210">TABLE 4</link></phrase></emphasis> Antiviral agents for herpesviruses<superscript><link linkend="ch0134s0000a0220"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0215"/>
</title>
            
            <tgroup cols="5">
              <tbody>
                <row>
                  <entry><phrase role="center">Antiviral agent (abbreviation)</phrase>
                  </entry>
                  <entry><phrase role="center">Trade name (pharmaceutical company<superscript><link linkend="ch0134s0000a0221"><emphasis>b</emphasis></link></superscript>)</phrase>
                    <anchor id="ch0134s0000a0216"/>
                  </entry>
                  <entry><phrase role="center">Mechanism of action/route of administration</phrase>
                  </entry>
                  <entry><phrase role="center">Major adverse effects</phrase>
                  </entry>
                  <entry><phrase role="center">Antiviral activity</phrase>
                  </entry>
                </row>
                <row>
                  <entry>Acyclovir (ACV)</entry>
                  <entry>Zovirax (GSK)</entry>
                  <entry><para id="ch0134s0000p0206">Converted to guanosine monophosphate by viral kinase; converted to triphosphate by cellular kinases; DNA chain terminator</para>
                    <para id="ch0134s0000p0207">Oral or intravenous formulations</para>
                  </entry>
                  <entry><para id="ch0134s0000p0208">Minimal toxicity</para>
                    <para id="ch0134s0000p0209">GI symptoms, headache, nephrotoxicity</para>
                    <para id="ch0134s0000p0210">Precipitation in renal tubules if maximum solubility exceeded</para>
                  </entry>
                  <entry>HSV-1, HSV-2, VZV</entry>
                </row>
                <row>
                  <entry>Valacyclovir (val-ACV)</entry>
                  <entry>Valtrex (GSK)</entry>
                  <entry><phrase role="small">L</phrase>-Valyl ester prodrug of ACV with increased bioavailability; activity same as ACV</entry>
                  <entry>GI symptoms, headache, dizziness, abdominal pain, nephrotoxicity, thrombotic thrombocytopenia, hemolytic uremic syndrome (high dosage)</entry>
                  <entry>HSV-1, HSV-2, VZV, CMV</entry>
                </row>
                <row>
                  <entry>Cidofovir (CDV)</entry>
                  <entry>Vistide (Gilead)</entry>
                  <entry><para id="ch0134s0000p0211">Cytidine nucleotide analogue; converted to di- and triphosphate by cellular kinases; DNA chain terminator (2 successive molecules required)</para>
                    <para id="ch0134s0000p0212">Intravenous administration with probenecid</para>
                  </entry>
                  <entry><para id="ch0134s0000p0213">CDV: renal toxicity, decreased intraocular pressure, neutropenia, fever</para>
                    <para id="ch0134s0000p0214">Probenecid: headache, GI symptoms, rash</para>
                  </entry>
                  <entry>CMV, HSV-1, HSV-2, VZV<superscript><link linkend="ch0134s0000a0222"><emphasis>c</emphasis></link></superscript><anchor id="ch0134s0000a0217"/></entry>
                </row>
                <row>
                  <entry>Foscarnet (FOS)</entry>
                  <entry>Foscavir (AstraZeneca)</entry>
                  <entry><para id="ch0134s0000p0215">Pyrophosphate analogue; noncompetitive inhibitor of DNA polymerase pyrophosphate binding site</para>
                    <para id="ch0134s0000p0216">Intravenous formulation only</para>
                  </entry>
                  <entry>Renal impairment, fever, nausea, anemia, diarrhea, vomiting, headache, seizures, altered serum electrolytes</entry>
                  <entry>CMV, HSV-1, HSV-2, EBV</entry>
                </row>
                <row>
                  <entry>Ganciclovir (GCV)</entry>
                  <entry>Cytovene (Roche)</entry>
                  <entry><para id="ch0134s0000p0217">Guanosine analogue; converted to monophosphate by HCMV UL97 kinase or HSV or VZV TK; DNA chain terminator</para>
                    <para id="ch0134s0000p0218">Oral and intravenous formulations</para>
                  </entry>
                  <entry>Fever, neutropenia, anemia, thrombocytopenia, impaired renal function, diarrhea</entry>
                  <entry>CMV, HSV-1, HSV-2</entry>
                </row>
                <row>
                  <entry>Valganciclovir (val-GCV)</entry>
                  <entry>Valcyte (Roche)</entry>
                  <entry><para id="ch0134s0000p0219">Oral prodrug of GCV with increased bioavailability</para>
                    <para id="ch0134s0000p0220">Activity same as GCV</para>
                  </entry>
                  <entry>Diarrhea, neutropenia, nausea, headache, anemia</entry>
                  <entry>CMV</entry>
                </row>
                <row>
                  <entry>Letermovir</entry>
                  <entry>Prevymis (Merck)</entry>
                  <entry>Inhibitor of HCMV terminase complex</entry>
                  <entry>Nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, abdominal pain</entry>
                  <entry>HCMV</entry>
                </row>
                <row>
                  <entry>Penciclovir (PCV)</entry>
                  <entry>Denavir (Novartis)</entry>
                  <entry><para id="ch0134s0000p0221">Guanosine analogue; mode of action similar to ACV; limited DNA chain elongation</para>
                    <para id="ch0134s0000p0222">Topical formulation only</para>
                  </entry>
                  <entry>Headache and application site reaction no different from placebo</entry>
                  <entry>HSV-1<superscript><link linkend="ch0134s0000a0223"><emphasis>d</emphasis></link></superscript><anchor id="ch0134s0000a0218"/></entry>
                </row>
                <row>
                  <entry>Famciclovir</entry>
                  <entry>Famvir (Novartis)</entry>
                  <entry><para id="ch0134s0000p0223">Oral prodrug of PCV</para>
                    <para id="ch0134s0000p0224">Mode of action same as PCV</para>
                  </entry>
                  <entry>Headache, GI symptoms, anorexia</entry>
                  <entry>HSV-1, HSV-2, VZV</entry>
                </row>
                <row>
                  <entry>Trifluridine</entry>
                  <entry>Viroptic (Monarch)</entry>
                  <entry><para id="ch0134s0000p0225">Mode of action not established, may inhibit viral DNA synthesis</para>
                    <para id="ch0134s0000p0226">Ophthalmic aqueous solution for topical use</para>
                  </entry>
                  <entry>Burning on instillation and palpebral edema, punctate keratopathy, hypersensitivity reaction, stromal edema, keratitis sicca, hyperemia, increased ocular pressure</entry>
                  <entry>HSV-1<superscript><link linkend="ch0134s0000a0224"><emphasis>e</emphasis></link></superscript><anchor id="ch0134s0000a0219"/></entry>
                </row>
                <row>
                  <entry>Docosanol</entry>
                  <entry>Abreva (GSK)</entry>
                  <entry>Prevents HSV entry into cells by inhibition of fusion between HSV envelope and cell membrane</entry>
                  <entry>Headache and skin rash</entry>
                  <entry>Oral; HSV</entry>
                </row>
                <row>
                  <entry>Maribavir</entry>
                  <entry>Livtencity (Takeda)</entry>
                  <entry>Nonprescription topical cream formulation; attaches to the UL97 encoded serine/tyrosine kinase and blocks viral replication</entry>
                  <entry>Taste disturbance, diarrhea, vomiting, fatigue</entry>
                  <entry>CMV</entry>
                </row>
              </tbody>
            </tgroup>
          </table>
          <para id="ch0134s0000p0227" role="table-footnote"><superscript><link linkend="ch0134s0000a0215"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0220"/>Abbreviations: GI (gastrointestinal) symptoms include nausea, vomiting, and diarrhea; HSV-1, herpes simplex virus 1; HSV-2, herpes simplex virus 2; VZV, varicella-zoster virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus.</para>
          <para id="ch0134s0000p0228" role="table-footnote"><superscript><link linkend="ch0134s0000a0216"><emphasis>b</emphasis></link></superscript><anchor id="ch0134s0000a0221"/>Pharmaceutical companies: AstraZeneca, Wilmington, DE; BMS, Gilead Sciences, Foster City, CA; GSK, GlaxoSmithKline, Research Triangle Park, NC; Monarch Pharmaceutical, Bristol, TN; Novartis, East Hanover, NJ; Roche Pharmaceuticals, Nutley, NJ.</para>
          <para id="ch0134s0000p0229" role="table-footnote"><superscript><link linkend="ch0134s0000a0217"><emphasis>c</emphasis></link></superscript><anchor id="ch0134s0000a0222"/>Cidofovir also has reported activity against human papillomavirus, polyomavirus, adenovirus, and poxvirus.</para>
          <para id="ch0134s0000p0230" role="table-footnote"><superscript><link linkend="ch0134s0000a0218"><emphasis>d</emphasis></link></superscript><anchor id="ch0134s0000a0223"/>Penciclovir is used to treat herpes labialis but also has activity against HSV-2.</para>
          <para id="ch0134s0000p0231" role="table-footnote"><superscript><link linkend="ch0134s0000a0219"><emphasis>e</emphasis></link></superscript><anchor id="ch0134s0000a0224"/>Trifluridine is used to treat herpes keratitis but also has activity against HSV2 and VZV.</para>
        </sect3>
        <sect3 id="ch0134s0011s0014">
          <title>Spectrum of Activity</title>
          <anchor id="ch0134s0011a0023"/>
          <anchor id="ch0134s0000a0225"/>
          <anchor id="ch0134s0000a0226"/>
          <para id="ch0134s0000p0232">ACV and val-ACV are active against HSV-1, HSV-2, VZV, and Epstein-Barr virus (EBV) (<link linkend="ch0134s0000li0004">4</link>). Of note, ACV and val-ACV are active only against replicating virus. Therefore, their role in the treatment of EBV-associated disease processes, which are primarily driven by latent virus, is limited (<link linkend="ch0134s0000li0143">143</link>). In addition, both drugs have some activity against HCMV. Although ACV and val-ACV are not recommended for HCMV treatment, they have been used prophylactically to prevent HCMV disease in some patients following transplantation (<link linkend="ch0134s0000li0144">144</link>, <link linkend="ch0134s0000li0145">145</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0015">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0024"/>
          <anchor id="ch0134s0000a0227"/>
          <para id="ch0134s0000p0233">There are no clinically significant drug-drug interactions in patients with normal renal function.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0009">
        <title>Cidofovir</title>
        <anchor id="ch0134s0011a0025"/>
        <anchor id="ch0134s0000a0228"/>
        <sect3 id="ch0134s0011s0016">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0026"/>
          <anchor id="ch0134s0000a0229"/>
          <para id="ch0134s0000p0234">Cidofovir (CDV) is a nucleotide analogue of deoxycytidine monophosphate, which does not require a virus-encoded enzyme for activation. After phosphorylation by cellular kinases, CDV diphosphate becomes the active nucleotide triphosphate, which inhibits the HCMV DNA polymerase. In HCMV, two successive CDV molecules must be incorporated for complete chain termination (<link linkend="ch0134s0000li0146">146</link>).</para>
          <para id="ch0134s0000p0235">CDV must be administered with probenecid (<link linkend="ch0134s0000li0147">147</link>, <link linkend="ch0134s0000li0148">148</link>). Approximately 90% of the CDV dose administered is recovered unchanged in the urine within 24 hours. The half-life is 2.4 to 3.2 h. When CDV is administered with probenecid, the renal clearance of CDV is reduced to a level consistent with creatinine clearance, suggesting that probenecid blocks active renal tubular secretion of CDV (<link linkend="ch0134s0000li0147">147</link>). <emphasis>In vitro</emphasis>, CDV is less than 6% bound to plasma or serum proteins.</para>
        </sect3>
        <sect3 id="ch0134s0011s0017">
          <title>Spectrum of Activity</title>
          <anchor id="ch0134s0011a0027"/>
          <anchor id="ch0134s0000a0230"/>
          <para id="ch0134s0000p0236">CDV is active against several herpesviruses, including HCMV, HSV, and VZV (<link linkend="ch0134s0000li0004">4</link>). CDV also has antiviral activity against poxviruses (<link linkend="ch0134s0000li0149">149</link>), adenovirus (<link linkend="ch0134s0000li0150">150</link>), polyomaviruses (<link linkend="ch0134s0000li0151">151</link>), and human papillomavirus (<link linkend="ch0134s0000li0152">152</link>, <link linkend="ch0134s0000li0153">153</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0018">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0028"/>
          <anchor id="ch0134s0000a0231"/>
          <para id="ch0134s0000p0237">No clinically significant interactions have been identified for CDV. However, the required administration of probenecid with CDV may produce drug-drug interactions resulting from the potential block of acidic drug transport in the kidney (<link linkend="ch0134s0000li0147">147</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0010">
        <title>Foscarnet</title>
        <anchor id="ch0134s0011a0029"/>
        <anchor id="ch0134s0000a0232"/>
        <sect3 id="ch0134s0011s0019">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0030"/>
          <anchor id="ch0134s0000a0233"/>
          <para id="ch0134s0000p0238">Pharmacokinetic data indicate that foscarnet (FOS) undergoes negligible metabolism, appears to be distributed widely by the circulation, and is eliminated via the renal route. The available data, however, indicate that the pharmacokinetics of the drug varies among patients and within the individual patient, particularly regarding plasma FOS levels (<link linkend="ch0134s0000li0154">154</link>). The FOS terminal half-life determined by urinary excretion is 87.5 ± 41.8 h, possibly due to release of FOS from bone (<link linkend="ch0134s0000li0155">155</link>). Approximately 90% of FOS is excreted as unchanged drug in urine. Systemic clearance of FOS decreases and half-life increases with diminishing renal function, which may require FOS dosage modification (<link linkend="ch0134s0000li0156">156</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0020">
          <title>Spectrum of Activity</title>
          <anchor id="ch0134s0011a0031"/>
          <anchor id="ch0134s0000a0234"/>
          <para id="ch0134s0000p0239">Although FOS is active against several herpesviruses, including HSV, HCMV, VZV, and EBV, it is most commonly used to treat drug-resistant HSV and HCMV.</para>
        </sect3>
        <sect3 id="ch0134s0011s0021">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0032"/>
          <anchor id="ch0134s0000a0235"/>
          <para id="ch0134s0000p0240">Because FOS is reported to decrease calcium concentrations in serum, caution is advised for patients receiving agents known to affect calcium levels in serum such as intravenous pentamidine. Renal impairment is a major adverse effect of FOS; therefore, the use of FOS in combination with other potentially nephrotoxic drugs such as aminoglycosides and amphotericin B (<link linkend="ch0134s0000li0157">157</link>) should be avoided.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0011">
        <title>Ganciclovir and Valganciclovir</title>
        <anchor id="ch0134s0011a0033"/>
        <anchor id="ch0134s0000a0236"/>
        <sect3 id="ch0134s0011s0022">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0034"/>
          <anchor id="ch0134s0000a0237"/>
          <para id="ch0134s0000p0241">Ganciclovir (GCV) is an acyclic nucleoside analogue of 2′-deoxyguanosine which requires phosphorylation by a viral kinase to become active. GCV monophosphate is subsequently phosphorylated to the di- and triphosphate forms by cellular kinases (<link linkend="ch0134s0000li0001">1</link>, <link linkend="ch0134s0000li0004">4</link>).</para>
          <para id="ch0134s0000p0242">Val-GCV, the<phrase role="small">L</phrase>-valyl ester prodrug of GCV, is rapidly converted to GCV after oral administration (<link linkend="ch0134s0000li0158">158</link>). Val-GCV should be administered with food. The bioavailability of val-GCV is 60.9% compared to 5.6% for the oral formulation of GCV. The half-life of GCV is 4 h in healthy volunteers and 6.5 h in transplant recipients (<link linkend="ch0134s0000li0159">159</link>, <link linkend="ch0134s0000li0160">160</link>). GCV is only 1 to 2% protein bound. Renal excretion of unchanged drug by glomerular filtration and active tubular secretion is the major route of elimination (91%).</para>
        </sect3>
        <sect3 id="ch0134s0011s0023">
          <title>Spectrum of Activity</title>
          <anchor id="ch0134s0011a0035"/>
          <anchor id="ch0134s0000a0238"/>
          <para id="ch0134s0000p0243">GCV is active against HCMV as well as HSV-1, HSV-2, VZV, EBV, human herpesvirus type 6 (HHV-6), HHV-7, and HHV-8 (<link linkend="ch0134s0000li0161">161</link>–<link linkend="ch0134s0000li0164">164</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0024">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0036"/>
          <anchor id="ch0134s0000a0239"/>
          <para id="ch0134s0000p0244">Coadministration of GCV with ddI results in significantly increased levels of ddI (<link linkend="ch0134s0000li0162">162</link>). Coadministration of GCV with ZDV requires dose modifications of both drugs because of their common adverse hematological effects of neutropenia and anemia. Dosage modifications may also be required with drugs that inhibit renal tubular secretion, such as probenecid. Imipenem/cilastatin should not be administered with GCV (<link linkend="ch0134s0000li0162">162</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0012">
        <title>Letermovir</title>
        <anchor id="ch0134s0011a0037"/>
        <anchor id="ch0134s0000a0240"/>
        <sect3 id="ch0134s0011s0025">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0038"/>
          <anchor id="ch0134s0000a0241"/>
          <para id="ch0134s0000p0245">Letermovir prevents HCMV replication by inhibiting the terminase complex (pUL51, pUL56, pUL89), resulting in an inability to cleave concatemeric genomic viral DNA and package genomes into preformed virus capsids. It is orally bioavailable and has a half-life of 12 hours. It is primarily excreted in the feces. In a phase III double-blind trial of HCMV-seropositive hematopoietic stem cell transplant recipients, the efficacy of letermovir in preventing active HCMV infection was compared to placebo through week 24 after transplant (<link linkend="ch0134s0000li0165">165</link>). The trial found that 37.5% of patients on letermovir developed active CMV infection versus 60.6% of patients on placebo. Most cases of active HCMV infection were asymptomatic DNAemia. HCMV disease was rare. Adverse events were similar in the two groups, and myelotoxic and nephrotoxic events were similar. The results of this study led to FDA approval for letermovir in 2017.</para>
          <anchor id="ch0134s0000a0242"/>
          <beginpage pagenum="2216"/>
        </sect3>
        <sect3 id="ch0134s0011s0026">
          <title>Spectrum of Activity</title>
          <anchor id="ch0134s0011a0039"/>
          <anchor id="ch0134s0000a0243"/>
          <para id="ch0134s0000p0246">Letermovir is active only against HCMV and does not have activity against other herpesviruses, including HSV and VZV.</para>
        </sect3>
        <sect3 id="ch0134s0011s0027">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0040"/>
          <anchor id="ch0134s0000a0244"/>
          <para id="ch0134s0000p0247">Letermovir is highly protein bound and metabolized in the liver. It is a P-glycoprotein and CYP3A4 inhibitor and can increase serum concentrations of amlodipine, atorvastatin, cilostazol, cyclosporine, and ibrutinib, among others.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0013">
        <title>Penciclovir and Famciclovir</title>
        <anchor id="ch0134s0011a0041"/>
        <anchor id="ch0134s0000a0245"/>
        <sect3 id="ch0134s0011s0028">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0042"/>
          <anchor id="ch0134s0000a0246"/>
          <para id="ch0134s0000p0248">Famciclovir is the oral prodrug diacetyl 6-deoxy analogue of penciclovir (PCV) (<link linkend="ch0134s0000li0166">166</link>), which undergoes rapid conversion to the active compound, PCV. Famciclovir was developed to improve the bioavailability of the parent compound (<link linkend="ch0134s0000li0167">167</link>). PCV is available only as a 1% cream for the topical treatment of herpes labialis (<link linkend="ch0134s0000li0168">168</link>). The bioavailability of PCV is 77%, and the half-life is 2 h. It can be given with or without food. PCV is &lt;20% protein bound and is eliminated in the urine (73%) and feces (27%) (<link linkend="ch0134s0000li0169">169</link>). Although PCV is structurally related to ACV, it has a higher affinity for the HSV thymidine kinases than ACV. However, ACV triphosphate has a higher affinity for the HSV DNA polymerase than does PCV triphosphate. As a result, the two compounds have similar anti-HSV potencies (<link linkend="ch0134s0000li0170">170</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0029">
          <title>Spectrum of Activity</title>
          <anchor id="ch0134s0011a0043"/>
          <anchor id="ch0134s0000a0247"/>
          <para id="ch0134s0000p0249">PCV and famciclovir are active against HSV-1, HSV-2, and VZV (<link linkend="ch0134s0000li0171">171</link>). Neither of these compounds is active against other human herpesviruses.</para>
        </sect3>
        <sect3 id="ch0134s0011s0030">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0044"/>
          <anchor id="ch0134s0000a0248"/>
          <para id="ch0134s0000p0250">No clinically significant drug interactions have been identified for PCV.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0014">
        <title>Trifluridine</title>
        <anchor id="ch0134s0011a0045"/>
        <anchor id="ch0134s0000a0249"/>
        <sect3 id="ch0134s0011s0031">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0046"/>
          <anchor id="ch0134s0000a0250"/>
          <para id="ch0134s0000p0251">Trifluridine is a fluorinated pyrimidine nucleoside approved for the topical treatment of epithelial keratitis caused by HSV (<link linkend="ch0134s0000li0172">172</link>). It has activity against HSV-1, HSV-2, and vaccinia virus (<link linkend="ch0134s0000li0173">173</link>). Intraocular penetration of trifluridine occurs after topical instillation into the eye. Decreased corneal integrity or stromal or uveal inflammation may enhance the penetration of trifluridine into the aqueous humor. Systemic absorption following therapeutic dosing with trifluridine appears to be negligible (<link linkend="ch0134s0000li0174">174</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0032">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0047"/>
          <anchor id="ch0134s0000a0251"/>
          <para id="ch0134s0000p0252">There are no reported drug interactions by the topical route of administration.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0015">
        <title>n-Docosanol</title>
        <anchor id="ch0134s0011a0048"/>
        <anchor id="ch0134s0000a0252"/>
        <sect3 id="ch0134s0011s0033">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0049"/>
          <anchor id="ch0134s0000a0253"/>
          <para id="ch0134s0000p0253"><emphasis>n</emphasis>-Docosanol exhibits <emphasis>in vitro</emphasis> antiviral activity against several lipid-enveloped viruses including HSV-1, HSV-2, and respiratory syncytial virus (<link linkend="ch0134s0000li0175">175</link>). A topical preparation of <emphasis>n</emphasis>-docosanol is available without prescription as a 10% cream for the treatment of herpes labialis.</para>
        </sect3>
        <sect3 id="ch0134s0011s0034">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0050"/>
          <anchor id="ch0134s0000a0254"/>
          <para id="ch0134s0000p0254">There are no reported drug interactions with topical administration.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0016">
        <title>Maribavir</title>
        <anchor id="ch0134s0011a0051"/>
        <anchor id="ch0134s0000a0255"/>
        <sect3 id="ch0134s0011s0035">
          <title>Pharmacology</title>
          <anchor id="ch0134s0011a0052"/>
          <anchor id="ch0134s0000a0256"/>
          <para id="ch0134s0000p0255">Maribavir is an antiviral agent in the benzimidazole drug class (<link linkend="ch0134s0000li0176">176</link>). It inhibits UL97 kinase activity directly, blocking viral replication. It was approved by the FDA in 2021 for the treatment of adults and pediatric patients (12 years of age and older) with posttransplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet (<link linkend="ch0134s0000li0177">177</link>–<link linkend="ch0134s0000li0179">179</link>).</para>
          <para id="ch0134s0000p0256">Maribavir is only available as an oral formulation. It goes through rapid absorption with a bioavailability of 30 to 40%, but the administration with meals high in fat decreases maribavir concentrations by 30%. It is highly plasma protein bound (&gt;97%), with a plasma half-life of 3 to 5 hours. It is extensively hepatically metabolized and primarily eliminated via biliary excretion. Its clearance is not impacted by renal impairment (&lt;3% urinary excretion) (<link linkend="ch0134s0000li0178">178</link>–<link linkend="ch0134s0000li0180">180</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0036">
          <title>Spectrum of Activity</title>
          <anchor id="ch0134s0011a0053"/>
          <anchor id="ch0134s0000a0257"/>
          <para id="ch0134s0000p0257">Maribavir has a very narrow spectrum of coverage since it is an inhibitor of the UL97 kinase enzyme of CMV. It therefore provides highly specific antiviral activity against CMV.</para>
          <para id="ch0134s0000p0258"><emphasis>In vitro</emphasis>, maribavir has potent efficacy against Epstein-Barr virus (EBV) via inhibition of viral DNA replication and of virus transcription, although there are no clinical data suggesting efficacy (<link linkend="ch0134s0000li0181">181</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0037">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0011a0054"/>
          <anchor id="ch0134s0000a0258"/>
          <para id="ch0134s0000p0259">Maribavir is not recommended to be coadministered with ganciclovir/valganciclovir because it may antagonize the antiviral activity of those antivirals by inhibiting human CMV pUL97 kinase, which is required for activation and phosphorylation of ganciclovir/valganciclovir.</para>
          <para id="ch0134s0000p0260">Maribavir is a substrate of CYP3A4. Coadministration of this drug with strong inducers of CYP3A4 is not recommended, except for selected anticonvulsants (<link linkend="ch0134s0000li0177">177</link>, <link linkend="ch0134s0000li0180">180</link>).</para>
        </sect3>
        <sect3 id="ch0134s0011s0038">
          <title>Other Drugs against Herpesviruses</title>
          <anchor id="ch0134s0011a0055"/>
          <anchor id="ch0134s0000a0259"/>
          <para id="ch0134s0000p0261">There are several antiviral agents that are undergoing clinical trials or that are approved for conditions other than antiviral therapy.</para>
          <para id="ch0134s0000p0262">Brincidofovir is an orally administered lipid conjugate of CDV (<link linkend="ch0134s0000li0182">182</link>). It has <emphasis>in vitro</emphasis> activity against all the herpesviruses, including GCV-resistant CMV and ACV-resistant HSV, as well as polyomaviruses, poxviruses, and adenovirus (<link linkend="ch0134s0000li0183">183</link>). However, severe diarrhea and increased mortality led to the failure of a phase III trial (<link linkend="ch0134s0000li0175">175</link>). New formulations may lead to future trials to pursue the treatment of targeted patients.</para>
          <para id="ch0134s0000p0263">Two helicase/primase inhibitors, pritelivir and amenamevir, have shown efficacy in phase II studies (<link linkend="ch0134s0000li0184">184</link>, <link linkend="ch0134s0000li0185">185</link>). Pritelivir and amenamevir show <emphasis>in vitro</emphasis> activity against HSV-1 and HSV-2, while amenamevir also shows activity against VZV.</para>
          <para id="ch0134s0000p0264">Two additional drugs that are approved for other medical conditions have been reported to have antiviral activity against HCMV, although no clinical trials have been conducted. These are leflunomide, which is approved for treatment of rheumatoid arthritis (<link linkend="ch0134s0000li0186">186</link>, <link linkend="ch0134s0000li0187">187</link>), and artesunate, which is an antimalarial agent (<link linkend="ch0134s0000li0188">188</link>, <link linkend="ch0134s0000li0189">189</link>).</para>
          <anchor id="ch0134s0000a0260"/>
          <beginpage pagenum="2217"/>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0011s0017">
        <title>AGENTS AGAINST INFLUENZA VIRUSES</title>
        <anchor id="ch0134s0011a0056"/>
        <anchor id="ch0134s0000a0261"/>
        <para id="ch0134s0000p0265">There are three classes of antivirals for the treatment of influenza: neuraminidase inhibitors, cap-dependent endonuclease inhibitors, and M2 protein inhibitors. The first two classes treat influenza A and B, while the last one only treats influenza A (<link linkend="ch0134s0000li0190">190</link>–<link linkend="ch0134s0000li0194">194</link>).</para>
        <para id="ch0134s0000p0266"><anchor id="ch0134s0000a0262"/><link linkend="ch0134s0000a0270">Table 5</link> summarizes information about the structure, mode of action, route of administration, and adverse effects of each drug. Recommendations on using antivirals to prevent and treat influenza are available from the Centers for Disease Control and Prevention website (<ulink url="http://www.cdc.gov/flu">http://www.cdc.gov/flu</ulink>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0012">
      <title>M2 Protein Inhibitors</title>
      <anchor id="ch0134s0012a0001"/>
      <anchor id="ch0134s0000a0263"/>
      <para id="ch0134s0000p0267">The virus-encoded M2 protein facilitates the hydrogen ion-mediated dissociation of the matrix protein-ribonucleoprotein complex within the endosome and the release of the viral ribonucleoprotein into the cytoplasm of the host cell. The M2 inhibitors block the passage of H<superscript>+</superscript> ions through the M2 ion channel, preventing the virus’s uncoating (<link linkend="ch0134s0000li0001">1</link>, <link linkend="ch0134s0000li0195">195</link>, <link linkend="ch0134s0000li0196">196</link>).</para>
      <sect2 id="ch0134s0012s0001">
        <title>Amantadine and Rimantadine</title>
        <anchor id="ch0134s0012a0002"/>
        <anchor id="ch0134s0000a0264"/>
        <para id="ch0134s0000p0268">The adamantanes differ in their metabolism and adverse effects but have similar antiviral activity against influenza A viruses. Neither drug has activity against influenza B viruses. Recent reports indicate that both the seasonal influenza virus, H3N2, and the current pandemic virus, H1N1, have a high incidence of resistance to both drugs (<link linkend="ch0134s0000li0001">1</link>, <link linkend="ch0134s0000li0197">197</link>, <link linkend="ch0134s0000li0198">198</link>); therefore, the adamantanes are no longer recommended for influenza prophylaxis or empiric therapy.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0013">
      <title>Neuraminidase Inhibitors</title>
      <anchor id="ch0134s0013a0001"/>
      <anchor id="ch0134s0000a0265"/>
      <para id="ch0134s0000p0269">The influenza virus neuraminidase is an envelope glycoprotein that cleaves the terminal sialic residues, releasing the virion from the infected cell. The virus-encoded neuraminidase allows the influenza virus to spread from cell to cell. There are three neuraminidase inhibitors approved for the treatment of influenza A and B viruses: oseltamivir, zanamivir, and peramivir (<link linkend="ch0134s0000li0199">199</link>, <link linkend="ch0134s0000li0201">201</link>). Oseltamivir is the most widely used. During the 2007–2008 period, many seasonal H1N1 influenza virus isolates were resistant to oseltamivir due to a single amino acid substitution, but they remained susceptible to zanamivir (<link linkend="ch0134s0000li0197">197</link>, <link linkend="ch0134s0000li0201">201</link>). However, for the 2013–2014 season, the CDC reported that 98.2% of the 2009 H1N1 pandemic virus strains were susceptible to oseltamivir, and 100% were susceptible to zanamivir (<ulink url="https://www.cdc.gov/flu">https://www.cdc.gov/flu</ulink>).</para>
      <sect2 id="ch0134s0013s0001">
        <title>Oseltamivir</title>
        <anchor id="ch0134s0013a0002"/>
        <anchor id="ch0134s0000a0266"/>
        <sect3 id="ch0134s0013s0001">
          <title>Pharmacology</title>
          <anchor id="ch0134s0013a0003"/>
          <anchor id="ch0134s0000a0267"/>
          <para id="ch0134s0000p0270">Oseltamivir phosphate is an ethyl ester prodrug that requires ester hydrolysis for conversion to the active form, oseltamivir carboxylate. After oral administration, oseltamivir phosphate is readily absorbed from the gastrointestinal tract and is extensively converted to oseltamivir carboxylate, predominantly by hepatic esterase (<link linkend="ch0134s0000li0202">202</link>). At least 75% of an oral dose reaches the systemic circulation as oseltamivir carboxylate. The binding of oseltamivir carboxylate to plasma protein is low. The plasma half-life is 6 to 10 h. There are fewer side effects if administered with food. Oseltamivir carboxylate is not further metabolized and is eliminated in the urine (<link linkend="ch0134s0000li0203">203</link>).</para>
          <para id="ch0134s0000p0271">Oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. It is also indicated for the prophylaxis of influenza in patients 1 year and older (<link linkend="ch0134s0000li0204">204</link>–<link linkend="ch0134s0000li0206">206</link>).</para>
        </sect3>
        <sect3 id="ch0134s0013s0002">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0013a0004"/>
          <anchor id="ch0134s0000a0268"/>
          <para id="ch0134s0000p0272">Studies of oseltamivir suggest that clinically significant drug interactions are unlikely because neither the drug nor the metabolite oseltamivir carboxylate is a substrate for the CYP450 isoenzymes or glucuronyl transferases. There is a risk for interaction with other agents excreted in the urine by the same pathways, such as probenecid (<link linkend="ch0134s0000li0203">203</link>). Oseltamivir should not be administered 2 weeks before or 48 hours after administering live influenza vaccines.</para>
          <anchor id="ch0134s0000a0269"/>
          <beginpage pagenum="2218"/>
          <table id="ch0134s0000t0005"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0134s0000a0270"/><link linkend="ch0134s0000a0262">TABLE 5</link></phrase></emphasis> Antiviral agents for influenza virus
</title>
            
            <tgroup cols="4">
              <tbody>
                <row>
                  <entry><phrase role="center">Antiviral agent</phrase>
                  </entry>
                  <entry><phrase role="center">Trade name (pharmaceutical company<superscript><link linkend="ch0134s0000a0275"><emphasis>a</emphasis></link></superscript>)</phrase>
                    <anchor id="ch0134s0000a0271"/>
                  </entry>
                  <entry><phrase role="center">Mechanism of action/route of administration</phrase>
                  </entry>
                  <entry><phrase role="center">Major adverse effects</phrase>
                  </entry>
                </row>
                <row>
                  <entry>Amantadine/rimantadine</entry>
                  <entry>Symmetrel/Flumadine</entry>
                  <entry><para id="ch0134s0000p0273">Prevents the release of nucleic acid by interfering with viral M2 protein; sialic acid analogue</para>
                    <para id="ch0134s0000p0274">Administered orally</para>
                  </entry>
                  <entry>CNS symptoms<superscript><link linkend="ch0134s0000a0276"><emphasis>b</emphasis></link></superscript><anchor id="ch0134s0000a0272"/>, GI symptoms<superscript><link linkend="ch0134s0000a0277"><emphasis>c</emphasis></link></superscript><anchor id="ch0134s0000a0273"/></entry>
                </row>
                <row>
                  <entry>Oseltamivir</entry>
                  <entry>Tamiflu (Genentech) (Gilead [licensor])</entry>
                  <entry><para id="ch0134s0000p0275">Competitive inhibitor of neuraminidase affecting the release of influenza virus particles from host cells</para>
                    <para id="ch0134s0000p0276">Administered orally</para>
                  </entry>
                  <entry>GI symptoms<superscript><link linkend="ch0134s0000a0277"><emphasis>c</emphasis></link></superscript> (usually mild), transient neuropsychiatric symptoms<superscript><link linkend="ch0134s0000a0278"><emphasis>d</emphasis></link></superscript><anchor id="ch0134s0000a0274"/></entry>
                </row>
                <row>
                  <entry>Peramivir</entry>
                  <entry>Rapivab (Biocryst)</entry>
                  <entry><para id="ch0134s0000p0277">Same as oseltamivir</para>
                    <para id="ch0134s0000p0278">Administered intravenously</para>
                  </entry>
                  <entry>GI symptoms<superscript><link linkend="ch0134s0000a0277"><emphasis>c</emphasis></link></superscript>, leukopenia/neutropenia</entry>
                </row>
                <row>
                  <entry>Zanamivir</entry>
                  <entry>Relenza (GSK)</entry>
                  <entry><para id="ch0134s0000p0279">Same as oseltamivir</para>
                    <para id="ch0134s0000p0280">Administered by oral inhalation</para>
                  </entry>
                  <entry>Respiratory function deterioration after inhalation</entry>
                </row>
                <row>
                  <entry>Baloxavir marboxil</entry>
                  <entry>Xofluza(Genentech INC)</entry>
                  <entry><para id="ch0134s0000p0281">Interferes with viral RNA transcription and blocks virus replication in influenza A and B viruses</para>
                    <para id="ch0134s0000p0282">Administered orally</para>
                  </entry>
                  <entry>Diarrhea (3%), bronchitis (2%), nasopharyngitis (1%), headache (1%), nausea (1%)</entry>
                </row>
              </tbody>
            </tgroup>
          </table>
          <para id="ch0134s0000p0283" role="table-footnote"><superscript><link linkend="ch0134s0000a0271"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0275"/>Pharmaceutical companies: BioCryst Pharmaceuticals, Durham, NC; Endo Pharmaceuticals, Inc., Chadds Ford, PA; Forrest Laboratories, Inc., St. Louis, MO; licensor: Gilead Sciences, Inc., Foster City, CA; GSK, GlaxoSmithKline, Research Triangle Park, NC; Genentech Inc.</para>
          <para id="ch0134s0000p0284" role="table-footnote"><superscript><link linkend="ch0134s0000a0272"><emphasis>b</emphasis></link></superscript><anchor id="ch0134s0000a0276"/>CNS symptoms include confusion, anxiety, insomnia, difficulty concentrating, dizziness, hallucinations, and seizures.</para>
          <para id="ch0134s0000p0285" role="table-footnote"><superscript><link linkend="ch0134s0000a0273"><emphasis>c</emphasis></link></superscript><anchor id="ch0134s0000a0277"/>GI (gastrointestinal) symptoms include nausea, vomiting, and anorexia.</para>
          <para id="ch0134s0000p0286" role="table-footnote"><superscript><link linkend="ch0134s0000a0274"><emphasis>d</emphasis></link></superscript><anchor id="ch0134s0000a0278"/>Neuropsychiatric symptoms include self-injury and delirium.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0013s0002">
        <title>Peramivir</title>
        <anchor id="ch0134s0013a0005"/>
        <anchor id="ch0134s0000a0279"/>
        <sect3 id="ch0134s0013s0003">
          <title>Pharmacology</title>
          <anchor id="ch0134s0013a0006"/>
          <anchor id="ch0134s0000a0280"/>
          <para id="ch0134s0000p0287">Peramivir was approved in 2014 for the treatment of uncomplicated influenza. Peramivir has poor oral bioavailability and is only available as an intravenous formulation, administered as a single dose. Peramivir is mainly excreted by the kidneys (<link linkend="ch0134s0000li0207">207</link>).</para>
        </sect3>
        <sect3 id="ch0134s0013s0004">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0013a0007"/>
          <anchor id="ch0134s0000a0281"/>
          <para id="ch0134s0000p0288">There are no significant known drug interactions (<link linkend="ch0134s0000li0207">207</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0013s0003">
        <title>Zanamivir</title>
        <anchor id="ch0134s0013a0008"/>
        <anchor id="ch0134s0000a0282"/>
        <para id="ch0134s0000p0289">Zanamivir has been shown to reduce the severity and duration of uncomplicated influenza illness in adults (<link linkend="ch0134s0000li0208">208</link>). Zanamivir is only administered by oral inhalation, providing high drug concentrations in the respiratory tract (<link linkend="ch0134s0000li0209">209</link>). Because of the respiratory route of administration, zanamivir is contraindicated in patients with underlying airway diseases such as asthma. As noted above, the H1N1 strains that have become resistant to oseltamivir remain susceptible to zanamivir.</para>
        <sect3 id="ch0134s0013s0005">
          <title>Pharmacology</title>
          <anchor id="ch0134s0013a0009"/>
          <anchor id="ch0134s0000a0283"/>
          <para id="ch0134s0000p0290">The absolute oral bioavailability of zanamivir is low, averaging 2%. After intranasal or oral inhaled administration, a median of 10 to 20% of the dose is systemically absorbed, with maximum concentrations in serum generally reached within 1 to 2 hours. The remaining 70 to 80% is left in the oropharynx and is eliminated in the feces. The median serum half-life ranges between 2.5 and 5.5 hours, and the systemically absorbed drug is excreted unchanged in the urine. The low absorption level of the drug after inhalation produces low concentrations in serum with only modest systemic zanamivir exposure (<link linkend="ch0134s0000li0203">203</link>).</para>
        </sect3>
        <sect3 id="ch0134s0013s0006">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0013a0010"/>
          <anchor id="ch0134s0000a0284"/>
          <para id="ch0134s0000p0291">Zanamivir is not metabolized; therefore, there is minimal potential for drug-drug interaction (<link linkend="ch0134s0000li0210">210</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0013s0004">
        <title>Cap-Dependent Endonuclease Inhibitors</title>
        <anchor id="ch0134s0013a0011"/>
        <anchor id="ch0134s0000a0285"/>
        <sect3 id="ch0134s0013s0007">
          <title>Pharmacology</title>
          <anchor id="ch0134s0013a0012"/>
          <anchor id="ch0134s0000a0286"/>
          <para id="ch0134s0000p0292">Baloxavir marboxil is a prodrug converted by hydrolysis to its active metabolite, baloxavir, after oral administration. It inhibits the endonuclease activity of the polymerase acidic protein, an influenza virus-specific enzyme in the RNA polymerase complex, resulting in inhibition of virus replication (<link linkend="ch0134s0000li0194">194</link>).</para>
          <para id="ch0134s0000p0293">Approximately 92% of the baloxavir is bound to serum proteins. Its metabolism is done primarily through UGTIA3 and secondary by CYP3A4. Its elimination is mainly by fecal route (80%).</para>
          <para id="ch0134s0000p0294">No clinically significant differences in the pharmacokinetics were observed based on age, sex, creatinine clearance (CrCl 50 m/min and above), or moderate hepatic impairment (Child-Pugh class B). The effect of severe renal or hepatic impairment on baloxavir pharmacokinetics has not been evaluated (<link linkend="ch0134s0000li0211">211</link>).</para>
        </sect3>
        <sect3 id="ch0134s0013s0008">
          <title>Drug Interactions</title>
          <anchor id="ch0134s0013a0013"/>
          <anchor id="ch0134s0000a0287"/>
          <para id="ch0134s0000p0295">Coadministration with polyvalent cation-containing products, such as calcium, aluminum, or magnesium, may decrease the plasma concentration of baloxavir by chelation, which may reduce its efficacy (<link linkend="ch0134s0000li0194">194</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0134s0013s0005">
        <title>AGENTS AGAINST SARS-CoV-2 VIRUS</title>
        <anchor id="ch0134s0013a0014"/>
        <anchor id="ch0134s0000a0288"/>
        <anchor id="ch0134s0000a0289"/>
        <para id="ch0134s0000p0296">Since the first SARS-CoV-2 cases were reported in China in December 2019, its treatment has evolved as the virus has constantly changed through random mutations. The current drugs prevent SARS-CoV-2 viral replication through various mechanisms, including blocking viral entry into host cells and inhibiting the activity of SARS-CoV-2 3-chymotrypsin-like protease (3CLpro) and RNA-dependent RNA polymerase (RdRp).</para>
        <para id="ch0134s0000p0297">As of 2022, the FDA has only approved remdesivir for treating COVID-19; the remaining antivirals, such as ritonavir-boosted nirmatrelvir (Paxlovid), molnupiravir, and anti-SARS-CoV-2 monoclonal antibodies (MAbs), have only received emergency use authorization (EUA) (<link linkend="ch0134s0000li0212">212</link>). <anchor id="ch0134s0000a0290"/><link linkend="ch0134s0000a0294">Table 6</link> summarizes information about the structure, mechanism of action, route of administration, and adverse effects of each drug.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0014">
      <title>Remdesivir</title>
      <anchor id="ch0134s0014a0001"/>
      <anchor id="ch0134s0000a0291"/>
      <para id="ch0134s0000p0298">Remdesivir was approved in October 2020 by the FDA to treat severe COVID-19 in adults and children 12 years old and older with a weight of at least 40 kg (<link linkend="ch0134s0000li0214">214</link>–<link linkend="ch0134s0000li0220">220</link>).</para>
      <para id="ch0134s0000p0299">In April 2022, the FDA extended the approval for the use of remdesivir in pediatric patients 28 days of age and older with a weight of at least 3 kg (<link linkend="ch0134s0000li0221">221</link>). That recommendation was supported by a phase II/III, single-arm, open-label clinical study. This small study involved 53 pediatric patients at least 28 days of age and weighing at least 3 kg with confirmed mild, moderate, or severe COVID-19 (<link linkend="ch0134s0000li0221">221</link>, <link linkend="ch0134s0000li0222">222</link>). The safety and pharmacokinetic results were similar to those in adults.</para>
      <para id="ch0134s0000p0300">Remdesivir is recommended to treat nonhospitalized patients with mild to moderate COVID-19 at high risk of progression to severe disease, and hospitalized patients. Remdesivir is not recommended in patients requiring oxygen on high-flow nasal cannula, noninvasive mechanical ventilation, mechanical ventilation, or extracorporeal membrane oxygenation, due to lack of benefit in this population (212–218, 220).</para>
      <sect2 id="ch0134s0014s0001">
        <title>Pharmacology</title>
        <anchor id="ch0134s0014a0002"/>
        <anchor id="ch0134s0000a0292"/>
        <para id="ch0134s0000p0301">Remdesivir is an adenosine nucleotide prodrug that, once metabolized to its active form nucleoside triphosphate, acts as an ATP analogue and competes with native ATP substrates for incorporation in RNA chains by the RNA-dependent RNA polymerase, thereby inhibiting viral replication.<emphasis>In vitro</emphasis>, it inhibits SARS-CoV-2 replication in animal cells (<link linkend="ch0134s0000li0223">223</link>). Its half-life is about 1 hour, and the half-life of its metabolite GS-441524 is around 25 hrs. Approximately 74% of remdesivir is recovered in feces and 18% in urine. Its protein binding is around 90%.</para>
      </sect2>
      <sect2 id="ch0134s0014s0002">
        <title>Drug Interactions</title>
        <anchor id="ch0134s0014a0003"/>
        <anchor id="ch0134s0000a0293"/>
        <para id="ch0134s0000p0302">There are no clinical studies on drug interaction with remdesivir.<emphasis>In vitro</emphasis> studies show that remdesivir is a minor substrate for drug-metabolizing enzyme CYP3A4 and is a substrate for organic anion transporting polypeptides 1B1 and P-glycoprotein (P-gp) transporters (<link linkend="ch0134s0000li0224">224</link>). It is also an inhibitor of CYP3A4, OATP1B1, OATP1B3, and MATE1. The clinical relevance of these <emphasis>in vitro</emphasis> findings is unknown (<link linkend="ch0134s0000li0213">213</link>).</para>
        <table id="ch0134s0000t0006"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0134s0000a0294"/><link linkend="ch0134s0000a0290">TABLE 6</link></phrase></emphasis> Agents against SARS-CoV-2
</title>
          
          <tgroup cols="5">
            <tbody>
              <row>
                <entry><phrase role="center">Antiviral agent</phrase>
                </entry>
                <entry><phrase role="center">Trade name (pharmaceutical company)</phrase>
                </entry>
                <entry><phrase role="center">Mechanism of action/route of administration</phrase>
                </entry>
                <entry><phrase role="center">Major adverse effects</phrase>
                </entry>
                <entry><phrase role="center">FDA status</phrase>
                </entry>
              </row>
              <row>
                <entry>Remdesivir</entry>
                <entry>Veklury (Gilead)</entry>
                <entry><para id="ch0134s0000p0303">Binds to the viral RdRp<superscript><link linkend="ch0134s0000a0297"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0295"/> and inhibits viral replication by terminating RNA transcription prematurely</para>
                  <para id="ch0134s0000p0304">Administered intravenously</para>
                </entry>
                <entry>Anaphylactic reaction, nausea, elevation of liver enzymes</entry>
                <entry>Approved</entry>
              </row>
              <row>
                <entry>Molnupiravir</entry>
                <entry>Lagevrio (Merck)</entry>
                <entry><para id="ch0134s0000p0305">Prodrug of a ribonucleoside analog that is converted to the active triphosphate form that serves as a competitive substrate for virally encoded RNA-dependent RNA polymerase leading to inhibition of replication</para>
                  <para id="ch0134s0000p0306">Administered orally</para>
                </entry>
                <entry><para id="ch0134s0000p0307">Anaphylactic reaction, diarrhea, nausea, and dizziness</para>
                  <para id="ch0134s0000p0308">Do not use during pregnancy</para>
                </entry>
                <entry>EUA</entry>
              </row>
              <row>
                <entry>Nirmatrelvir/ritonavir</entry>
                <entry>Paxlovid (Pfizer)</entry>
                <entry><para id="ch0134s0000p0309">A SARS-CoV-2 protease inhibitor that blocks the activity of the SARS-CoV-2-3CL protease, preventing viral replication</para>
                  <para id="ch0134s0000p0310">Administered orally</para>
                </entry>
                <entry>Dysgeusia, diarrhea, hypertension, myalgia</entry>
                <entry>EUA</entry>
              </row>
              <row>
                <entry>Casirivimab/imdevimab<superscript><link linkend="ch0134s0000a0298"><emphasis>b</emphasis></link></superscript><anchor id="ch0134s0000a0296"/></entry>
                <entry>REGEN-COV (Regeneron Pharmaceuticals, Inc.)</entry>
                <entry><para id="ch0134s0000p0311">Two recombinant human IgG1 monoclonal antibodies that bind epitopes of the spike protein receptor-binding domain of SARS-CoV-2, blocking viral entry</para>
                  <para id="ch0134s0000p0312">Administered by intravenous and subcutaneous routes</para>
                </entry>
                <entry>Anaphylaxis and infusion-related reactions</entry>
                <entry>EUA</entry>
              </row>
              <row>
                <entry>Bamlanivimab/etesevimab<superscript><link linkend="ch0134s0000a0298"><emphasis>b</emphasis></link></superscript></entry>
                <entry><para id="ch0134s0000p0313">LY-CoV555</para>
                  <para id="ch0134s0000p0314">(Lilly)</para>
                </entry>
                <entry><para id="ch0134s0000p0315">Same as casirivimab/imdevimab</para>
                  <para id="ch0134s0000p0316">Administered intravenously</para>
                </entry>
                <entry>Anaphylaxis and infusion-related reactions</entry>
                <entry>EUA</entry>
              </row>
              <row>
                <entry>Sotrovimab<superscript><link linkend="ch0134s0000a0298"><emphasis>b</emphasis></link></superscript></entry>
                <entry><para id="ch0134s0000p0317">Xevudy</para>
                  <para id="ch0134s0000p0318">(GlaxoSmithKline and Vir Biotechnology)</para>
                </entry>
                <entry><para id="ch0134s0000p0319">Same as casirivimab/imdevimab</para>
                  <para id="ch0134s0000p0320">Administered intravenously</para>
                </entry>
                <entry>Anaphylaxis and infusion-related reactions</entry>
                <entry>EUA</entry>
              </row>
              <row>
                <entry>Bebtelovimab<superscript><link linkend="ch0134s0000a0298"><emphasis>b</emphasis></link></superscript></entry>
                <entry>(Lilly)</entry>
                <entry><para id="ch0134s0000p0321">Same as casirivimab/imdevimab</para>
                  <para id="ch0134s0000p0322">Administered intravenously</para>
                </entry>
                <entry>Anaphylaxis and infusion-related reactions</entry>
                <entry>EUA</entry>
              </row>
              <row>
                <entry>Tixagevimab plus cilgavimab<superscript><link linkend="ch0134s0000a0298"><emphasis>b</emphasis></link></superscript></entry>
                <entry><para id="ch0134s0000p0323">Evusheld</para>
                  <para id="ch0134s0000p0324">(AstraZeneca)</para>
                </entry>
                <entry><para id="ch0134s0000p0325">Same as casirivimab/imdevimab</para>
                  <para id="ch0134s0000p0326">Administered by intramuscular route</para>
                </entry>
                <entry>Anaphylaxis and infusion-related reactions, headaches, fatigue</entry>
                <entry>EUA</entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para id="ch0134s0000p0327" role="table-footnote"><superscript><link linkend="ch0134s0000a0295"><emphasis>a</emphasis></link></superscript><anchor id="ch0134s0000a0297"/>RdRp, RNA-dependent RNA polymerase.</para>
        <para id="ch0134s0000p0328" role="table-footnote"><superscript><link linkend="ch0134s0000a0296"><emphasis>b</emphasis></link></superscript><anchor id="ch0134s0000a0298"/>These antivirals are no longer recommended for prevention or treatment of SARS-CoV-2 infections, given decreased efficacy on the circulating Omicron subvariants.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0015">
      <title>Molnupiravir</title>
      <anchor id="ch0134s0015a0001"/>
      <anchor id="ch0134s0000a0299"/>
      <para id="ch0134s0000p0329">On December 2021, the FDA issued an emergency use authorization for molnupiravir to treat adults with mild to moderate COVID-19 at high risk of progression to severe disease (<link linkend="ch0134s0000li0225">225</link>, <link linkend="ch0134s0000li0226">226</link>), based on a phase II/III, double-blind, parallel-group, randomized, placebo-controlled trial (MOVe-OUT trial) (<link linkend="ch0134s0000li0226">226</link>). This study showed that a 5-day course of molnupiravir given within 5 days of symptom onset reduced the risk of hospitalization or death from 9.7% (68/699) to 6.8% (48/709) (difference, −3.0 percentage points; 95% CI, −5.9 to −0.1). Nine deaths were reported in the placebo group and one in the treatment group (<link linkend="ch0134s0000li0225">225</link>, <link linkend="ch0134s0000li0226">226</link>). The MOVe-OUT trial excluded participants aged &lt;18 years. Molnupiravir has demonstrated activity against the Omicron variant (212, 227–229).</para>
      <sect2 id="ch0134s0015s0001">
        <title>Pharmacology</title>
        <anchor id="ch0134s0015a0002"/>
        <anchor id="ch0134s0000a0300"/>
        <para id="ch0134s0000p0330">Molnupiravir is metabolized to the cytidine nucleoside analogue N4-hydroxycytidine (NHC), which is incorporated into SARS-CoV-2 RNA by the viral RdRp. It results in an accumulation of errors in the viral genome, leading to inhibition of replication (viral error catastrophe or viral lethal mutagenesis) (<link linkend="ch0134s0000li0226">226</link>). Molnupiravir’s half-life is about 3.3 hours, and ≤3% of an oral dose is eliminated in the urine as the active metabolite NHC. Molnupiravir is not protein serum bound.</para>
        <para id="ch0134s0000p0331">Renal clearance is not a meaningful route of elimination for NHC, and it has not been evaluated in patients with estimated glomerular filtration rate (eGFR) less than 30 ml/min/1.73 m<superscript>2</superscript> or on dialysis.</para>
        <para id="ch0134s0000p0332">Preclinical studies indicate that hepatic elimination is not a significant route of NHC elimination; therefore, hepatic impairment is unlikely in NHC exposure.</para>
        <para id="ch0134s0000p0333">The FDA recommends against molnupiravir use in pregnancy, because fetal toxicity has been reported in animal studies, nor in children aged &lt;18 years, due to potential effects on bone and cartilage growth (<link linkend="ch0134s0000li0212">212</link>, <link linkend="ch0134s0000li0226">226</link>).</para>
        <anchor id="ch0134s0000a0301"/>
        <beginpage pagenum="2220"/>
      </sect2>
      <sect2 id="ch0134s0015s0002">
        <title>Drug Interactions</title>
        <anchor id="ch0134s0015a0003"/>
        <anchor id="ch0134s0000a0302"/>
        <para id="ch0134s0000p0334"><emphasis>In vitro</emphasis>, molnupiravir has minimal drug interactions through CYP3A4. The interaction between molnupiravir and concomitant medications, including other treatments for mild-to-moderate COVID-19, has not been evaluated (<link linkend="ch0134s0000li0226">226</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0016">
      <title>Nirmatrelvir/Ritonavir</title>
      <anchor id="ch0134s0016a0001"/>
      <anchor id="ch0134s0000a0303"/>
      <para id="ch0134s0000p0335">On December 2021, the FDA issued an emergency use authorization for nirmatrelvir/ritonavir (Paxlovid) to treat adults and children 12 years and older, with a weight of at least 40 kg, who are at high risk for progression to severe COVID-19, including hospitalization or death (<link linkend="ch0134s0000li0230">230</link>), based on the EPIC-H.R. study. This phase II/III, double-blind, randomized, placebo-controlled trial, in nonhospitalized adult patients at high risk of progressing to severe COVID-19 disease and treated with nirmatrelvir/ritonavir within 3 days after symptom onset, showed a reduction in hospitalization or death from 7% (27/385, 7 deaths) to 0.8% (3/389 patients, 0 deaths). The absolute risk reduction was −6.3 percentage points (95% CI, –9.04 to –3.59; <emphasis>P</emphasis> &lt; 0.001), and the relative risk reduction was 89.1% (modified intention-to-treat analysis, comprising 774 of the 1,361 patients in the full analysis population).</para>
      <para id="ch0134s0000p0336">Similar efficacy was noted in the group randomized within 5 days of symptom onset (<link linkend="ch0134s0000li0227">227</link>, <link linkend="ch0134s0000li0228">228</link>, <link linkend="ch0134s0000li0231">231</link>, <link linkend="ch0134s0000li0232">232</link>). Case reports have described SARS-CoV-2 viral rebound and recurrence of COVID-19 symptoms in some patients who have completed treatment with nirmatrelvir/ritonavir; however, the clinical implications of these findings are unknown (<link linkend="ch0134s0000li0232">232</link>, <link linkend="ch0134s0000li0233">233</link>). Paxlovid has demonstrated activity against all SARS-CoV-2 variants, including Omicron (<link linkend="ch0134s0000li0229">229</link>, <link linkend="ch0134s0000li0231">231</link>, <link linkend="ch0134s0000li0232">232</link>, <link linkend="ch0134s0000li0234">234</link>–<link linkend="ch0134s0000li0236">236</link>).</para>
      <sect2 id="ch0134s0016s0001">
        <title>Pharmacology</title>
        <anchor id="ch0134s0016a0002"/>
        <anchor id="ch0134s0000a0304"/>
        <para id="ch0134s0000p0337">Nirmatrelvir/ritonavir is a SARS-CoV-2 protease inhibitor that blocks the activity of the SARS-CoV-2 3CL protease. Coadministration with low-dose ritonavir helps slow its metabolism and allows for higher concentrations. It inhibits viral replication at the proteolytic stage before viral RNA replication. Preclinical studies did not demonstrate mutagenic DNA interactions (<link linkend="ch0134s0000li0232">232</link>).</para>
        <para id="ch0134s0000p0338">It has a half-life of around 6 hours, and its protein binding is close to 69%. Nirmatrelvir has minimal metabolism when dosed with ritonavir; however, ritonavir is mainly metabolized by CYP3A4 enzymes. The excretion of nirmatrelvir/ritonavir is mainly by the renal route.</para>
      </sect2>
      <sect2 id="ch0134s0016s0002">
        <title>Drug Interactions</title>
        <anchor id="ch0134s0016a0003"/>
        <anchor id="ch0134s0000a0305"/>
        <para id="ch0134s0000p0339">Nirmatrelvir/ritonavir is a potent inhibitor of CYP3A and may increase plasma concentrations of drugs primarily metabolized by CYP3A. Its coadministration with drugs that are primarily cleared via CYP3A may be associated with severe and even life-threatening events (<link linkend="ch0134s0000li0232">232</link>).</para>
      </sect2>
      <sect2 id="ch0134s0016s0003">
        <title>ANTI-SARS-CoV-2 MONOCLONAL ANTIBODIES</title>
        <anchor id="ch0134s0016a0004"/>
        <anchor id="ch0134s0000a0306"/>
        <para id="ch0134s0000p0340">The anti-SARS-CoV-2 monoclonal antibodies (MAbs) target the virus spike proteins and block their entry into host cells. Several MAbs became available, but their antiviral activity decreased due to changes in the circulating viral variants. The FDA recommends using MAbs based on variant susceptibility and regional variant frequency.</para>
        <para id="ch0134s0000p0341">Since the beginning of the pandemic, Alpha, Delta, and Omicron variants have been the most common variants in the United States.</para>
        <para id="ch0134s0000p0342">Most of the efficacy clinical trials of the MAbs were conducted prior to the emergence of the Omicron variant. The Omicron variant has been dominant in the United States since December 2021. Omicron and its subvariants have markedly reduced<emphasis>in vitro</emphasis> susceptibility to several existing MAbs, and as of March 2023, no therapeutic or prophylactic SARS-CoV-2 MAbs were authorized by the FDA.</para>
        <para id="ch0134s0000p0343">Since COVID-19 information changes rapidly, we recommend visiting the FDA website for the latest announcements regarding authorized MAbs.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0017">
      <title>Casirivimab/Imdevimab</title>
      <anchor id="ch0134s0017a0001"/>
      <anchor id="ch0134s0000a0307"/>
      <para id="ch0134s0000p0344">Casirivimab/imdevimab (Regen-Cov) has received emergency use authorization to treat mild to moderate COVID-19 in adults and children (12 years of age and older, weighing at least 40 kg) at high risk for progression to severe COVID-19 including hospitalization and death (<link linkend="ch0134s0000li0237">237</link>, <link linkend="ch0134s0000li0244">244</link>, <link linkend="ch0134s0000li0246">246</link>). It also has been emergently authorized for postexposure prophylaxis of COVID-19 in individuals who are at high risk of progression to severe COVID-19 and are not fully vaccinated or are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (<link linkend="ch0134s0000li0237">237</link>).</para>
      <para id="ch0134s0000p0345">Two studies supported these recommendations. The COV-2067 study, a phase I/II/III randomized controlled trial, showed a 70% risk reduction in COVID-19-related hospitalization or all-cause death in patients at risk for severe COVID-19. A second randomized controlled trial showed an 81% risk reduction in the development of COVID-19 in subjects who received it prophylactically postexposure (<link linkend="ch0134s0000li0237">237</link>).</para>
      <para id="ch0134s0000p0346">Casirivimab/imdevimab is no longer recommended as a treatment for COVID-19 since it is inactive against Omicron and its subvariants (<link linkend="ch0134s0000li0234">234</link>, <link linkend="ch0134s0000li0237">237</link>).</para>
      <sect2 id="ch0134s0017s0001">
        <title>Pharmacology</title>
        <anchor id="ch0134s0017a0002"/>
        <anchor id="ch0134s0000a0308"/>
        <para id="ch0134s0000p0347">Casirivimab and imdevimab are two recombinant human IgG1 monoclonal antibodies that bind noncompetitively to nonoverlapping epitopes of the spike protein receptor-binding domain of SARS-CoV-2, thereby blocking viral entry into host cells.</para>
        <para id="ch0134s0000p0348">The half-life for casirivimab is around 31 days and that for imdevimab is 26 days. The effects of age, sex, race, body weight, disease severity, and hepatic impairment on the pharmacokinetics of casirivimab/imdevimab are unknown. Renal impairment is not expected to impact the pharmacokinetics of this drug since MAbs with molecular weight of &gt;69 kDa are known not to undergo renal elimination, similarly to dialysis (<link linkend="ch0134s0000li0237">237</link>).</para>
        <para id="ch0134s0000p0349">Severe hypersensitivity reactions, including anaphylaxis, have been reported with the administration of Regen-Cov (<link linkend="ch0134s0000li0237">237</link>). Other adverse events include infusion reactions which could occur up to 24 hours after the infusion. Signs and symptoms of infusion reactions include fever, difficulty breathing, and reduced oxygen saturation Patients should be monitored closely after infusion or administration of casirivimab/imdevimab.</para>
      </sect2>
      <sect2 id="ch0134s0017s0002">
        <title>Drug Interactions</title>
        <anchor id="ch0134s0017a0003"/>
        <anchor id="ch0134s0000a0309"/>
        <para id="ch0134s0000p0350">Casirivimab and imdevimab are MAbs that are not renally excreted or metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are renally excreted, or substrates, inducers, or inhibitors of cytochrome P450 enzymes, are unlikely.</para>
        <anchor id="ch0134s0000a0310"/>
        <beginpage pagenum="2221"/>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0018">
      <title>Bamlanivimab/Etesevimab</title>
      <anchor id="ch0134s0018a0001"/>
      <anchor id="ch0134s0000a0311"/>
      <para id="ch0134s0000p0351">Bamlanivimab/etesevimab received an emergency use authorization in February 2021 for treating mild-to-moderate COVID-19 in adult and pediatric patients (12 years of age and older, weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization and death (<link linkend="ch0134s0000li0238">238</link>, <link linkend="ch0134s0000li0246">246</link>). It also has emergency use authorization for postexposure prophylaxis of COVID-19 in individuals who are at high risk of progression to severe COVID-19, including hospitalization or death, are not fully vaccinated or not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination, and have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per CDC definitions; or who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (<link linkend="ch0134s0000li0246">246</link>). These criteria are based on randomized controlled trials (Blaze-1 and Blaze-2) showing an 87% risk reduction in COVID-19-related hospitalization or all-cause death through day 29, and a randomized controlled trial showing a 57% risk reduction in the development of COVID-19 in subjects who received it prophylactically (<link linkend="ch0134s0000li0238">238</link>).</para>
      <para id="ch0134s0000p0352">Due to the high frequency of the Omicron variant, bamlanivimab/etesevimab is not currently recommended in any U.S. region (<link linkend="ch0134s0000li0234">234</link>, <link linkend="ch0134s0000li0245">245</link>, <link linkend="ch0134s0000li0247">247</link>).</para>
      <sect2 id="ch0134s0018s0001">
        <title>Pharmacology</title>
        <anchor id="ch0134s0018a0002"/>
        <anchor id="ch0134s0000a0312"/>
        <para id="ch0134s0000p0353">Bamlanivimab and etesevimab are recombinant human IgG1 monoclonal antibodies that bind to different but overlapping epitopes in the receptor binding domain of the SARS-CoV-2 spike protein. Using both antibodies together is expected to reduce the risk of viral resistance (<link linkend="ch0134s0000li0238">238</link>). Bamlanivimab and etesevimab are degraded into small peptides and component amino acids via catabolic pathways in the same manner as endogenous IgG antibodies. The half-life elimination for bamlanivimab is 17 days and that for etesevimab is 25 days.</para>
        <para id="ch0134s0000p0354">Severe hypersensitivity reactions, including anaphylaxis, have been reported with administration. Patients should be monitored closely after infusion.</para>
      </sect2>
      <sect2 id="ch0134s0018s0002">
        <title>Drug Interactions</title>
        <anchor id="ch0134s0018a0003"/>
        <anchor id="ch0134s0000a0313"/>
        <para id="ch0134s0000p0355">Bamlanivimab and etesevimab are monoclonal antibodies and are presumed not to have drug interactions.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0019">
      <title>Sotrovimab</title>
      <anchor id="ch0134s0019a0001"/>
      <anchor id="ch0134s0000a0314"/>
      <para id="ch0134s0000p0356">Sotrovimab is no longer recommended to treat COVID-19 infections in the United States (<link linkend="ch0134s0000li0212">212</link>, <link linkend="ch0134s0000li0245">245</link>). It has substantially decreased <emphasis>in vitro</emphasis> neutralization activity against the Omicron BA.2, BA.4, and BA.5 subvariants; however, it is still active against the Omicron BA.1 and BA.1.1 subvariants (<link linkend="ch0134s0000li0211">211</link>, <link linkend="ch0134s0000li0234">234</link>, <link linkend="ch0134s0000li0239">239</link>, <link linkend="ch0134s0000li0248">248</link>–<link linkend="ch0134s0000li0250">250</link>).</para>
      <para id="ch0134s0000p0357">Its use was initially recommended based on the I/II/III COMET-ICE trial, a randomized, multicenter, double-blind, placebo-controlled trial in nonhospitalized adult patients with mild to moderate COVID-19, at risk for disease progression, treated with sotrovimab within 5 days of symptom onset. A total of 1,057 eligible subjects were randomized to receive sotrovimab (<emphasis>n</emphasis> = 528) or placebo (<emphasis>n</emphasis> = 529). The study showed a risk reduction of 79% (adjusted relative risk reduction) in COVID-19-related hospitalization or death (<link linkend="ch0134s0000li0239">239</link>, <link linkend="ch0134s0000li0248">248</link>).</para>
      <sect2 id="ch0134s0019s0001">
        <title>Pharmacology</title>
        <anchor id="ch0134s0019a0002"/>
        <anchor id="ch0134s0000a0315"/>
        <para id="ch0134s0000p0358">Sotrovimab is a recombinant human IgG1(κ) MAb that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2 but does not compete with human ACE2 receptor binding. Sotrovimab inhibits an undefined step that occurs after virus attachment and prior to fusion of the viral and cell membranes. It contains two amino acid Fc modifications to increase half-life and bioavailability in the respiratory mucosa, thereby permitting therapeutic concentrations for longer durations (<link linkend="ch0134s0000li0239">239</link>).</para>
        <para id="ch0134s0000p0359">The effect of other variables, including age, sex, race, body weight, disease severity, and hepatic impairment, on the pharmacokinetics of sotrovimab is unknown (<link linkend="ch0134s0000li0239">239</link>). Renal impairment is not expected to impact the pharmacokinetics of sotrovimab, since MAbs with molecular weight of &gt;69 kDa do not undergo renal elimination. Similarly, dialysis is not expected to impact its safety.</para>
      </sect2>
      <sect2 id="ch0134s0019s0002">
        <title>Drug Interactions</title>
        <anchor id="ch0134s0019a0003"/>
        <anchor id="ch0134s0000a0316"/>
        <para id="ch0134s0000p0360">Sotrovimab monoclonal antibody is presumed not to have drug interactions.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0020">
      <title>Bebtelovimab</title>
      <anchor id="ch0134s0020a0001"/>
      <anchor id="ch0134s0000a0317"/>
      <para id="ch0134s0000p0361">Bebtelovimab was the only monoclonal antibody recommended to treat COVID-19 in patients at high risk of progressing to severe disease (<link linkend="ch0134s0000li0212">212</link>, <link linkend="ch0134s0000li0240">240</link>).</para>
      <para id="ch0134s0000p0362">Bebtelovimab received an emergency authorization in February 2022 for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older, weighing at least 40 kg) who have a high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate (<link linkend="ch0134s0000li0240">240</link>).</para>
      <para id="ch0134s0000p0363">Its use is based primarily on preclinical studies showing<emphasis>in vitro</emphasis> neutralization activity against the Omicron subvariants circulating at the time of authorization and data from a small and limited clinical trial (Blaze-4) (<link linkend="ch0134s0000li0212">212</link>, <link linkend="ch0134s0000li0234">234</link>, <link linkend="ch0134s0000li0240">240</link>, <link linkend="ch0134s0000li0242">242</link>, <link linkend="ch0134s0000li0243">243</link>).</para>
      <para id="ch0134s0000p0364">In the phase II Blaze-4 trial (arms 9 to 11), patients with COVID-19 at low risk of disease progression were randomized to one dose of bamlanivimab/etesevimab plus bebtelovimab, bebtelovimab alone, or placebo. The mean decline in viral load at day 5 was greater in the two bebtelovimab arms than in the placebo arm. The median time to sustained symptom resolution was 6 days in the bebtelovimab-alone arm and 8 days in the placebo arm (<emphasis>P</emphasis> = 0.003). There are no clinical efficacy data on the treatment of patients at high risk of progressing to severe COVID 19 (<link linkend="ch0134s0000li0240">240</link>). Bebtelovimab is not currently recommended due to inability to neutralize circulating Omicron variants BQ.1 and BQ.1.1.</para>
      <sect2 id="ch0134s0020s0001">
        <title>Pharmacology</title>
        <anchor id="ch0134s0020a0002"/>
        <anchor id="ch0134s0000a0318"/>
        <para id="ch0134s0000p0365">Bebtelovimab is a recombinant neutralizing human IgG1(λ) monoclonal antibody to the spike protein of SARS-CoV-2 and is unmodified in the Fc region. It binds the spike protein and blocks spike protein attachment to the human ACE2 receptor with an IC<subscript>50</subscript> value of 0.39 nM.</para>
        <para id="ch0134s0000p0366">Following a single intravenous dose of 175 mg, the mean elimination half-life of bebtelovimab was 11.5 days (<link linkend="ch0134s0000li0240">240</link>).</para>
        <para id="ch0134s0000p0367">No dosage adjustment is recommended in patients with any degree of renal impairment. Dialysis is not expected to affect the pharmacokinetics of bebtelovimab. Additionally, no dose adjustment is needed in patients with mild hepatic impairment. There are no studies on patients with moderate or severe hepatic impairment (<link linkend="ch0134s0000li0240">240</link>).</para>
        <anchor id="ch0134s0000a0319"/>
        <beginpage pagenum="2222"/>
      </sect2>
      <sect2 id="ch0134s0020s0002">
        <title>Drug Interactions</title>
        <anchor id="ch0134s0020a0003"/>
        <anchor id="ch0134s0000a0320"/>
        <para id="ch0134s0000p0368">Bebtelovimab is not renally excreted or metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications are unlikely.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0134s0021">
      <title>Tixagevimab/Cilgavimab</title>
      <anchor id="ch0134s0021a0001"/>
      <anchor id="ch0134s0000a0321"/>
      <para id="ch0134s0000p0369">Tixagevimab/cilgavimab (Evusheld), a long-acting monoclonal antibodies combination, received emergency use authorization as pre-exposure prophylaxis agents against COVID-19 in immunocompromised individuals or those who cannot be vaccinated or mount postvaccination immune response, based on the PROVENT study (<link linkend="ch0134s0000li0212">212</link>, <link linkend="ch0134s0000li0241">241</link>). This study is a randomized, double-blind, placebo-controlled clinical trial in adults older than 59 or with a prespecified chronic medical condition or at increased risk of SARS-CoV-2 infection for other reasons, who had not received a COVID-19 vaccine and did not have a history of SARS-CoV-2 infection or test positive for SARS-CoV-2 infection at the start of the trial (<link linkend="ch0134s0000li0251">251</link>). Tixagevimab/cilgavimab reduced the risk of developing COVID-19 by 77% compared to placebo. In additional analyses, the risk of developing COVID-19 for tixagevimab/cilgavimab recipients kept reduced at 6 months (<link linkend="ch0134s0000li0251">251</link>). Tixagevimab/cilgavimab is not currently authorized for use in the U.S. due to the high frequency of non-susceptible variants such as XBB.1.5.</para>
      <sect2 id="ch0134s0021s0001">
        <title>Pharmacology</title>
        <anchor id="ch0134s0021a0002"/>
        <anchor id="ch0134s0000a0322"/>
        <para id="ch0134s0000p0370">Tixagevimab and cilgavimab are recombinant human IgG1(κ) MAbs with amino acid substitutions to extend antibody half-life, reduce antibody effector function, and minimize the potential risk of antibody enhancement of disease (<link linkend="ch0134s0000li0241">241</link>). The half-life of tixagevimab/cilgavimab is between 83 to 88 days. Its metabolism is through catabolic pathways similar to endogenous IgG, and it is unlikely to undergo renal excretion. The impact of hepatic impairment is unknown (<link linkend="ch0134s0000li0241">241</link>).</para>
      </sect2>
      <sect2 id="ch0134s0021s0002">
        <title>Drug Interactions</title>
        <anchor id="ch0134s0021a0003"/>
        <anchor id="ch0134s0000a0323"/>
        <para id="ch0134s0000p0371">Drug-to-drug interaction studies have not been performed; however, based on key elimination pathways, tixagevimab/cilgavimab interactions with concomitant medications that are renally excreted or with substrates, inducers, or inhibitors of CYP enzymes are unlikely.</para>
      </sect2>
      <sect2 id="ch0134s0021s0003">
        <title>COVID-19 Convalescent Plasma (CCP)</title>
        <anchor id="ch0134s0021a0004"/>
        <anchor id="ch0134s0000a0324"/>
        <para id="ch0134s0000p0372">In August 2020, the FDA issued an emergency use authorization for COVID-19 convalescent plasma for the treatment of hospitalized patients with COVID-19 (<link linkend="ch0134s0000li0252">252</link>, <link linkend="ch0134s0000li0253">253</link>). Later, in December 2021, CCP was indicated only for outpatients or inpatients with COVID-19 who have an immunosuppressive disease or receive immunosuppressive treatment.</para>
        <para id="ch0134s0000p0373">Currently, there is no consensus on using CCP in immunocompromised and nonhospitalized, immunocompetent patients with COVID-19, given the lack of trials against Omicron, the dominant variant in the U.S. However,<emphasis>in vitro</emphasis> data suggest that CCP collected from vaccinated and unvaccinated individuals who have recovered from Omicron infection exhibits neutralizing activity against this variant.</para>
      </sect2>
      <sect2 id="ch0134s0021s0004">
        <title>REFERENCES</title>
        <anchor id="ch0134s0021a0005"/>
        <anchor id="ch0134s0000a0325"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0134s0000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">De Clercq E, Li G.</emphasis> 2016. Approved antiviral drugs over the past 50 years. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">29:</emphasis>695–747.</para>
          </listitem>
          <listitem id="ch0134s0000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Li G, De Clercq E.</emphasis> 2017. Current therapy for chronic hepatitis C: the role of direct-acting antivirals. <citetitle><emphasis>Antiviral Res</emphasis></citetitle> <emphasis role="strong">142:</emphasis>83–122.</para>
          </listitem>
          <listitem id="ch0134s0000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Fung J, Lai CL, Seto WK, Yuen MF.</emphasis> 2011. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">66:</emphasis>2715–2725.</para>
          </listitem>
          <listitem id="ch0134s0000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Field HJ, Vere Hodge RA.</emphasis> 2013. Recent developments in anti-herpesvirus drugs. <citetitle><emphasis>Br Med Bull</emphasis></citetitle> <emphasis role="strong">106:</emphasis>213–249.</para>
          </listitem>
          <listitem id="ch0134s0000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Panel on Antiretroviral Guidelines for Adults and Adolescents.</emphasis> Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. <ulink url="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/wha">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/wha</ulink> ts-new-guidelines. Accessed December 2021.</para>
          </listitem>
          <listitem id="ch0134s0000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children.</emphasis> Guidelines for use of antiretroviral agents in pediatric HIV infection. <ulink url="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines</ulink>. Accessed September 2021.</para>
          </listitem>
          <listitem id="ch0134s0000li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission.</emphasis> 2017. Recommendation for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <ulink url="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines</ulink>. Accessed November 2020.</para>
          </listitem>
          <listitem id="ch0134s0000li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O’Shaughnessy MV, Montaner JS.</emphasis> 2002. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">346:</emphasis>811–820.</para>
          </listitem>
          <listitem id="ch0134s0000li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Capparelli EV, Letendre SL, Ellis RJ, Patel P, Holland D, McCutchan JA.</emphasis> 2005. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">49:</emphasis>2504–2506.</para>
          </listitem>
          <listitem id="ch0134s0000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, Hatano H, Xie Y, Martin JN, Ganz P, Deeks SG.</emphasis> 2009. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. <citetitle><emphasis>AIDS</emphasis></citetitle> <emphasis role="strong">23:</emphasis>2021–2027.</para>
          </listitem>
          <listitem id="ch0134s0000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Marcus JL, Neugebauer RS, Leyden WA, Chao CR, Xu L, Quesenberry CP Jr, Klein DB, Towner WJ, Horberg MA, Silverberg MJ.</emphasis> 2016. Use of abacavir and risk of cardiovascular disease among HIV-infected individuals. <citetitle><emphasis>J Acquir Immune Defic Syndr</emphasis></citetitle> <emphasis role="strong">71:</emphasis>413–419.</para>
          </listitem>
          <listitem id="ch0134s0000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, Smurzynski M, Bosch RJ, Bastow B, Schouten JT, ACTG A5001/ALLRT Protocol Team.</emphasis> 2011. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">52:</emphasis>929–940.</para>
          </listitem>
          <listitem id="ch0134s0000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, PREDICT-1 Study Team.</emphasis> 2008. HLA-B*5701 screening for hypersensitivity to abacavir. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">358:</emphasis>568–579.</para>
          </listitem>
          <listitem id="ch0134s0000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Pruvost A, Negredo E, Benech H, Theodoro F, Puig J, Grau E, García E, Moltó J, Grassi J, Clotet B.</emphasis> 2005. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1907–1914.</para>
          </listitem>
          <listitem id="ch0134s0000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Ray AS, Olson L, Fridland A.</emphasis> 2004. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1089–1095.</para>
          </listitem>
          <listitem id="ch0134s0000li0016" role="bibliographyEntry">
            <anchor id="ch0134s0000a0326"/>
            <para>16.<emphasis role="strong">Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A.</emphasis> 2009. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. <citetitle><emphasis>J Acquir Immune Defic Syndr</emphasis></citetitle> <emphasis role="strong">52:</emphasis>56–63.</para>
          </listitem>
          <listitem id="ch0134s0000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Perry CM.</emphasis> 2009. Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">69:</emphasis>843–857.</para>
          </listitem>
          <listitem id="ch0134s0000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Foudraine NA, Hoetelmans RM, Lange JM, de Wolf F, van Benthem BH, Maas JJ, Keet IP, Portegies P.</emphasis> 1998. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">351:</emphasis>1547–1551.</para>
          </listitem>
          <listitem id="ch0134s0000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Fortuin-de Smidt M, de Waal R, Cohen K, Technau KG, Stinson K, Maartens G, Boulle A, Igumbor EU, Davies MA.</emphasis> 2017. First-line antiretroviral drug discontinuations in children. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">12:</emphasis>e0169762.</para>
          </listitem>
          <listitem id="ch0134s0000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Havlir DV, Tierney C, Friedland GH, Pollard RB, Smeaton L, Sommadossi JP, Fox L, Kessler H, Fife KH, Richman DD.</emphasis> 2000. In vivo antagonism with zidovudine plus stavudine combination therapy. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">182:</emphasis>321–325.</para>
          </listitem>
          <listitem id="ch0134s0000li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Piscitelli SC, Gallicano KD.</emphasis> 2001. Interactions among drugs for HIV and opportunistic infections. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">344:</emphasis>984–996.</para>
          </listitem>
          <listitem id="ch0134s0000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J, Stein DK, Bellos N, Scarsella A, Yan M, Abram ME, Cheng A, Rhee MS.</emphasis> 2017. Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. <citetitle><emphasis>J Acquir Immune Defic Syndr</emphasis></citetitle> <emphasis role="strong">75:</emphasis>226–231.</para>
          </listitem>
          <listitem id="ch0134s0000li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, Zhong L, Ramanathan S, Rhee MS, Fordyce MW, Yale K.</emphasis> 2013. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. <citetitle><emphasis>J Acquir Immune Defic Syndr</emphasis></citetitle> <emphasis role="strong">63:</emphasis>449–455.</para>
          </listitem>
          <listitem id="ch0134s0000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M.</emphasis> 2019. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. <citetitle><emphasis>AIDS</emphasis></citetitle> <emphasis role="strong">33:</emphasis>1455–1465.</para>
          </listitem>
          <listitem id="ch0134s0000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S, GS-US-292-0104/0111 Study Team.</emphasis> 2015. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">385:</emphasis>2606–2615.</para>
          </listitem>
          <listitem id="ch0134s0000li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Durand-Gasselin L, Pruvost A, Dehée A, Vaudre G, Tabone MD, Grassi J, Leverger G, Garbarg-Chenon A, Bénech H, Dollfus C.</emphasis> 2008. High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">52:</emphasis>2555–2563.</para>
          </listitem>
          <listitem id="ch0134s0000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Castello G, Mela G, Cerruti A, Mencoboni M, Lerza R.</emphasis> 1995. Azidothymidine and interferon-alpha in vitro effects on hematopoiesis: protective in vitro activity of IL-1 and GM-CSF. <citetitle><emphasis>Exp Hematol</emphasis></citetitle> <emphasis role="strong">23:</emphasis>1367–1371.</para>
          </listitem>
          <listitem id="ch0134s0000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Cimoch PJ, Lavelle J, Pollard R, Griffy KG, Wong R, Tarnowski TL, Casserella S, Jung D.</emphasis> 1998. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. <citetitle><emphasis>J Acquir Immune Defic Syndr Hum Retrovirol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>227–234.</para>
          </listitem>
          <listitem id="ch0134s0000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Moore RD, Bartlett JG.</emphasis> 2011. Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">53:</emphasis>600–604.</para>
          </listitem>
          <listitem id="ch0134s0000li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, Hogg RS, Montaner JS, Harrigan PR.</emphasis> 2010. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">50:</emphasis>98–105.</para>
          </listitem>
          <listitem id="ch0134s0000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Lee FJ, Amin J, Carr A.</emphasis> 2014. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks’ follow-up. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">9:</emphasis>e97482.</para>
          </listitem>
          <listitem id="ch0134s0000li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Johnson LB, Saravolatz LD.</emphasis> 2009. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1123–1128.</para>
          </listitem>
          <listitem id="ch0134s0000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Briz V, Garrido C, Poveda E, Morello J, Barreiro P, de Mendoza C, Soriano V.</emphasis> 2009. Raltegravir and etravirine are active against HIV type 1 group O. <citetitle><emphasis>AIDS Res Hum Retroviruses</emphasis></citetitle> <emphasis role="strong">25:</emphasis>225–227.</para>
          </listitem>
          <listitem id="ch0134s0000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Häggblom A, Lindbäck S, Gisslén M, Flamholc L, Hejdeman B, Palmborg A, Leval A, Herweijer E, Valgardsson S, Svedhem V.</emphasis> 2017. HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">12:</emphasis>e0171227.</para>
          </listitem>
          <listitem id="ch0134s0000li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Mmiro FA, Aizire J, Mwatha AK, Eshleman SH, Donnell D, Fowler MG, Nakabiito C, Musoke PM, Jackson JB, Guay LA.</emphasis> 2009. Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. <citetitle><emphasis>J Acquir Immune Defic Syndr</emphasis></citetitle> <emphasis role="strong">52:</emphasis>32–39.</para>
          </listitem>
          <listitem id="ch0134s0000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Samuel R, Julian MN, Paredes R, Parboosing R, Moodley P, Singh L, Naidoo A, Gordon M.</emphasis> 2016. HIV-1 drug resistance by ultra-deep sequencing following short course zidovudine, single-dose nevirapine, and single-dose tenofovir with emtricitabine for prevention of mother-to-child transmission. <citetitle><emphasis>J Acquir Immune Defic Syndr</emphasis></citetitle> <emphasis role="strong">73:</emphasis>384–389.</para>
          </listitem>
          <listitem id="ch0134s0000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Molina J-M, et al, DRIVE-FORWARD Trial Group.</emphasis> 2020. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. <citetitle><emphasis>Lancet HIV</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e16–e26.</para>
          </listitem>
          <listitem id="ch0134s0000li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Eron JJ Jr.</emphasis> 2000. HIV-1 protease inhibitors. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">30</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>S160–S170.</para>
          </listitem>
          <listitem id="ch0134s0000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, Leschenko S, Baldridge A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H.</emphasis> 2007. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. <citetitle><emphasis>J Biol Chem</emphasis></citetitle> <emphasis role="strong">282:</emphasis>28709–28720.</para>
          </listitem>
          <listitem id="ch0134s0000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Menéndez-Arias L, Tözsér J.</emphasis> 2008. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. <citetitle><emphasis>Trends Pharmacol Sci</emphasis></citetitle> <emphasis role="strong">29:</emphasis>42–49.</para>
          </listitem>
          <listitem id="ch0134s0000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Ford J, Khoo SH, Back DJ.</emphasis> 2004. The intracellular pharmacology of antiretroviral protease inhibitors. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>982–990.</para>
          </listitem>
          <listitem id="ch0134s0000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Zeldin RK, Petruschke RA.</emphasis> 2004. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">53:</emphasis>4–9.</para>
          </listitem>
          <listitem id="ch0134s0000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Boffito M, Maitland D, Samarasinghe Y, Pozniak A.</emphasis> 2005. The pharmacokinetics of HIV protease inhibitor combinations. <citetitle><emphasis>Curr Opin Infect Dis</emphasis></citetitle> <emphasis role="strong">18:</emphasis>1–7.</para>
          </listitem>
          <listitem id="ch0134s0000li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Youle M.</emphasis> 2007. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>1195–1205.</para>
          </listitem>
          <listitem id="ch0134s0000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW.</emphasis> 2003. A review of low-dose ritonavir in protease inhibitor combination therapy. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">36:</emphasis>1585–1592.</para>
          </listitem>
          <listitem id="ch0134s0000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Orrick JJ, Steinhart CR.</emphasis> 2004. Atazanavir. <citetitle><emphasis>Ann Pharmacother</emphasis></citetitle> <emphasis role="strong">38:</emphasis>1664–1674.</para>
          </listitem>
          <listitem id="ch0134s0000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Havlir DV, O’Marro SD.</emphasis> 2004. Atazanavir: new option for treatment of HIV infection. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">38:</emphasis>1599–1604.</para>
          </listitem>
          <listitem id="ch0134s0000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Elliot ER, Amara A, Pagani N, Else L, Moyle G, Schoolmeesters A, Higgs C, Khoo S, Boffito M.</emphasis> 2017. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">72:</emphasis>2035–2041.</para>
          </listitem>
          <listitem id="ch0134s0000li0049" role="bibliographyEntry">
            <anchor id="ch0134s0000a0327"/>
            <para>49.<emphasis role="strong">Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS.</emphasis> 2012. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>5409–5413.</para>
          </listitem>
          <listitem id="ch0134s0000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Wire MB, Shelton MJ, Studenberg S.</emphasis> 2006. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. <citetitle><emphasis>Clin Pharmacokinet</emphasis></citetitle> <emphasis role="strong">45:</emphasis>137–168.</para>
          </listitem>
          <listitem id="ch0134s0000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Fellay J, Marzolini C, Decosterd L, Golay KP, Baumann P, Buclin T, Telenti A, Eap CB.</emphasis> 2005. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. <citetitle><emphasis>Eur J Clin Pharmacol</emphasis></citetitle> <emphasis role="strong">60:</emphasis>865–873.</para>
          </listitem>
          <listitem id="ch0134s0000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL.</emphasis> 2007. Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma. <citetitle><emphasis>Br J Clin Pharmacol</emphasis></citetitle> <emphasis role="strong">63:</emphasis>315–321.</para>
          </listitem>
          <listitem id="ch0134s0000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Isaac A, Taylor S, Cane P, Smit E, Gibbons SE, White DJ, Drake SM, Khoo S, Back DJ.</emphasis> 2004. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>498–502.</para>
          </listitem>
          <listitem id="ch0134s0000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Yeni P.</emphasis> 2003. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. <citetitle><emphasis>J Acquir Immune Defic Syndr</emphasis></citetitle> <emphasis role="strong">34</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S91–S94.</para>
          </listitem>
          <listitem id="ch0134s0000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Kiser JJ.</emphasis> 2008. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV. <citetitle><emphasis>Curr Opin HIV AIDS</emphasis></citetitle> <emphasis role="strong">3:</emphasis>330–341.</para>
          </listitem>
          <listitem id="ch0134s0000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Covens K, Kabeya K, Schrooten Y, Dekeersmaeker N, Van Wijngaerden E, Vandamme AM, De Wit S, Van Laethem K.</emphasis> 2009. Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>325–328.</para>
          </listitem>
          <listitem id="ch0134s0000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Mould DR, Zhang X, Nieforth K, Salgo M, Buss N, Patel IH.</emphasis> 2005. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. <citetitle><emphasis>Clin Pharmacol Ther</emphasis></citetitle> <emphasis role="strong">77:</emphasis>515–528.</para>
          </listitem>
          <listitem id="ch0134s0000li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Vandekerckhove L, Verhofstede C, Vogelaers D.</emphasis> 2009. Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">63:</emphasis>1087–1096.</para>
          </listitem>
          <listitem id="ch0134s0000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Hayward P.</emphasis> 2018. Highlights of HIV drug therapy 2018. <citetitle><emphasis>Lancet HIV</emphasis></citetitle> <emphasis role="strong">5:</emphasis>e684–e684.</para>
          </listitem>
          <listitem id="ch0134s0000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, Weinheimer S, Marsolais C, Lewis S.</emphasis> 2018. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">379:</emphasis>645–654.</para>
          </listitem>
          <listitem id="ch0134s0000li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Depatureaux A, Charpentier C, Collin G, Leoz M, Descamps D, Vessière A, Damond F, Rousset D, Brun-Vézinet F, Plantier JC.</emphasis> 2010. Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>4016–4019.</para>
          </listitem>
          <listitem id="ch0134s0000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Price RW, Parham R, Kroll JL, Wring SA, Baker B, Sailstad J, Hoh R, Liegler T, Spudich S, Kuritzkes DR, Deeks SG.</emphasis> 2008. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. <citetitle><emphasis>Antivir Ther</emphasis></citetitle> <emphasis role="strong">13:</emphasis>369–374.</para>
          </listitem>
          <listitem id="ch0134s0000li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Xiong S, Borrego P, Ding X, Zhu Y, Martins A, Chong H, Taveira N, He Y.</emphasis> 2016. A helical short-peptide fusion inhibitor with highly potent activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus. <citetitle><emphasis>J Virol</emphasis></citetitle> <emphasis role="strong">91:</emphasis>e01839–e16.</para>
          </listitem>
          <listitem id="ch0134s0000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">MacArthur RD, Novak RM.</emphasis> 2008. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47:</emphasis>236–241.</para>
          </listitem>
          <listitem id="ch0134s0000li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Beccari MV, Mogle BT, Sidman EF, Mastro KA, Asiago-Reddy E, Kufel WD.</emphasis> 2019. Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">63:</emphasis>e00110–19.</para>
          </listitem>
          <listitem id="ch0134s0000li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Blair HA.</emphasis> 2020. Ibalizumab: a review in multidrug-resistant HIV-1 infection. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">80:</emphasis>189–196.</para>
          </listitem>
          <listitem id="ch0134s0000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST.</emphasis> 2009. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">53:</emphasis>450–457.</para>
          </listitem>
          <listitem id="ch0134s0000li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H, GS-US-380-1489, GS-US-380-1490 Study Investigators.</emphasis> 2020. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. <citetitle><emphasis>Lancet HIV</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e389–e400.</para>
          </listitem>
          <listitem id="ch0134s0000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">HIV i-Base.</emphasis> 2019. HIV Pipeline 2018: new drugs in development. <ulink url="https://i-base.info/htb/wp-content/uploads/2019/07/PIPELINE-2019-FINAL-full-version.pdf">https://i-base.info/htb/wp-content/uploads/2019/07/PIPELINE-2019-FINAL-full-version.pdf</ulink>. Accessed 23 November 2020.</para>
          </listitem>
          <listitem id="ch0134s0000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">US National Library of Medicine, Clinical <ulink url="http://Trials.gov">Trials.gov</ulink>.</emphasis> 2018–2021. GSK1265744 (Cabotegravir, CAB) for named patient/compassionate use in HIV. <ulink url="https://clinicaltrials.gov/ct2/show/NCT03462810">https://clinicaltrials.gov/ct2/show/NCT03462810</ulink>. Accessed 2 December 2021.</para>
          </listitem>
          <listitem id="ch0134s0000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Yang L-L, Li Q, Zhou L-B, Chen S-Q.</emphasis> 2019. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">54:</emphasis>547–555.</para>
          </listitem>
          <listitem id="ch0134s0000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Pena MJ, Chueca N, D’Avolio A, Zarzalejos JM, Garcia F.</emphasis> 2018. Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: rare but possible. <citetitle><emphasis>Open Forum</emphasis></citetitle> <citetitle><emphasis>Infect Dis</emphasis></citetitle> <emphasis role="strong">6:</emphasis>ofy332.</para>
          </listitem>
          <listitem id="ch0134s0000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">McMahon C, Trevaskis JL, Carter C, Holsapple K, White K, Das M, Collins S, Martin H, Burns-Naas LA.</emphasis> 2020. Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">15:</emphasis>e0229617.</para>
          </listitem>
          <listitem id="ch0134s0000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Bhagwat P, Ofotokun I, McComsey GA, Brown TT, Moser C, Sugar CA, Currier JS.</emphasis> 2018. Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race. <citetitle><emphasis>Open Forum</emphasis></citetitle> <citetitle><emphasis>Infect Dis</emphasis></citetitle> <emphasis role="strong">5:</emphasis>ofy201.</para>
          </listitem>
          <listitem id="ch0134s0000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Raesima MM, Ogbuabo CM, Thomas V, Forhan SE, Gokatweng G, Dintwa E, Petlo C, Motswere-Chirwa C, Rabold EM, Tinker SC, Odunsi S, Malima S, Mmunyane O, Modise T, Kefitlhile K, Dare K, Letebele M, Roland ME, Moore CA, Modi S, Williamson DM.</emphasis> 2019. Dolutegravir use at conception—additional surveillance data from Botswana. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">381:</emphasis>885–887.</para>
          </listitem>
          <listitem id="ch0134s0000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G, Isaacson A, Davey S, Mabuta J, Mmalane M, Gaolathe T, Essex M, Lockman S, Makhema J, Shapiro RL.</emphasis> 2019. Neural-tube defects and antiretroviral treatment regimens in Botswana. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">381:</emphasis>827–840.</para>
          </listitem>
          <listitem id="ch0134s0000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Bernardino JI, Mocroft A, Wallet C, de Wit S, Katlama C, Reiss P, Mallon PW, Richert L, Molina JM, Knobel H, Morlat P, Babiker A, Pozniac A, Raffi F, Arribas JR, NEAT001/ANRS143 Trial Study Group.</emphasis> 2019. Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">14:</emphasis>e0209911.</para>
          </listitem>
          <listitem id="ch0134s0000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Kerchberger AM, Sheth AN, Angert CD, Mehta CC, Summers NA, Ofotokun I, Gustafson D, Weiser SD, Sharma A, Adimora AA, French AL, Augenbraun M, Cocohoba J, Kassaye S, Bolivar H, Govindarajulu U, Konkle-Parker D, Golub ET, Lahiri CD.</emphasis> 2020. Weight gain associated with integrase stand transfer inhibitor use in women. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">71:</emphasis>593–600.</para>
          </listitem>
          <listitem id="ch0134s0000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Podany AT, Scarsi KK, Fletcher CV.</emphasis> 2017. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. <citetitle><emphasis>Clin Pharmacokinet</emphasis></citetitle> <emphasis role="strong">56:</emphasis>25–40.</para>
          </listitem>
          <listitem id="ch0134s0000li0080" role="bibliographyEntry">
            <anchor id="ch0134s0000a0328"/>
            <para>80.<emphasis role="strong">Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P, STARTMRK Investigators.</emphasis> 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">374:</emphasis>796–806.</para>
          </listitem>
          <listitem id="ch0134s0000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Elliot E, Chirwa M, Boffito M.</emphasis> 2017. How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use. <citetitle><emphasis>Curr Opin Infect Dis</emphasis></citetitle> <emphasis role="strong">30:</emphasis>58–73.</para>
          </listitem>
          <listitem id="ch0134s0000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Ramanathan S, Mathias AA, German P, Kearney BP.</emphasis> 2011. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. <citetitle><emphasis>Clin Pharmacokinet</emphasis></citetitle> <emphasis role="strong">50:</emphasis>229–244.</para>
          </listitem>
          <listitem id="ch0134s0000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Arribas JR, Eron J.</emphasis> 2013. Advances in antiretroviral therapy. <citetitle><emphasis>Curr Opin HIV AIDS</emphasis></citetitle> <emphasis role="strong">8:</emphasis>341–349.</para>
          </listitem>
          <listitem id="ch0134s0000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J, Walmsley SL, Cox J, Reynes J, Morlat P, Vittecoq D, Livrozet J-M, Fernandez PV, Gatell JM, DeJesus E, DeVente J, Lalezari JP, McCurdy LH, Sloan LA, Young B, LaMarca A, Hawkins T, VIKING Study Group.</emphasis> 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">207:</emphasis>740–748.</para>
          </listitem>
          <listitem id="ch0134s0000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC.</emphasis> 2010. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>254–258.</para>
          </listitem>
          <listitem id="ch0134s0000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S, Extended SAILING Study Team.</emphasis> 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">382:</emphasis>700–708.</para>
          </listitem>
          <listitem id="ch0134s0000li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, Pappa KA, Wynne B, Gartland M, Aboud M, van Wyk J, Smith KY.</emphasis> 2020. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. <citetitle><emphasis>J Acquir Immune Defic Syndr</emphasis></citetitle> <emphasis role="strong">83:</emphasis>310–318.</para>
          </listitem>
          <listitem id="ch0134s0000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M.</emphasis> 2018. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">391:</emphasis>839–849.</para>
          </listitem>
          <listitem id="ch0134s0000li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, Niedziela-Majka A, Yant SR, Yu H, Kukolj G, Cihlar T, Lazerwith SE, White KL, Jin H.</emphasis> 2016. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>7086–7097.</para>
          </listitem>
          <listitem id="ch0134s0000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Gilead Sciences.</emphasis> 2019. Highlights of prescribing information: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide). <ulink url="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210251s006lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210251s006lbl.pdf</ulink>. Accessed 12 October 2021.</para>
          </listitem>
          <listitem id="ch0134s0000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">GlaxoSmithKline and ViiV Healthcare.</emphasis> 2021. Highlights of prescribing information: Vocabria (cabotegravir). <ulink url="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212887s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212887s000lbl.pdf</ulink>. Accessed 6 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">GlaxoSmithKline and ViiV Healthcare.</emphasis> 2021. Highlights of prescribing information: Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. <ulink url="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf</ulink>. Accessed 8 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D’Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR.</emphasis> 2020. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">382:</emphasis>1124–1135.</para>
          </listitem>
          <listitem id="ch0134s0000li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, Latiff G, Pokrovsky V, Bredeek F, Smith G, Cahn P, Kim YS, Ford SL, Talarico CL, Patel P, Chounta V, Crauwels H, Parys W, Vanveggel S, Mrus J, Huang J, Harrington CM, Hudson KJ, Margolis DA, Smith KY, Williams PE, Spreen WR.</emphasis> 2020. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">382:</emphasis>1112–1123.</para>
          </listitem>
          <listitem id="ch0134s0000li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Poordad F, Dieterich D.</emphasis> 2012. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. <citetitle><emphasis>J Viral Hepat</emphasis></citetitle> <emphasis role="strong">19:</emphasis>449–464.</para>
          </listitem>
          <listitem id="ch0134s0000li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">AASLD-IDSA.</emphasis> 2017. HCV guidance: recommendations for testing, managing, and treating hepatitis C. <ulink url="http://www.hcvguidelines.org">http://www.hcvguidelines.org</ulink>. Accessed 18 August 2017.</para>
          </listitem>
          <listitem id="ch0134s0000li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Pockros PJ.</emphasis> 2010. New direct-acting antivirals in the development for hepatitis C virus infection. <citetitle><emphasis>Therap Adv Gastroenterol</emphasis></citetitle> <emphasis role="strong">3:</emphasis>191–202.</para>
          </listitem>
          <listitem id="ch0134s0000li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E.</emphasis> 2016. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>2954–2964.</para>
          </listitem>
          <listitem id="ch0134s0000li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR.</emphasis> 2015. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">163:</emphasis>1–13.</para>
          </listitem>
          <listitem id="ch0134s0000li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B.</emphasis> 2014. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">370:</emphasis>1594–1603.</para>
          </listitem>
          <listitem id="ch0134s0000li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B.</emphasis> 2014. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">370:</emphasis>1604–1614.</para>
          </listitem>
          <listitem id="ch0134s0000li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM.</emphasis> 2014. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">384:</emphasis>1756–1765.</para>
          </listitem>
          <listitem id="ch0134s0000li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S, POLARIS-1 and POLARIS-4 Investigators.</emphasis> 2017. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">376:</emphasis>2134–2146.</para>
          </listitem>
          <listitem id="ch0134s0000li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman C, Davis MN, Hinestrosa F, Dvory-Sobol H, Huang KC, Osinusi A, McNally J, Brainard DM, McHutchison JG, Thompson AJ, Sulkowski MS, GS-US-342-1553 Investigators.</emphasis> 2017. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1083–1089.</para>
          </listitem>
          <listitem id="ch0134s0000li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ.</emphasis> 2017. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">66:</emphasis>389–397.</para>
          </listitem>
          <listitem id="ch0134s0000li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Evans MJ, Rice CM, Goff SP.</emphasis> 2004. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">101:</emphasis>13038–13043.</para>
          </listitem>
          <listitem id="ch0134s0000li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Tellinghuisen TL, Foss KL, Treadaway J.</emphasis> 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. <citetitle><emphasis>PLoS Pathog</emphasis></citetitle> <emphasis role="strong">4:</emphasis>e1000032.</para>
          </listitem>
          <listitem id="ch0134s0000li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW, ION-3 Investigators.</emphasis> 2014. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">370:</emphasis>1879–1888.</para>
          </listitem>
          <listitem id="ch0134s0000li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM, AI444040 Study Group.</emphasis> 2014. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">370:</emphasis>211–220.</para>
          </listitem>
          <listitem id="ch0134s0000li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR, PEARL-III Study, PEARL-IV Study.</emphasis> 2014. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">370:</emphasis>1983–1992.</para>
          </listitem>
          <listitem id="ch0134s0000li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S.</emphasis> 2015. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">385:</emphasis>2502–2509.</para>
          </listitem>
          <listitem id="ch0134s0000li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.</emphasis> 2015. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">385:</emphasis>1075–1086.</para>
          </listitem>
          <listitem id="ch0134s0000li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S, ASTRAL-1 Investigators.</emphasis> 2015. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">373:</emphasis>2599–2607.</para>
          </listitem>
          <listitem id="ch0134s0000li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA, ALLY-3 Study Team.</emphasis> 2015. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">61:</emphasis>1127–1135.</para>
          </listitem>
          <listitem id="ch0134s0000li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators.</emphasis> 2014. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">370:</emphasis>1889–1898.</para>
          </listitem>
          <listitem id="ch0134s0000li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M, ASTRAL-2 Investigators, ASTRAL-3 Investigators.</emphasis> 2015. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">373:</emphasis>2608–2617.</para>
          </listitem>
          <listitem id="ch0134s0000li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P.</emphasis> 1999. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2451–2456.</para>
          </listitem>
          <listitem id="ch0134s0000li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Bonney D, Razali H, Turner A, Will A.</emphasis> 2009. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. <citetitle><emphasis>Br J Haematol</emphasis></citetitle> <emphasis role="strong">145:</emphasis>667–669.</para>
          </listitem>
          <listitem id="ch0134s0000li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE.</emphasis> 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. <citetitle><emphasis>Nat Med</emphasis></citetitle> <emphasis role="strong">6:</emphasis>1375–1379.</para>
          </listitem>
          <listitem id="ch0134s0000li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Leyssen P, Balzarini J, De Clercq E, Neyts J.</emphasis> 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. <citetitle><emphasis>J Virol</emphasis></citetitle> <emphasis role="strong">79:</emphasis>1943–1947.</para>
          </listitem>
          <listitem id="ch0134s0000li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Liu V, Dhillon GS, Weill D.</emphasis> 2010. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. <citetitle><emphasis>Transpl Infect Dis</emphasis></citetitle> <emphasis role="strong">12:</emphasis>38–44.</para>
          </listitem>
          <listitem id="ch0134s0000li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, Hansbarger CO, Levy H, Koster FT, Baum K, Lindemulder A, Wang W, Riser L, Fernandez H, Whitley RJ, Collaborative Antiviral Study Group.</emphasis> 2004. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">39:</emphasis>1307–1313.</para>
          </listitem>
          <listitem id="ch0134s0000li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, Engelthaler DM, Le MH, Keim PS, Spence RP, Went GT.</emphasis> 2009. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">53:</emphasis>4115–4126.</para>
          </listitem>
          <listitem id="ch0134s0000li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Patterson JL, Fernandez-Larsson R.</emphasis> 1990. Molecular mechanisms of action of ribavirin. <citetitle><emphasis>Rev Infect Dis</emphasis></citetitle> <emphasis role="strong">12:</emphasis>1139–1146.</para>
          </listitem>
          <listitem id="ch0134s0000li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD.</emphasis> 2009. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">53:</emphasis>2120–2128.</para>
          </listitem>
          <listitem id="ch0134s0000li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Perronne C.</emphasis> 2006. Antiviral hepatitis and antiretroviral drug interactions. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">44</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S119–S125.</para>
          </listitem>
          <listitem id="ch0134s0000li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, Wang C, Anderson J, Mondou E, Snow A, Sorbel J, Rousseau F, Corey L.</emphasis> 2005. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>60–66.</para>
          </listitem>
          <listitem id="ch0134s0000li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Fontana RJ.</emphasis> 2009. Side effects of long-term oral antiviral therapy for hepatitis B. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">49</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S185–S195.</para>
          </listitem>
          <listitem id="ch0134s0000li0129" role="bibliographyEntry">
            <anchor id="ch0134s0000a0330"/>
            <para>129.<emphasis role="strong">Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, Thio C, Benhamou Y.</emphasis> 2005. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. <citetitle><emphasis>AIDS</emphasis></citetitle> <emphasis role="strong">19:</emphasis>221–240.</para>
          </listitem>
          <listitem id="ch0134s0000li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Younger HM, Bathgate AJ, Hayes PC.</emphasis> 2004. Review article: nucleoside analogues for the treatment of chronic hepatitis B. <citetitle><emphasis>Aliment Pharmacol Ther</emphasis></citetitle> <emphasis role="strong">20:</emphasis>1211–1230.</para>
          </listitem>
          <listitem id="ch0134s0000li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J.</emphasis> 2008. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. <citetitle><emphasis>AIDS</emphasis></citetitle> <emphasis role="strong">22:</emphasis>1399–1410.</para>
          </listitem>
          <listitem id="ch0134s0000li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Mohanty SR, Cotler SJ.</emphasis> 2005. Management of hepatitis B in liver transplant patients. <citetitle><emphasis>J Clin Gastroenterol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>58–63.</para>
          </listitem>
          <listitem id="ch0134s0000li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, Häussinger D.</emphasis> 2005. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. <citetitle><emphasis>Gut</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1009–1013.</para>
          </listitem>
          <listitem id="ch0134s0000li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Wai CT, Chu CJ, Hussain M, Lok AS.</emphasis> 2002. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">36:</emphasis>1425–1430.</para>
          </listitem>
          <listitem id="ch0134s0000li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H, Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America.</emphasis> 2009. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">58</emphasis>(RR-4)<emphasis role="strong">:</emphasis>1–207, quiz CE1–CE4.</para>
          </listitem>
          <listitem id="ch0134s0000li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T.</emphasis> 2006. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">44:</emphasis>318–325.</para>
          </listitem>
          <listitem id="ch0134s0000li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL.</emphasis> 2007. The HBV drug entecavir—effects on HIV-1 replication and resistance. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">356:</emphasis>2614–2621.</para>
          </listitem>
          <listitem id="ch0134s0000li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM.</emphasis> 2007. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. <citetitle><emphasis>J Viral Hepat</emphasis></citetitle> <emphasis role="strong">14:</emphasis>176–182.</para>
          </listitem>
          <listitem id="ch0134s0000li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Nash K.</emphasis> 2009. Telbivudine in the treatment of chronic hepatitis B. <citetitle><emphasis>Adv Ther</emphasis></citetitle> <emphasis role="strong">26:</emphasis>155–169.</para>
          </listitem>
          <listitem id="ch0134s0000li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K, GS-US-320-0110 Investigators.</emphasis> 2016. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <citetitle><emphasis>Lancet Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">1:</emphasis>185–195.</para>
          </listitem>
          <listitem id="ch0134s0000li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Ormrod D, Scott LJ, Perry CM.</emphasis> 2000. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">59:</emphasis>839–863.</para>
          </listitem>
          <listitem id="ch0134s0000li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Talarico CL, Burnette TC, Miller WH, Smith SL, Davis MG, Stanat SC, Ng TI, He Z, Coen DM, Roizman B, Biron KK.</emphasis> 1999. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">43:</emphasis>1941–1946.</para>
          </listitem>
          <listitem id="ch0134s0000li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Whitley RJ, Gnann JW Jr.</emphasis> 1992. Acyclovir: a decade later. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">327:</emphasis>782–789.</para>
          </listitem>
          <listitem id="ch0134s0000li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Hazar V, Kansoy S, Küpesiz A, Aksoylar S, Kantar M, Ye</emphasis>ş<emphasis role="strong">ilipek A.</emphasis> 2004. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation. <citetitle><emphasis>Bone Marrow Transplant</emphasis></citetitle> <emphasis role="strong">33:</emphasis>931–935.</para>
          </listitem>
          <listitem id="ch0134s0000li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Reischig T, Jindra P, Mares J, Cechura M, Svecová M, Hes O, Opatrný K Jr, Treska V.</emphasis> 2005. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. <citetitle><emphasis>Transplantation</emphasis></citetitle> <emphasis role="strong">79:</emphasis>317–324.</para>
          </listitem>
          <listitem id="ch0134s0000li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Xiong X, Smith JL, Chen MS.</emphasis> 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">41:</emphasis>594–599.</para>
          </listitem>
          <listitem id="ch0134s0000li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJ, Jaffe HS.</emphasis> 1995. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">39:</emphasis>1247–1252.</para>
          </listitem>
          <listitem id="ch0134s0000li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Wolf DL, Rodríguez CA, Mucci M, Ingrosso A, Duncan BA, Nickens DJ.</emphasis> 2003. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. <citetitle><emphasis>J Clin Pharmacol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>43–51.</para>
          </listitem>
          <listitem id="ch0134s0000li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Duraffour S, Mertens B, Meyer H, van den Oord JJ, Mitera T, Matthys P, Snoeck R, Andrei G.</emphasis> 2013. Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e55808.</para>
          </listitem>
          <listitem id="ch0134s0000li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Matthes-Martin S, Feuchtinger T, Shaw PJ, Engelhard D, Hirsch HH, Cordonnier C, Ljungman P, Fourth European Conference on Infections in Leukemia.</emphasis> 2012. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). <citetitle><emphasis>Transpl Infect Dis</emphasis></citetitle> <emphasis role="strong">14:</emphasis>555–563.</para>
          </listitem>
          <listitem id="ch0134s0000li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Kuten SA, Patel SJ, Knight RJ, Gaber LW, DeVos JM, Gaber AO.</emphasis> 2014. Observations on the use of cidofovir for BK virus infection in renal transplantation. <citetitle><emphasis>Transpl Infect Dis</emphasis></citetitle> <emphasis role="strong">16:</emphasis>975–983.</para>
          </listitem>
          <listitem id="ch0134s0000li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Shehab N, Sweet BV, Hogikyan ND.</emphasis> 2005. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. <citetitle><emphasis>Pharmacotherapy</emphasis></citetitle> <emphasis role="strong">25:</emphasis>977–989.</para>
          </listitem>
          <listitem id="ch0134s0000li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Fusconi M, Grasso M, Greco A, Gallo A, Campo F, Remacle M, Turchetta R, Pagliuca G, DE Vincentiis M.</emphasis> 2014. Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. <citetitle><emphasis>Acta Otorhinolaryngol Ital</emphasis></citetitle> <emphasis role="strong">34:</emphasis>375–381.</para>
          </listitem>
          <listitem id="ch0134s0000li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Lietman PS.</emphasis> 1992. Clinical pharmacology: foscarnet. <citetitle><emphasis>Am J Med</emphasis></citetitle> <emphasis role="strong">92</emphasis>(2A)<emphasis role="strong">:</emphasis>8S–11S.</para>
          </listitem>
          <listitem id="ch0134s0000li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Chrisp P, Clissold SP.</emphasis> 1991. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">41:</emphasis>104–129.</para>
          </listitem>
          <listitem id="ch0134s0000li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Aweeka F, Gambertoglio J, Mills J, Jacobson MA.</emphasis> 1989. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">33:</emphasis>742–745.</para>
          </listitem>
          <listitem id="ch0134s0000li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Schwarz A, Perez-Canto A.</emphasis> 1998. Nephrotoxicity of antiinfective drugs. <citetitle><emphasis>Int J Clin Pharmacol Ther</emphasis></citetitle> <emphasis role="strong">36:</emphasis>164–167.</para>
          </listitem>
          <listitem id="ch0134s0000li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Curran M, Noble S.</emphasis> 2001. Valganciclovir. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">61:</emphasis>1145–1150, discussion 1151–1152.</para>
          </listitem>
          <listitem id="ch0134s0000li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O’Grady J, Robinson C, To Z, Wren K, Banken L, Buhles W, Brown F.</emphasis> 2000. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">44:</emphasis>2811–2815.</para>
          </listitem>
          <listitem id="ch0134s0000li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Zuideveld KP, Valganciclovir Solid Organ Transplant Study Group.</emphasis> 2005. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. <citetitle><emphasis>Transplantation</emphasis></citetitle> <emphasis role="strong">79:</emphasis>1477–1483.</para>
          </listitem>
          <listitem id="ch0134s0000li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, Hamilton S, Huang ML, Wald A.</emphasis> 2008. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">198:</emphasis>23–30.</para>
          </listitem>
          <listitem id="ch0134s0000li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Cvetkovi</emphasis>ć <emphasis role="strong">RS, Wellington K.</emphasis> 2005. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">65:</emphasis>859–878.</para>
          </listitem>
          <listitem id="ch0134s0000li0163" role="bibliographyEntry">
            <anchor id="ch0134s0000a0331"/>
            <para>163.<emphasis role="strong">Sun HY, Wagener MM, Singh N.</emphasis> 2008. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. <citetitle><emphasis>Am J Transplant</emphasis></citetitle> <emphasis role="strong">8:</emphasis>2111–2118.</para>
          </listitem>
          <listitem id="ch0134s0000li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Torres-Madriz G, Boucher HW.</emphasis> 2008. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47:</emphasis>702–711.</para>
          </listitem>
          <listitem id="ch0134s0000li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C.</emphasis> 2017. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">377:</emphasis>2433–2444.</para>
          </listitem>
          <listitem id="ch0134s0000li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL.</emphasis> 1989. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">33:</emphasis>1765–1773.</para>
          </listitem>
          <listitem id="ch0134s0000li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Luber AD, Flaherty JF Jr.</emphasis> 1996. Famciclovir for treatment of herpesvirus infections. <citetitle><emphasis>Ann Pharmacother</emphasis></citetitle> <emphasis role="strong">30:</emphasis>978–985.</para>
          </listitem>
          <listitem id="ch0134s0000li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Schmid-Wendtner MH, Korting HC.</emphasis> 2004. Penciclovir cream—improved topical treatment for herpes simplex infections. <citetitle><emphasis>Skin Pharmacol Physiol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>214–218.</para>
          </listitem>
          <listitem id="ch0134s0000li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Simpson D, Lyseng-Williamson KA.</emphasis> 2006. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">66:</emphasis>2397–2416.</para>
          </listitem>
          <listitem id="ch0134s0000li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D.</emphasis> 2003. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">16:</emphasis>114–128.</para>
          </listitem>
          <listitem id="ch0134s0000li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA.</emphasis> 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">36:</emphasis>2747–2757.</para>
          </listitem>
          <listitem id="ch0134s0000li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Chilukuri S, Rosen T.</emphasis> 2003. Management of acyclovir-resistant herpes simplex virus. <citetitle><emphasis>Dermatol Clin</emphasis></citetitle> <emphasis role="strong">21:</emphasis>311–320.</para>
          </listitem>
          <listitem id="ch0134s0000li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Pepose JS, Margolis TP, LaRussa P, Pavan-Langston D.</emphasis> 2003. Ocular complications of smallpox vaccination. <citetitle><emphasis>Am J Ophthalmol</emphasis></citetitle> <emphasis role="strong">136:</emphasis>343–352.</para>
          </listitem>
          <listitem id="ch0134s0000li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS.</emphasis> 1982. Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">23:</emphasis>329–353.</para>
          </listitem>
          <listitem id="ch0134s0000li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Katz DH, Marcelletti JF, Khalil MH, Pope LE, Katz LR.</emphasis> 1991. Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">88:</emphasis>10825–10829.</para>
          </listitem>
          <listitem id="ch0134s0000li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Trofe J, Pote L, Wade E, Blumberg E, Bloom RD.</emphasis> 2008. Maribavir: a novel antiviral agent with activity against cytomegalovirus. <citetitle><emphasis>Ann Pharmacother</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1447–1457.</para>
          </listitem>
          <listitem id="ch0134s0000li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Takeda Pharmaceutical.</emphasis> 2022. Highlights of prescribing information: Livtencity (maribavir). <ulink url="https://content.takeda.com/?contenttype=pi&amp;product=liv&amp;language=eng&amp;country=usa&amp;documentnumber=1">https://content.takeda.com/?contenttype=pi&amp;product=liv&amp;language=eng&amp;country=usa&amp;documentnumber=1</ulink>. Accessed 2 September 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB.</emphasis> 2003. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1334–1342.</para>
          </listitem>
          <listitem id="ch0134s0000li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, Talarico CL, Shaw S, Jacobson MA, Drew WL.</emphasis> 2002. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>2969–2.</para>
          </listitem>
          <listitem id="ch0134s0000li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J, Marty FM, Papanicolaou GA, Silveira FP, Witzke O, Wu J, Sundberg AK, Fournier M, SOLSTICE Trial Investigators.</emphasis> 2021. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">75:</emphasis>690–701.</para>
          </listitem>
          <listitem id="ch0134s0000li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Gandhi RG, Kotton CN.</emphasis> 2022. Evaluating the safety of maribavir for the treatment of cytomegalovirus. <citetitle><emphasis>Ther Clin Risk Manag</emphasis></citetitle> <emphasis role="strong">18:</emphasis>223–232.</para>
          </listitem>
          <listitem id="ch0134s0000li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Price NB, Prichard MN.</emphasis> 2011. Progress in the development of new therapies for herpesvirus infections. <citetitle><emphasis>Curr Opin Virol</emphasis></citetitle> <emphasis role="strong">1:</emphasis>548–554.</para>
          </listitem>
          <listitem id="ch0134s0000li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Florescu DF, Pergam SA, Neely MN, Qiu F, Johnston C, Way S, Sande J, Lewinsohn DA, Guzman-Cottrill JA, Graham ML, Papanicolaou G, Kurtzberg J, Rigdon J, Painter W, Mommeja-Marin H, Lanier R, Anderson M, van der Horst C.</emphasis> 2012. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. <citetitle><emphasis>Biol Blood Marrow Transplant</emphasis></citetitle> <emphasis role="strong">18:</emphasis>731–738.</para>
          </listitem>
          <listitem id="ch0134s0000li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Tyring S, Wald A, Zadeikis N, Dhadda S, Takenouchi K, Rorig R.</emphasis> 2012. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">205:</emphasis>1100–1110.</para>
          </listitem>
          <listitem id="ch0134s0000li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang ML, Selke S, Stobernack HP, Ruebsamen-Schaeff H, Birkmann A.</emphasis> 2014. Helicase-primase inhibitor pritelivir for HSV-2 infection. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">370:</emphasis>201–210.</para>
          </listitem>
          <listitem id="ch0134s0000li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Avery RK, Bolwell BJ, Yen-Lieberman B, Lurain N, Waldman WJ, Longworth DL, Taege AJ, Mossad SB, Kohn D, Long JR, Curtis J, Kalaycio M, Pohlman B, Williams JW.</emphasis> 2004. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. <citetitle><emphasis>Bone Marrow Transplant</emphasis></citetitle> <emphasis role="strong">34:</emphasis>1071–1075.</para>
          </listitem>
          <listitem id="ch0134s0000li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL.</emphasis> 2006. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. <citetitle><emphasis>Transpl Infect Dis</emphasis></citetitle> <emphasis role="strong">8:</emphasis>38–43.</para>
          </listitem>
          <listitem id="ch0134s0000li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M.</emphasis> 2008. The antiviral activities of artemisinin and artesunate. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47:</emphasis>804–811.</para>
          </listitem>
          <listitem id="ch0134s0000li0189" role="bibliographyEntry">
            <para>189.<emphasis role="strong">Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stamminger T, Caplan O, Saleh N, Efferth T, Marschall M, Wolf DG.</emphasis> 2008. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1455–1457.</para>
          </listitem>
          <listitem id="ch0134s0000li0190" role="bibliographyEntry">
            <para>190.<emphasis role="strong">American Academy of Pediatrics Committee on Infectious Diseases.</emphasis> 2007. Antiviral therapy and prophylaxis for influenza in children. <citetitle><emphasis>Pediatrics</emphasis></citetitle> <emphasis role="strong">119:</emphasis>852–860.</para>
          </listitem>
          <listitem id="ch0134s0000li0191" role="bibliographyEntry">
            <para>191.<emphasis role="strong">Monto AS.</emphasis> 2003. The role of antivirals in the control of influenza. <citetitle><emphasis>Vaccine</emphasis></citetitle> <emphasis role="strong">21:</emphasis>1796–1800.</para>
          </listitem>
          <listitem id="ch0134s0000li0192" role="bibliographyEntry">
            <para>192.<emphasis role="strong">Oxford JS.</emphasis> 2007. Antivirals for the treatment and prevention of epidemic and pandemic influenza. <citetitle><emphasis>Influenza Other Respir Viruses</emphasis></citetitle> <emphasis role="strong">1:</emphasis>27–34.</para>
          </listitem>
          <listitem id="ch0134s0000li0193" role="bibliographyEntry">
            <para>193.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2022. Influenza antiviral medications. <ulink url="https://www.cdc.gov/flu/professionals/antivirals/index.htm">https://www.cdc.gov/flu/professionals/antivirals/index.htm</ulink>. Accessed 22 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0194" role="bibliographyEntry">
            <para>194.<emphasis role="strong">Genentech.</emphasis> 2022. Highlights of prescribing information: Xofluza (baloxavir marboxil). <ulink url="https://www.gene.com/download/pdf/xofluza_prescribing.pdf">https://www.gene.com/download/pdf/xofluza_prescribing.pdf</ulink>. Accessed 22 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0195" role="bibliographyEntry">
            <para>195.<emphasis role="strong">Jing X, Ma C, Ohigashi Y, Oliveira FA, Jardetzky TS, Pinto LH, Lamb RA.</emphasis> 2008. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">105:</emphasis>10967–10972.</para>
          </listitem>
          <listitem id="ch0134s0000li0196" role="bibliographyEntry">
            <para>196.<emphasis role="strong">van der Vries E, Schutten M, Boucher CA.</emphasis> 2011. The potential for multidrug-resistant influenza. <citetitle><emphasis>Curr Opin Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>599–604.</para>
          </listitem>
          <listitem id="ch0134s0000li0197" role="bibliographyEntry">
            <para>197.<emphasis role="strong">Hurt AC, Holien JK, Parker MW, Barr IG.</emphasis> 2009. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">69:</emphasis>2523–2531.</para>
          </listitem>
          <listitem id="ch0134s0000li0198" role="bibliographyEntry">
            <para>198.<emphasis role="strong">Suzuki Y, Saito R, Zaraket H, Dapat C, Caperig-Dapat I, Suzuki H.</emphasis> 2010. Rapid and specific detection of amantadine-resistant influenza A viruses with a Ser31Asn mutation by the cycling probe method. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>57–63.</para>
          </listitem>
          <listitem id="ch0134s0000li0199" role="bibliographyEntry">
            <para>199.<emphasis role="strong">Dobson J, Whitley RJ, Pocock S, Monto AS.</emphasis> 2015. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">385:</emphasis>1729–1737.</para>
          </listitem>
          <listitem id="ch0134s0000li0200" role="bibliographyEntry">
            <anchor id="ch0134s0000a0332"/>
            <para>200.<emphasis role="strong">McLaughlin MM, Skoglund EW, Ison MG.</emphasis> 2015. Peramivir: an intravenous neuraminidase inhibitor. <citetitle><emphasis>Expert Opin Pharmacother</emphasis></citetitle> <emphasis role="strong">16:</emphasis>1889–1900.</para>
          </listitem>
          <listitem id="ch0134s0000li0201" role="bibliographyEntry">
            <para>201.<emphasis role="strong">Cheng PK, To AP, Leung TW, Leung PC, Lee CW, Lim WW.</emphasis> 2010. Oseltamivir- and amantadine-resistant influenza virus A (H1N1). <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">16:</emphasis>155–156.</para>
          </listitem>
          <listitem id="ch0134s0000li0202" role="bibliographyEntry">
            <para>202.<emphasis role="strong">Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, Ward P.</emphasis> 2002. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. <citetitle><emphasis>Drug Metab Dispos</emphasis></citetitle> <emphasis role="strong">30:</emphasis>13–19.</para>
          </listitem>
          <listitem id="ch0134s0000li0203" role="bibliographyEntry">
            <para>203.<emphasis role="strong">Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, Centers for Disease Control and Prevention (CDC).</emphasis> 2011<emphasis role="strong">.</emphasis> Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">60:</emphasis>1–24.</para>
          </listitem>
          <listitem id="ch0134s0000li0204" role="bibliographyEntry">
            <para>204.<emphasis role="strong">Bowles SK, Lee W, Simor AE, Vearncombe M, Loeb M, Tamblyn S, Fearon M, Li Y, McGeer A, Oseltamivir Compassionate Use Program Group.</emphasis> 2002. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. <citetitle><emphasis>J Am Geriatr Soc</emphasis></citetitle> <emphasis role="strong">50:</emphasis>608–616.</para>
          </listitem>
          <listitem id="ch0134s0000li0205" role="bibliographyEntry">
            <para>205.<emphasis role="strong">Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, Dutkowski R, Ward P, Carr J.</emphasis> 2004. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">189:</emphasis>440–449.</para>
          </listitem>
          <listitem id="ch0134s0000li0206" role="bibliographyEntry">
            <para>206.<emphasis role="strong">Whitley RJ.</emphasis> 2007. The role of oseltamivir in the treatment and prevention of influenza in children. <citetitle><emphasis>Expert Opin Drug Metab Toxicol</emphasis></citetitle> <emphasis role="strong">3:</emphasis>755–767.</para>
          </listitem>
          <listitem id="ch0134s0000li0207" role="bibliographyEntry">
            <para>207.<emphasis role="strong">Wester A, Shetty AK.</emphasis> 2016. Peramivir injection in the treatment of acute influenza: a review of the literature. <citetitle><emphasis>Infect Drug Resist</emphasis></citetitle> <emphasis role="strong">9:</emphasis>201–214.</para>
          </listitem>
          <listitem id="ch0134s0000li0208" role="bibliographyEntry">
            <para>208.<emphasis role="strong">Moscona A.</emphasis> 2005. Neuraminidase inhibitors for influenza. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">353:</emphasis>1363–1373.</para>
          </listitem>
          <listitem id="ch0134s0000li0209" role="bibliographyEntry">
            <para>209.<emphasis role="strong">Ison MG, Gnann JW Jr, Nagy-Agren S, Treannor J, Paya C, Steigbigel R, Elliott M, Weiss HL, Hayden FG, NIAID Collaborative Antiviral Study Group.</emphasis> 2003. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. <citetitle><emphasis>Antivir Ther</emphasis></citetitle> <emphasis role="strong">8:</emphasis>183–190.</para>
          </listitem>
          <listitem id="ch0134s0000li0210" role="bibliographyEntry">
            <para>210.<emphasis role="strong">Cass LM, Efthymiopoulos C, Bye A.</emphasis> 1999. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. <citetitle><emphasis>Clin Pharmacokinet</emphasis></citetitle> <emphasis role="strong">36</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>1–11.</para>
          </listitem>
          <listitem id="ch0134s0000li0211" role="bibliographyEntry">
            <para>211.<emphasis role="strong">Cao Y, et al.</emphasis> 2022. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. <citetitle><emphasis>Nature</emphasis></citetitle> <emphasis role="strong">608:</emphasis>593–602.</para>
          </listitem>
          <listitem id="ch0134s0000li0212" role="bibliographyEntry">
            <para>212.<emphasis role="strong">National Institutes of Health.</emphasis> 2022. Antiviral drugs that are approved, authorized, or under evaluation for the treatment of COVID-19. <ulink url="https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/summary-recommendations/">https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/summary-recommendations/</ulink>. Accessed 24 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0213" role="bibliographyEntry">
            <para>213.<emphasis role="strong">Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members.</emphasis> 2020. Remdesivir for the treatment of COVID-19—final report. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">383:</emphasis>1813–1826.</para>
          </listitem>
          <listitem id="ch0134s0000li0214" role="bibliographyEntry">
            <para>214.<emphasis role="strong">Ali K, et al, Canadian Treatments for COVID-19 (CATCO), Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group.</emphasis> 2022. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. <citetitle><emphasis>CMAJ</emphasis></citetitle> <emphasis role="strong">194:</emphasis>E242–E251.</para>
          </listitem>
          <listitem id="ch0134s0000li0215" role="bibliographyEntry">
            <para>215.<emphasis role="strong">Ader F, et al, DisCoVeRy Study Group.</emphasis> 2022. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>209–221.</para>
          </listitem>
          <listitem id="ch0134s0000li0216" role="bibliographyEntry">
            <para>216.<emphasis role="strong">WHO Solidarity Trial Consortium.</emphasis> 2022. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">399:</emphasis>1941–1953.</para>
          </listitem>
          <listitem id="ch0134s0000li0217" role="bibliographyEntry">
            <para>217.<emphasis role="strong">Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM, GS-US-540-5774 Investigators.</emphasis> 2020. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">324:</emphasis>1048–1057.</para>
          </listitem>
          <listitem id="ch0134s0000li0218" role="bibliographyEntry">
            <para>218.<emphasis role="strong">Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A, GS-US-540-5773 Investigators.</emphasis> 2020. Remdesivir for 5 or 10 days in patients with severe COVID-19. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">383:</emphasis>1827–1837.</para>
          </listitem>
          <listitem id="ch0134s0000li0219" role="bibliographyEntry">
            <para>219.<emphasis role="strong">US Food and Drug Administration.</emphasis> 2020. Approves first treatment for COVID-19. <ulink url="https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19">https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19</ulink>. Accessed 22 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0220" role="bibliographyEntry">
            <para>220.<emphasis role="strong">Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA, GS-US-540-9012 (PINETREE) Investigators.</emphasis> 2022. Early remdesivir to prevent progression to severe COVID-19 in outpatients. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">386:</emphasis>305–315.</para>
          </listitem>
          <listitem id="ch0134s0000li0221" role="bibliographyEntry">
            <para>221.<emphasis role="strong">US Food Drug and Administration.</emphasis> 2022. Coronavirus (COVID-19) update: FDA approves first COVID-19 treatment for young children. <ulink url="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children</ulink>. Accessed 23 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0222" role="bibliographyEntry">
            <para>222.<emphasis role="strong">National Institutes of Health.</emphasis> 2022. Study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of remdesivir in participants from birth to &lt;18 years of age with coronavirus disease 2019 (COVID-19) (CARAVAN). <ulink url="https://www.clinicaltrials.gov/ct2/show/NCT04431453">https://www.clinicaltrials.gov/ct2/show/NCT04431453</ulink>. Accessed 23 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0223" role="bibliographyEntry">
            <para>223.<emphasis role="strong">Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, van Doremalen N, Leighton I, Yinda CK, Pérez-Pérez L, Okumura A, Lovaglio J, Hanley PW, Saturday G, Bosio CM, Anzick S, Barbian K, Cihlar T, Martens C, Scott DP, Munster VJ, de Wit E.</emphasis> 2020. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. <citetitle><emphasis>Nature</emphasis></citetitle> <emphasis role="strong">585:</emphasis>273–276.</para>
          </listitem>
          <listitem id="ch0134s0000li0224" role="bibliographyEntry">
            <para>224.<emphasis role="strong">Bhimraj A, et al.</emphasis> 2022. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. <ulink url="https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-v9.0.1.pdf">https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-v9.0.1.pdf</ulink>. Accessed 22 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0225" role="bibliographyEntry">
            <para>225.<emphasis role="strong">Merck.</emphasis> 2021. Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID -19 in positive interim analysis of phase 3 study. <ulink url="https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat">https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat</ulink>. Accessed 18 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0226" role="bibliographyEntry">
            <para>226.<emphasis role="strong">US Food and Drug Administration.</emphasis> 2022. Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules. <ulink url="https://www.fda.gov/media/155054/download">https://www.fda.gov/media/155054/download</ulink>. Accessed 20 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0227" role="bibliographyEntry">
            <anchor id="ch0134s0000a0333"/>
            <para>227.<emphasis role="strong">Fischer WA II, et al.</emphasis> 2022. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. <citetitle><emphasis>Sci Transl Med</emphasis></citetitle> <emphasis role="strong">14:</emphasis>eabl7430.</para>
          </listitem>
          <listitem id="ch0134s0000li0228" role="bibliographyEntry">
            <para>228.<emphasis role="strong">Jayk Bernal A, et al.</emphasis> 2022. Molnupiravir for oral treatment of COVID-19 in non-hospitalized patients. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">386:</emphasis>509–520.</para>
          </listitem>
          <listitem id="ch0134s0000li0229" role="bibliographyEntry">
            <para>229.<emphasis role="strong">Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, André E, Leyssen P, Neyts J, Jochmans D.</emphasis> 2022. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. <citetitle><emphasis>bioRxiv</emphasis></citetitle> <emphasis role="strong">198:</emphasis>105252.</para>
          </listitem>
          <listitem id="ch0134s0000li0230" role="bibliographyEntry">
            <para>230.<emphasis role="strong">US Food and Drug Administration.</emphasis> 2021. Emergency use authorization (EUA) for Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets): Center for Drug Evaluation and Research (CDER) review. <ulink url="https://www.fda.gov/media/155194/download">https://www.fda.gov/media/155194/download</ulink>. Accessed 21 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0231" role="bibliographyEntry">
            <para>231.<emphasis role="strong">Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM, EPIC-HR Investigators.</emphasis> 2022. Oral Nirmatrelvir for high-risk, non-hospitalized adults with COVID-19. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">386:</emphasis>1397–1408.</para>
          </listitem>
          <listitem id="ch0134s0000li0232" role="bibliographyEntry">
            <para>232.<emphasis role="strong">US Food and Drug Administration.</emphasis> 2022. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. <ulink url="https://www.fda.gov/media/155050/download">https://www.fda.gov/media/155050/download</ulink>. Accessed 10 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0233" role="bibliographyEntry">
            <para>233.<emphasis role="strong">Gupta K, Strymish J, Stack G, Charness M.</emphasis> 2022. Rapid relapse of symptomatic SARS-CoV-2 infection following early suppression with nirmatrelvir/ritonavir. <citetitle><emphasis>Research Square.</emphasis></citetitle> <ulink url="https://www.researchsquare.com/article/rs-1588371/v1">https://www.researchsquare.com/article/rs-1588371/v1</ulink>.</para>
          </listitem>
          <listitem id="ch0134s0000li0234" role="bibliographyEntry">
            <para>234.<emphasis role="strong">Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y.</emphasis> 2022. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">386:</emphasis>1475–1477.</para>
          </listitem>
          <listitem id="ch0134s0000li0235" role="bibliographyEntry">
            <para>235.<emphasis role="strong">Greasley SE, Noell S, Plotnikova O, Ferre R, Liu W, Bolanos B, Fennell K, Nicki J, Craig T, Zhu Y, Stewart AE, Steppan CM.</emphasis> 2022. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. <citetitle><emphasis>J Biol Chem</emphasis></citetitle> <emphasis role="strong">298:</emphasis>101972.</para>
          </listitem>
          <listitem id="ch0134s0000li0236" role="bibliographyEntry">
            <para>236.<emphasis role="strong">Rai DK, et al.</emphasis> 2022. Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 variants of concern. <citetitle><emphasis>bioRxiv.</emphasis></citetitle> <ulink url="https://www.biorxiv.org/content/10.1101/2022.01.17.476644v1">https://www.biorxiv.org/content/10.1101/2022.01.17.476644v1</ulink>.</para>
          </listitem>
          <listitem id="ch0134s0000li0237" role="bibliographyEntry">
            <para>237.<emphasis role="strong">US Food and Drug Administration.</emphasis> 2022. Fact sheet for health care providers: emergency use authorization (EUA) of REGEN-COV (casirivimab and imdevimab). <ulink url="https://www.fda.gov/media/145611/download">https://www.fda.gov/media/145611/download</ulink>. Accessed 25 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0238" role="bibliographyEntry">
            <para>238.<emphasis role="strong">US Food and Drug Administration.</emphasis> 2022. Fact sheet for health care providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. <ulink url="https://www.fda.gov/media/145802/download">https://www.fda.gov/media/145802/download</ulink>. Accessed 26 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0239" role="bibliographyEntry">
            <para>239.<emphasis role="strong">US Food and Drug Administration.</emphasis> 2022. Fact sheet for health care providers: emergency use authorization (EUA) of sotrovimab. <ulink url="https://www.fda.gov/media/149534/download">https://www.fda.gov/media/149534/download</ulink>. Accessed 28 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0240" role="bibliographyEntry">
            <para>240.<emphasis role="strong">US Food and Drug Administration.</emphasis> 2022. Fact sheet for health care providers: emergency use authorization (EUA) for bebtelovimab. <ulink url="https://www.fda.gov/media/156152/download">https://www.fda.gov/media/156152/download</ulink>. Accessed 2 September 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0241" role="bibliographyEntry">
            <para>241.<emphasis role="strong">US Food and Drug Administration.</emphasis> 2022. Fact sheet for health care providers: emergency use authorization for evusheld (tixagevimab co-packaged with cilgavimab). <ulink url="https://www.fda.gov/media/154701/download">https://www.fda.gov/media/154701/download</ulink>. Accessed 29 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0242" role="bibliographyEntry">
            <para>242.<emphasis role="strong">Hachmann NP, Miller J, Collier AY, Ventura JD, Yu J, Rowe M, Bondzie EA, Powers O, Surve N, Hall K, Barouch DH.</emphasis> 2022. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">387:</emphasis>86–88.</para>
          </listitem>
          <listitem id="ch0134s0000li0243" role="bibliographyEntry">
            <para>243.<emphasis role="strong">Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y.</emphasis> 2022. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">387:</emphasis>468–470.</para>
          </listitem>
          <listitem id="ch0134s0000li0244" role="bibliographyEntry">
            <para>244.<emphasis role="strong">Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Kohli A, Sachdeva Y, Graber X, Kowal B, DiCioccio T, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Trial Investigators.</emphasis> 2021. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">384:</emphasis>238–251.</para>
          </listitem>
          <listitem id="ch0134s0000li0245" role="bibliographyEntry">
            <para>245.<emphasis role="strong">Infectious Diseases Society of America.</emphasis> 2022. IDSA guidelines on the treatment and management of patients with COVID-19. <ulink url="https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/">https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</ulink>. Accessed 20 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0246" role="bibliographyEntry">
            <para>246.<emphasis role="strong">The Medical Letter on Drugs and Therapeutics.</emphasis> 2020. An EUA for bamlanivimab—a monoclonal antibody for COVID-19. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">325:</emphasis>880–881.</para>
          </listitem>
          <listitem id="ch0134s0000li0247" role="bibliographyEntry">
            <para>247.<emphasis role="strong">Administration for Strategic Preparedness &amp; Response, USHHS.</emphasis> 2022. Bamlanivimab/etesevimab. <ulink url="https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Bamlanivimab-etesevimab/Pages/default.aspx">https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Bamlanivimab-etesevimab/Pages/default.aspx</ulink>. Accessed 26 August 2022.</para>
          </listitem>
          <listitem id="ch0134s0000li0248" role="bibliographyEntry">
            <para>248.<emphasis role="strong">Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, Sarkis E, Solis J, Zheng H, Scott N, Cathcart AL, Hebner CM, Sager J, Mogalian E, Tipple C, Peppercorn A, Alexander E, Pang PS, Free A, Brinson C, Aldinger M, Shapiro AE, COMET-ICE Investigators.</emphasis> 2021. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">385:</emphasis>1941–1950.</para>
          </listitem>
          <listitem id="ch0134s0000li0249" role="bibliographyEntry">
            <para>249.<emphasis role="strong">Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J, Sato K, Genotype to Phenotype Japan (G2P-Japan) Consortium.</emphasis> 2022. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>942–943.</para>
          </listitem>
          <listitem id="ch0134s0000li0250" role="bibliographyEntry">
            <para>250.<emphasis role="strong">Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z, Ho DD.</emphasis> 2022. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. <citetitle><emphasis>Nature</emphasis></citetitle> <emphasis role="strong">604:</emphasis>553–556.</para>
          </listitem>
          <listitem id="ch0134s0000li0251" role="bibliographyEntry">
            <para>251.<emphasis role="strong">Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT, PROVENT Study Group.</emphasis> 2022. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">386:</emphasis>2188–2200.</para>
          </listitem>
          <listitem id="ch0134s0000li0252" role="bibliographyEntry">
            <para>252.<emphasis role="strong">Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, Chu Y, Feng Y, Wang Q.</emphasis> 2020. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">71:</emphasis>2688–2694.</para>
          </listitem>
          <listitem id="ch0134s0000li0253" role="bibliographyEntry">
            <para>253.<emphasis role="strong">US Food and Drug Administration.</emphasis> 2021. Fact sheet for health care providers: emergency use authorization (EUA) of COVID-19 convalescent plasma for treatment of coronavirus disease 2019 (COVID-19). <ulink url="https://www.fda.gov/media/141478/download">https://www.fda.gov/media/141478/download</ulink>. Accessed 15 August 2022.</para>
          </listitem>
        </itemizedlist>
        <anchor id="ch0134s0000a0329"/>
        <beginpage pagenum="2226"/>
      </sect2>
    </sect1>
  </chapter>
